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Chapter 1
INTRODUCTION
Kidney function in health and disease
The kidneys are complex organs and consist of approximately 1 million 
filtration units per organ, termed nephrons. Each nephron contains over 
twenty different cell types that, together, play a role in the homeostasis of the 
organism by taking care of the removal of waste products and the retention 
of vital components such as electrolytes, peptides and H2O (1-4). To this end, 
blood enters the first segment of the nephron, the glomerulus, where filtration 
will occur under hydrodynamic pressure. The ultrafiltrate containing H2O and 
small solutes will enter the proximal tubule epithelial cells where a fraction 
of the electrolytes, H2O and other molecules such as amino acids and glucose 
will be reabsorbed. In addition, active secretion of waste products and drugs 
from the efferent arteriole and the interstitium into the pro-urine takes place, 
mediated by transporters present in proximal tubule epithelial cells (PTEC). 
Downstream the proximal segment, the Loop of Henle, the distal convoluted 
tubule and collecting tubule and -duct cells are equipped with water- and ion 
channels and play key roles in the fine tuning of fluid and ion homeostasis. 
Moreover, the kidneys fulfill an endocrine and metabolic function, which 
contributes further to the maintenance of the physiological balance in the 
human body and in preventing the development of acute or chronic renal 
failure (5). 
The incidence of acute kidney injury (AKI) is an increasing global concern and 
is characterized by a high mortality rate of over 50% in critically ill patients. 
AKI is defined as an abrupt loss of kidney function and renal replacement 
therapy such as hemodialysis is urgently required (6-8). The onset of acute 
kidney injury (AKI) is often complex, but cardiac failure, renal thrombosis, 
obstruction of the urinary tract and sepsis-induced acute tubular necrosis are 
known causal factors (7). Although less severe AKI is partially reversible, still 
the disease is associated with adverse irreversible outcomes and predisposes 
to chronic kidney disease (CKD) (6). CKD is classified in five stages based on 
measured or estimated glomerular filtration rate (m/eGFR). Stage 1 reflects 
normal kidney function (mGFR >90 ml/min/1.73m2) though evidence for 
reduced kidney function is present, whereas stage 5 represents end-stage 
renal disease (ESRD) with a severe decline in kidney function of over 80% 
and renal replacement therapy is required. In addition to unresolved AKI, 
the development of chronic kidney disease (CKD) can be caused by a wide 
variety of underlying diseases (e.g. cardiovascular disease, diabetes mellitus, 
11
1auto-immune disease, sepsis), aging or nephrotoxic agents (7, 9-12). But also 
conditions in which the kidneys are primarily affected are known, often 
due to genetic disorders, like polycystic kidney disease, Alport syndrome, 
nephropathic cystinosis, nephrotic syndrome and electrolyte and acid-
base balance disorders (2, 13-16). As the kidneys have an important role in 
many physiological processes, it has been shown that renal dysfunction in 
turn also contributes to the onset or progression of other diseases such as 
cardiovascular disease, mineral and bone disorders, anemia and neurological 
disorders (10, 17-19). Over the past years, more knowledge is gained to unravel 
the molecular mechanisms of kidney (-related) diseases, using state-of-
the-art platforms such as whole exome sequencing, metabolomics and 
proteomics. Nevertheless, many causes have, as of yet, not been elucidated 
and appropriate therapeutic modalities are often absent or only diminish the 
progression of renal disease. 
Pitfalls of CKD treatment 
The preferred treatment option for ESRD is organ transplantation. 
Unfortunately, a profound shortage in donor organs results in a waiting list 
for a patient of about 3 - 5 years, depending on blood type (20). Alternatively, 
patients are treated with peritoneal or hemodialysis, if possible at home 
to affect the patients’ lifestyle as minimal as possible (figure 1.1). In more 
advanced stages, i.e. severe clinical complications associated with ESRD, 
patients have to be treated at a medical center to have better monitored and 
more successful dialysis sessions. A major drawback of in-center dialysis is 
the frequency and the duration; 3 times a week for approximately 4 hours 
per dialysis session, which has an enormous impact on the independency and 
the socioeconomic status of the patient. In addition, hemodialysis treatment 
has its restrictions as this method removes only a minor fraction of the waste 
products, predominantly the small uremic solutes (Molecular Weight (MW) 
<500 Da), from the patients’ blood (10). Next to the hampered clearance 
capacity, the endocrine and metabolic functions cannot be replaced by 
hemodialysis. In a retrospective cohort study performed by Bradbury et al., it 
was shown that hemodialysis has a high yearly mortality risk of approximately 
5-27%. The mortality rate was highest during the first three months after 
treatment initiation predominantly due to cardiac arrest (21). In patients 
chronically treated with hemodialysis the most frequent cause of death is 
cardiovascular disease. Together, the mortality rate in hemodialysis treated 
patients is 10-20 times higher than in the general population (22). 
12
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1Figure 1.1 Schematic presentation of three available renal replacement therapies. (a) The transplanted donor organ is implemented in the patient, while both affected 
kidneys will remain in the body. A donor organ is the preferred treatment option for 
patients suffering from ESRD. (b) During peritoneal dialysis, a permanent tube will be 
connected to the patients’ abdomen and the peritoneum will be used as a membrane 
which allow for the removal of small waste products from the blood into the dialysis 
waste fluid. Peritoneal home-dialysis is possible as long as infections are suppressed and 
the quality of the peritoneum is maintained. (c) For hemodialysis, vascular access can 
be accomplished via three ways i) a central venous catheter ii) an arteriovenous fistula 
which is a surgical connection between an artery and a vein to achieve a suitable access 
point or iii) an arteriovenous graft which is a biocompatible tube surgically connected 
between an artery and a vein. The patients’ blood will pass the dialyser, which consists of 
numerous hollow fiber membranes, and ultrafiltration processes occur. During dialysis, 
small waste products will be removed from the blood into the dialysis waste fluid and 
the filtered blood will return to the patient. In general, hemodialysis is performed three 
times a week and four hours per session, often in a dialysis center or hospital. 
14
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The clinical impact of uremic toxins
Over the last years, knowledge on the role of accumulated waste products 
in the pathophysiology of kidney (-related) disease has greatly expanded. 
Retention solutes that interact negatively with biological systems are called 
uremic toxins. Dietary protein breakdown is a classical source of uremic toxin 
generation, as well as more alternative sources such as environmental factors. 
In addition, elevated levels of native molecules such as β2-microglobulin 
or parathyroid hormone are classified as uremic toxins as they modify 
physiological processes (10). Uremic toxins can be divided in three classes, 
based on their chemical properties that affect the clearance capacity during 
dialysis. Class 1 consists of small water-soluble solutes (MW <500 Da) such 
as urea, which can be easily removed using dialysis. Class 2 contains the 
middle molecules (MW >500 Da) such as β2-microglobulin, which can only 
be cleared using large-pore dialyzer membranes. Class 3 is composed of the 
protein-bound uremic toxins such as the tryptophan end-metabolites indoxyl 
sulfate (figure 1.2) or kynurenic acid. In general, the latter solutes have a MW 
<500 Da but are difficult to remove by dialysis as they are bound to plasma 
proteins which greatly extents their MW (23). The European Uremic Toxin Work 
Group (http://www.uremic-toxins.org/) is one of the leading international 
workgroups performing uremic toxin-related research. The EUTox workgroup 
identified over 100 uremic toxins and developed a web-based database to 
provide and collect knowledge on the pathologies associated with many of 
these solutes in CKD (www.uremic-toxins.org/DataBase, 9, 23, 24). For example, 
elevated plasma levels of cationic metabolites, such as guanidines derived 
from the arginine metabolism, were found to exert pro-inflammatory effects 
on the expression of leukocyte surface molecules and showed the possible 
interference of leukocytes with endothelial cells resulting in cardiovascular 
events (18, 25). In addition, anionic tryptophan and tyrosine end-metabolites, 
indoxyl sulfate, p-cresyl sulfate and p-cresyl glucuronide, associated also 
with cardiovascular disease via leucocyte activation and endothelial damage 
(19, 26). Moreover, elevated tryptophan-derived kynurenic acid levels might 
initiate neurological disorders, lipid metabolism disorder and anemia (17). 
Moreover, these anionic as well as cationic uremic toxins showed to interfere 
with renal drug handling. For example the renal clearance of the histamine 
H2-receptor antagonist, cimetidine, was found to be compromised (27-29). It 
was suggested that in uremia, various toxins directly or competitively inhibit 
in- and efflux transporters and drug-metabolism enzymes present in PTEC 
(30, 31), hence, contributing to CKD progression. 
15
1The current status of bioartificial kidney engineering
During the last decades hemodialysis treatment, pioneered by Dr. Kolff in 
the 1940’s (32), has not been successfully modified to significantly improve 
waste product removal. To date, dialysis remains the only treatment option 
to partially replace kidney function. The development of an extracorporeal 
bioarticial kidney (BAK) device containing human PTEC to aid uremic 
toxin removal could be a promising new platform. PTEC are equipped with 
drug transporters to facilitate transepithelial transport of protein-bound 
endo- and xeno-biotics from the blood compartment into the lumen. At the 
basolateral membrane, organic anion transporter 1 and -3 (OAT1/3) mediate 
the uptake of anionic solutes, like indoxyl sulfate and multi drug resistance 
protein 2 and -4 (MRP2; MRP4) and Breast Cancer Resistance Protein (BCRP) 
facilitate their efflux (4, 33). For organic cations, organic cation transporter 
2 (OCT2) mediates their uptake, and the Multidrug and Toxin Extrusion 
proteins MATE1 and MATE2K as well as P-glycoprotein (P-gp) and BCRP may 
be responsible for their luminal excretion (4, 33). In principle, implementing 
PTEC in an extracorporeal dialysis device containing numerous hollow fiber 
membranes could enhance uremic toxin removal and consequently reduce 
uremia and its associated complications in CKD patients (33). In the late 
80’s of last century, the first BAK device was initiated by Aebischer et al., in 
which PTECs derived from animal sources where cultured on hollow fiber 
membranes (34). Several years later, Humes et al. developed a multifiber 
bioreactor containing porcine cells that showed transport of electrolytes, 
glucose, para-amminohippurate and, moreover, where metabolically active 
(35). Nowadays, it is known that animal-derived cell models, such as the 
frequently used dog- and porcine-derived, MDCK and LLC-PK1, respectively, 
lack many of the required proteins to support uremic toxins secretion via a 
BAK device (33). In addition, the application of non-human cell sources to 
treat human subjects is not preferable; therefore, many BAK studies using 
primary human PTEC were performed (36-39). Nowadays, the differentiation 
of stem cells into renal lineages is a promising platform to aid autologous BAK 
engineering. Hence, in depth research is required to unravel differentiation 
processes towards kidney-like cells and its associated cellular function prior 
to BAK implementation (40-42). The main focus in the majority of recently 
published BAK studies was to investigate the immunomodulatory effects in 
patients suffering from AKI (36, 38). Initially, promising results were obtained 
in phase I and II clinical trials, in which critically ill patients showed reduced 
cytokine levels and long-term survival improvement compared to the non-
treated group. Unfortunately, a clinical phase IIb trial failed due to difficulties 
16
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1Figure 1.2 Biosynthesis of indoxyl sulfate.The dietery amino acid L-tryptophan is converted into indole in the gut lumen by 
the bacterial enzyme L-tryptophanase. Next, indole will enter the liver via the portal 
venous system and will be oxidized by cytochrome P450 2E1 (CYP2E1) into indoxyl. 
Subsequently, indoxyl will be sulfanized (SULTs: sulfotransferases) into indoxyl sulfate 
and the protein-bound end-metabolite will be removed from the systemic circulation 
into the pro-urine via active transport in the proximal segment of the kidneys. 
* = human serum albumin
18
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in the manufacturing process of the BAK and the study design (43). Therefore, 
alternative platforms should be investigated which require well characterized 
cell models in combination with appropriate biomaterials to support cellular 
maintenance.
 
OUTLINE OF THE THESIS 
The aim of this thesis was to develop new therapeutic interventions for 
patients suffering from renal insufficiency, as current treatment modalities 
lack the ability to replace or ameliorate kidney function. Acute and chronic 
kidney diseases have major adverse effects on many biological systems in 
the human body and contribute to high morbidity and mortality rates. 
Appropriate therapeutic platforms to aid renal function could finally result 
in improved quality of life for patients and reduced mortality. In Chapter 2 
we describe the successful development of conditionally immortalized PTEC 
(ciPTEC) models isolated from human kidney tissue. The newly established 
models were thoroughly characterized and compared with the ciPTEC 
model isolated from urine, as cells exfoliated in urine are often thought to 
be partly dedifferentiated. Using genetic, protein and functional approaches, 
physiological characteristics of these models were investigated in detail and 
their potency to aid BAK engineering was evaluated. In Chapter 3 we show 
the molecular mechanism of dexamethasone treatment as a possible new 
therapeutic intervention to reduce AKI-mediated PTEC injury. We unravelled 
the effects of dexamethasone on mitochondrial metabolism in an experimental 
inflammatory condition by analyzing various mitochondrial markers like 
reactive oxygen species (ROS), mitochondrial membrane potential, oxygen 
consumption, oxidative phosphorylation system (OXPHOS) complex activity 
but also mitochondrial mass, protein expression of OXPHOS complexes and 
cellular pH levels. In Chapter 4 the current knowledge of bioengineering in 
the field of regenerative nephrology is described. In this review, a historical 
overview of bioartificial kidney development and the current state-of-the-art, 
including implementation of bioengineered membranes and the relevance of 
extracellular matrices was described. Next, the use of relevant renal epithelial 
cell lines versus the use of stem cells that need to be implemented in a suitable 
device are discussed. Moreover, the future of regenerative nephrology is being 
discussed including synthetic biotechnology approaches to improve the BAK. 
In Chapter 5, the development of a living membrane by culturing ciPTEC on 
polyethersulfone (PES)-based biofunctionalized 2D membranes is shown. In 
19
1this study, the coating was optimized to preserve high membrane permeance 
and to obtain optimal culture conditions on PES biomaterials. The properties 
of creatinine transport in tight epithelial cell monolayers on biofunctionalized 
PES membranes were studied and compared to a commercially available culture 
insert system. Chapter 6 describes the next step towards BAK engineering. 
The coating, as applied in 2D biofunctionalized PES membranes, was 
optimized for 3D hollow fiber membrane (HFM) approaches and membrane 
properties were studied. Again, the coating appeared to be crucial to develop 
a successful bioartificial renal tubule containing a tight cell monolayer. 
As a first step in uremic solute transport, the active uptake of a known 
fluorescent OCT2 substrate in bioartificial renal tubules was investigated in 
real-time using a tailor made flow system. In the final experimental part of 
this thesis, Chapter 7, the transepithelial clearance of protein-bound anionic 
uremic toxins in bioartifical renal tubules was studied. First, the handling of 
anionic uremic toxins was investigated in flat monolayers and the pivotal 
role of in- and efflux transporters was demonstrated. Next, the properties 
of ciPTEC monolayers on biofunctionalized polyethersulfone hollow fiber 
membranes with respect to epithelial barrier function was studied. Finally, the 
transepithelial transport of protein-bound indoxyl sulfate and kynurenic acid 
in bioartifical renal tubules was investigated in real-time using a similar flow 
system as described in chapter 6. A general discussion in the context of the 
current knowledge regarding bioartificial kidney engineering accompanied by 
future perspectives is presented in Chapter 8, followed by a summary of this 
thesis in Chapter 9. 
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ABSTRACT
Promising renal replacement therapies include the development of a 
bioartificial kidney using functional human kidney cell models. In this 
study, human conditionally immortalized proximal tubular epithelial cell 
(ciPTEC) lines originating from kidney tissue (ciPTEC-T1 and ciPTEC-T2) were 
compared to ciPTEC previously isolated from urine (ciPTEC-U). 
Subclones of all ciPTEC isolates formed tight cell layers on Transwell inserts 
as determined by transepithelial resistance, inulin diffusion, E-cadherin 
expression and immunocytochemistry. Extracellular matrix genes collagen I 
and -IV α1 were highly present in both kidney tissue derived matured cell 
lines (p<0.001) compared to matured ciPTEC-U, whereas matured ciPTEC-U 
showed a more pronounced fibronectin I and laminin 5 gene expression 
(p<0.01 and p<0.05, respectively). Expression of the influx carrier Organic 
Cation Transporter 2 (OCT2), and the efflux pumps P-glycoprotein (P-
gp), Multidrug Resistance Protein 4 (MRP4) and Breast Cancer Resistance 
Protein (BCRP) were confirmed in the three cell lines using real-time PCR and 
Western blotting. The activities of OCT2 and P-gp were sensitive to specific 
inhibition in all models (p<0.001). The highest activity of MRP4 and BCRP was 
demonstrated in ciPTEC-U (p<0.05). Finally, active albumin reabsorption was 
highest in ciPTEC-T2 (p<0.001), while Na+-dependent phosphate reabsorption 
was most abundant in ciPTEC-U (p<0.01). 
In conclusion, ciPTEC established from human urine or kidney tissue 
display comparable functional PTEC specific transporters and physiological 
characteristics, providing ideal human tools for bioartificial kidney development.
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INTRODUCTION
Worldwide, about 2 million people suffering from renal disorders are treated 
with hemo- or peritoneal dialysis and this number still increases. Main factors 
contributing to this increase are aging, an increased incidence of diabetes 
mellitus and hypertension (1-3). Known limitations of the current dialysis 
methods as treatment modalities are related to the relatively poor clearance 
of protein-bound uremic retention solutes (4). Up to now, a large number 
of compounds have been classified as uremic retention solutes (5) and their 
accumulation may have severe clinical implications, such as renal fibrosis, 
bone disorders, cardiovascular disease and mental disorders (6). The preferred 
treatment of patients with end-stage renal disease (ESRD) is transplantation 
(7), which improves their quality of life and substantially reduces costs 
associated with extended dialysis (8). However, tremendous shortages of 
donor organs as well as complications arising from immunosuppressive 
treatment and organ rejection after transplantation are profound problems 
worldwide (9-11). 
To replace kidney function, tissue engineering is a promising avenue of 
research to overcome the limitations of currently available renal replacement 
therapies (12). The development of functional and stable human renal 
epithelial cell models that are able to actively excrete uremic retention solutes, 
is a promising step towards a bioartificial kidney device. In the kidney, a 
heterogeneous cell system is present of which the proximal tubular epithelial 
cells (PTEC) play an important role in the excretion of endo- and xenobiotics, 
including uremic retention solutes. The excretory pathway is mediated via 
a complex interplay involving solute carriers, like OCT2 (SLC22A2), OAT3 
(SLC22A6) and OAT3 (SLC22A8) (13), and ATP-binding cassette efflux pumps, 
such as p-glycoprotein; P-gp (ABCB1), MRP4 (ABCC4) and BCRP (ABCG2) 
(14). Besides waste product excretion, reabsorption of filtered solutes, such as 
phosphate, glucose, urate and albumin, occurs in PTEC (15-18). 
In our group, a stable PTEC cell line isolated from human urine was developed 
(ciPTEC-U) (19). This cell line demonstrated functional characteristics of 
important in- and efflux transporters as well as active albumin and sodium-
dependent phosphate transport (19), has proven to be valuable in elucidating 
renal pathological mechanisms (20-23) and in studying renal physiological 
transport pathways (24,25). However, as this cell line originates from urine, it 
could be argued that ciPTEC-U might not reflect the physiological situation 
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as close as cells directly derived from kidney tissue. Cells originating from 
urine are often thought to be exfoliated from tissue due to apoptosis-
induced loss of function (26). Recently it was shown that overcrowding of 
epithelial cells due to proliferation and migration, induces the extrusion 
of living cells to maintain homeostasis in epithelial cell numbers (27). The 
aim of this study was to compare ciPTEC-U (19) with newly established 
human proximal tubular epithelial cell lines from human kidney tissue with 
respect to important functional properties. Human PTEC were isolated 
from nephrectomized kidneys followed by subcloning and immortalization 
techniques. Characterizing the newly established human proximal tubular 
epithelial cell lines will allow us to determine whether the sample source 
influences renal functional properties of cell lines in culture. Insights in 
these characteristics allows to identify the most suitable cell line for further 
development of a bioartificial kidney device. 
MATERIALS AND METHODS
Chemicals and cell culture materials
All chemicals were purchased from Sigma-Aldrich (Zwijndrecht, The 
Netherlands) unless stated otherwise. Cell culture plates were purchased 
from Greiner Bio-One (Monroe, NC) and Transwell inserts were obtained 
from Corning Costar (cat. no 3460, New York, NY).
Ethics statement
The kidney tissue used for cell line development in this study was obtained 
from non-transplanted donors, after given informed consent. These organs 
could not be transplanted due to quality loss of the veins during surgery. No 
clinical history of renal disorders or any other chronic disease was identified. 
Isolation and culture of ciPTEC from kidney tissue
Purification and isolation of renal epithelial cells from kidney tissue was 
performed as described previously (28). In short, epithelial cells were isolated 
by a gradient sieving procedure and subjected to collagenase digestion (29). 
The collected primary fraction was transferred to supplemented PTEC culture 
media: phenol-red free DMEM-HAM’s F12 medium (catalogue number 11039, 
Lonza, Basel, Switzerland) containing 10% (v/v) FCS (Greiner Bio-One, 
Monroe, NC), 5 mg/ml insulin, 5 mg/ml transferrin, 5 ng/ml selenium, 36 ng/
ml hydrocortisone, 10 ng/ml EGF and 40 pg/ml tri-iodothyronine. Primary 
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cells were immortalized within the first two passages. Immortalization was 
performed using a combination of hTERT and SV40t as described previously 
(19,30). To obtain a homogeneous culture, cells were subcloned using 
irradiated NIH 3T3 fibroblast as non-dividing feeder cells (30). After culturing 
for 2 weeks at 33°C, 5% (v/v) CO2, single cell clones were visible and picked 
using cloning discs drained in trypsin-EDTA (MP Biomedicals, Solon, OH). 
Single cell clones were transferred to a well plate and grown until confluent 
at 33°C, 5% (v/v) CO2. Optimal seeding conditions were determined for each 
obtained ciPTEC line in well plates and Transwell inserts (50 µg/ml collagen 
IV coating for ciPTEC-U (C6745-1ml) by testing morphological characteristics 
and monolayer integrity properties using a cell density range (data not shown). 
According to the conditions described previously (19), ciPTEC were cultured 
for 24 h at 33°C 5% (v/v) CO2 to proliferate and subsequently transferred to 
37°C, 5% (v/v) CO2 for 7 days to mature. Up to at least 40 cell passage numbers 
were used to investigate proliferation and functional properties following 
prolonged culturing. Phase contrast images were captured using a Leica DM 
IL phase contrast microscope.
Immunocytochemistry
To investigate morphology and polarization characteristics of the ciPTEC 
monolayers, immunocytochemistry was performed using cells cultured 
on polyester Transwell inserts. Matured ciPTEC were fixed using 2% (w/v) 
paraformaldehyde in HBSS supplemented with 2% (w/v) sucrose for 5 min 
and permeabilized in 0.3% (v/v) triton X-100 in HBSS for 10 min. To prevent 
non-specific binding of antibodies, cells were exposed to block solution 
containing 2% (w/v) bovine serum albumin fraction V (Roche, Woerden, 
The Netherlands) and 0.1% (v/v) tween-20 in HBSS for 30 min. Cells were 
incubated with antibodies diluted in block solution against the tight junction 
protein zonula occludens 1 (ZO-1, 1:50 dilution, Invitrogen, Carlsbad, CA) for 
1 h, followed by incubation with goat-anti-rabbit-Alexa488 conjugate (1:200, 
Life Technologies Europe BV, Bleiswijk, The Netherlands) for 30 min. Finally, 
DAPI nuclei staining (300 nM, Life Technologies Europe BV) was performed for 
5 min. Protein expression and localization were examined using the Olympus 
FV1000 Confocal Laser Scanning Microscope (Olympus, Tokyo, Japan) 
and images were captured using the Olympus software FV10-ASW version 
1.7. Next, cell size measurements were performed using Image J software 
(version 1.40g). 
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Transepithelial barrier functions
Transepithelial resistance of matured ciPTEC monolayers on Transwell 
inserts was measured using the Millicell electrical resistance volt-ohm system 
(Millipore, Billerca, MA). Measurements were performed as described in the 
manufacturer’s protocol. To determine the tightness of the ciPTEC monolayers, 
inulin-FITC (Sigma-Aldrich) diffusion was measured of matured ciPTEC 
cultured on Transwell inserts. Both apical and basolateral compartments 
were washed once with HBSS buffer (Life Technologies Europe BV), prior to 
0.1 mg/ml inulin-FITC in HBSS basolateral exposure for 1h at 37°C, 5% (v/v) 
CO2. Fluorescence was detected by measuring samples (200 µl) at excitation 
wavelength 485 nm and emission wavelength 535 nm, using a CytoFluor II 
Microplate reader (MTX Lab Systems, Vienna, VA).
To investigate monolayer development further, the presence of E-cadherin, a 
calcium-dependent cell-cell adhesion protein abundantly expressed in PTEC 
cells (31), was investigated in proliferating and matured cells. After harvesting, 
cells were fixed and permeabilized using 4% (w/v) PFA and 0.1 % (v/v) saponin 
in HBSS on ice for 10 min. After centrifuging, cell pellets were resuspended 
in rat anti-E-cadherin antibody (1:100 in HBSS) and incubated at RT for 30 
min. Next, cells were centrifuged again, pellets resuspended in goat anti-
rat Alexa 488 conjugate (1:200, Life Technologies Europe BV, Bleiswijk, The 
Netherlands) and incubated at RT for 30 min. After a final centrifuge step, 
cells were resuspended in HBSS buffer and measured using a flowcytometer 
(FACSCalibur BD, software BD CellQuest Pro version 6.0, Becton Dickinson, 
Franklin Lakes, NJ) gating on live cells (a total of 15,000 cells counted). 
Separate cell fractions were incubated solely with goat anti-rat Alexa 488 
conjugate and signal measured was set as a negative control. Next to the 
extracted geometric mean data, representative flowcytometer histograms are 
shown to illustrate signal intensities (Alexa 488/FL1 signal).
Gene expression of relevant transporters and 
extracellular matrix proteins in ciPTEC
Total RNA was isolated from proliferating and matured cells using TRIzol 
(Life Technologies Europe BV) and chloroform extraction according to 
the manufacturer’s protocol. The Omniscript RT kit (Qiagen, Venlo, The 
Netherlands) was used to synthesize cDNA. The mRNA expression levels of 
PTEC transporter genes were detected using gene specific primer-probe sets 
(Table S2.1, Applied Biosystems, CA, USA) and TaqMan Universal PCR Master 
Mix (Applied Biosystems). The quantitative PCR reactions were performed 
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using the CFX96 Real Time PCR system (Bio-Rad Laboratories, Veenendaal, 
The Netherlands) and data were analyzed using the CFX Manager software 
(Bio-Rad Laboratories). The mRNA expression levels of extracellular matrix 
(ECM) genes were investigated using primer sets (Table S2.2) and SybrGreen 
PCR Master Mix (Qiagen). The quantitative PCR reactions were performed 
using the ABI 7900HT sequence detection system (Applied Biosystems, 
Nieuwekerk a/d IJssel, The Netherlands). Data of matured cells were 
normalized to expression levels of the reference gene GAPDH, and were 
expressed as fold increase compared to matured ciPTEC-U (19). To compare 
expression levels from the proliferating towards matured stage per cell 
line, data of matured cells were expressed as fold increase compared to the 
corresponding proliferating cells (supplemental figures S2.1 and S2.2). 
Determination of proximal tubular specific transporter 
proteins 
To detect proteins of interest in proliferating and matured cells, membrane 
fractions were obtained by ultracentrifugation. Confluent cell layers cultured 
in T175 flasks were harvested and homogenized in 30 ml buffer containing 18 
mM Tris-HCL (pH 7.4), 6 mM EGTA, 0.3 M mannitol and protease inhibitors 
(100 mM phenylmethane sulphonylfluoride, 5 mg/ml aprotinin, 5 mg/ml 
leupeptin, and 5 mg/ml pepstatin). The suspension was homogenized using a 
tight fitting Dounce homogenizer (Kimble Chase LLC, Vineland, NJ) followed 
by ultracentrifugation (Sorval WX80, Thermo Fisher Scientific, Walhtam, MA) 
at 100,000 x g for 45 min at 4°C. Finally, the membrane pellets were resuspended 
in 100 µl RIPA buffer containing 1% (w/v) Igepal CA630, 0.5% (w/v) Na-
deoxycholate, 0.1% (v/v) SDS (Amersham Biosciences, NJ, USA) and protease 
inhibitors (0.01% (v/v) phenylmethane sulphonylfluoride, 3% (v/v) aprotinin 
and 1 mM sodium orthovanadate). The amount of total protein was measured 
using the Bio-Rad protein detection reagent system (Bio-Rad Laboratories). 
Protein expression of Organic Cation Transporter 2 (OCT2), P-glycoprotein 
(P-gp), Multidrug Resistance Protein 4 (MRP4) and Breast Cancer Resistance 
Protein (BCRP) was investigated by Western blotting using 12%, 6%, 6% and 
10% (w/v) sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE), respectively. The iBlot Dry Blotting System (Life Technologies Europe 
BV) was used for transferring proteins from the gels onto a nitrocellulose 
membrane. To prevent non-specific binding of antibodies, membranes were 
blocked in PBS supplemented with 0.1% (v/v) tween-20 (PBS-T) and 5% (w/v) 
milk powder (Campina, Woerden, The Netherlands) for 30 min. Subsequently, 
membranes were washed three times in PBS-T. Next, membranes were 
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incubated for 1.5 h with rabbit anti-OCT2 antibody (1:500, Alpha Diagnostic 
International, San Antonio, TX), mouse anti-P-gp antibody (1:200, Abcam, 
Cambridge, UK), rabbit anti-MRP4 antibody (1:100, M49, (32)) or mouse anti-
BCRP (1:200, Abcam®, Cambridge, UK). As a loading control mouse anti-
β-actin (1:100,000) or rabbit anti-Na, K-ATPase antibody (a-subunit, 1:2,000, 
C356-M09 (33)) was used. Subsequently, after three washing steps in PBS-T, 
membranes were exposed to secondary antibodies Alexa fluor® 680 goat 
anti-rabbit IgG (1:10,000, Life Technologies Europe BV), IRDye 800 goat anti-
mouse IgG (1:10,000, Rockland, PA) or IRDye 800 goat anti-rabbit IgG (1:10,000, 
Rockland, PA) for 1.5 h. Fluorescence was quantified using the Odyssey 
Infrared Imaging System (version 2.1, LICOR® Biosciences, Lincoln, NE). Data 
of proliferating and matured cells were normalized to protein expression 
levels of the loading control and plotted in absolute pixel intensities. 
Transport assays of renal in- and efflux proteins
The activity of the renal OCT influx proteins was measured as previously 
described by Schophuizen et al. (25). In short, harvested matured cell suspensions 
were exposed to the fluorescent OCT substrate 4-(4-(dimethylamino)styryl)-
N-methylpyridinium iodide (ASP+) in the presence or absence of 5 mM OCT 
inhibitor tetrapentylammonium chloride (TPA). Data plotted were corrected 
for cell numbers.
 
The activity of the renal efflux protein P-gp in ciPTEC was examined by 
measuring the amount of calcein accumulation (34). In short, matured cells 
were exposed to 1 µM calcein-AM (Life Technologies Europe BV) in the 
presence or absence of 5 µM P-gp inhibitor PSC833 (Tocris Biosciences, Bristol, 
UK) for 1 h at 37°C, 5% (v/v) CO2. Fluorescence in lysed cells was measured and 
data plotted were corrected for protein concentrations. 
To evaluate transport characteristics of the renal efflux transporters BCRP 
and MRP4 (32,35), ciPTEC were exposed to kynurenic acid, the end product of 
tryptophan metabolism. Kynurenic acid is a known uremic retention solute 
and a substrate for both renal efflux transporters (24,36). To investigate the 
transport properties of these proteins, cells were cultured in 24 well plates and 
matured monolayers were gently washed three times using krebs-henseleit 
buffer supplemented with 10 mM Hepes (pH 7.4, adjusted with Tris-HCl). 
Subsequently, cells were pre-incubated with supplemented krebs-henseleit 
buffer in the presence or absence of 5 µM KO143, a known BCRP inhibitor (37), 
and 5 µM MK 571 a known MRP inhibitor (38) (Alexis Biochemicals, Leiden, 
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The Netherlands) at 37°C, 5% (v/v) CO2 for 2 h. After pre-incubation, cells 
were exposed to 10 µM 3H-kynurenic acid (Scopus Research BV, Wageningen, 
The Netherlands) at 37°C for 2 h. The uptake was terminated by washing 
the cells 3 times with ice-cold supplemented krebs-henseleit buffer. Cells 
were lysed using 0.1% (v/v) triton X-100. To each sample 2 ml of scintillation 
liquid was added and radioactivity was detected using liquid scintillation 
counting. Counts measured in supplemented krebs-henseleit buffer (blank) 
were subtracted and data plotted were corrected for protein concentrations.
Albumin and phosphate uptake assays 
To investigate albumin uptake mediated by endocytosis, matured ciPTEC were 
exposed to serum free medium for 4 h at 37°C, 5% (v/v) CO2. Subsequently, cells 
were exposed to 50 µg/ml BSA-FITC and incubated at 37°C, 5% (v/v) CO2 for 
30 min. In addition, experiments were performed at 4°C to inhibit endocytosis. 
After the incubation period, cells were harvested and centrifuged at 1,500 x 
g for 5 min. The cell pellet was resuspended in 4% (w/v) paraformaldehyde 
in PBS. Finally, intracellular albumin was measured using a flowcytometer 
(FACSCalibur BD, software BD CellQuest Pro version 6.0, Becton Dickinson, 
Franklin Lakes, NJ) gating on live cells (15,000 cells counted). Data was 
analyzed using FlowJo software (version 9.2) and relative net uptake data was 
plotted next to the actual flowcytometer histograms. 
Phosphate uptake was performed in confluent monolayers cultured at 33°C 
and 37°C, 5% (v/v) CO2 with 32PO4 (Perkin Elmer, Waltham, MA) as described 
earlier by Malmstrom et al. (19,39). Cells were cultured in 24 well plates and 
gently washed three times using wash buffer (20 mM Hepes, 5.6 mM CaCl2, 
10.8 mM KCl, 2.4 mM MgCl2, 274 mM NaCl) at 37°C. To determine the sodium- 
dependent uptake of phosphate, experiments were performed in the absence 
of sodium by replacing NaCl with 274 mM N-methyl-D-glucamine. The uptake 
buffer was added for 5 min at 37°C consisting of wash buffer, supplemented 
with 0.22 mM phosphate with 1.0 µCi/mL 32PO4 added as tracer. The uptake 
was terminated by washing the cells five times with ice-cold wash buffer. Cells 
were lysed using 0.5 ml 0.05 M Na+-deoxycholate in 0.1 M NaOH. To each 
sample 2 ml of scintillation liquid was added and radioactivity was detected 
using liquid scintillation counting. Counts measured in wash buffer (blank) 
were subtracted and data plotted were corrected for protein concentrations.
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Data analysis
All data are expressed as mean ± SEM Statistical analysis was performed 
using one-way ANOVA analysis followed by Dunnett’s Multiple Comparison 
test or, where appropriate, an unpaired t test with GraphPad Prism version 
5.02 (La Jolla, CA). A p-value of <0.05 was considered significant. 
RESULTS
Successful development of ciPTEC lines from human 
kidney tissue isolates
To appreciate the functional capacity of ciPTEC-U (19), new PTEC cell lines 
were generated from human kidney tissue and characterized to compare 
with ciPTEC-U. PTEC isolates were obtained from three different kidney 
donors and primary cells were grown successfully. All cell cultures that were 
immortalized using SV40t and hTERT, were found resistant to both hygromycin 
B and geneticin (G418) thereby confirming successful transduction. Next, cells 
were subcloned to obtain homogenous cell lines after which cell proliferation 
could be maintained for up to at least cell passage 42 without morphological 
changes. From the original three kidney isolates, different subclones were 
obtained. Based on mRNA expression levels of PTEC transporters, morphology 
and monolayer tightness, two out of twenty six kidney subclones were selected 
(ciPTEC-T1 and -T2) for detailed characterization. The ciPTEC-T1 and -T2 
originated from the same donor and were compared in great detail with 
ciPTEC-U (19). Figure 2.1a represents a flow chart of the isolation and selection 
procedure performed in this study. Representative phase contrast images of 
the selected clones ciPTEC-T1 and -T2 are shown in Figure 2.1b. Transduction 
of kidney tissue derived cultures with hTERT solely did not result in suitable 
cell lines as determined by morphology and cell proliferation (data not shown).
Morphological characteristics and extracellular matrix 
investigation
Optimal seeding conditions to obtain confluent layers of ciPTEC in well plates 
and Transwell inserts were determined as indicated in table 2.1. A collagen IV 
coating of 50 µg/ml stimulated the development of a homogeneous tight layer 
of ciPTEC-U on Transwell inserts. Interestingly, no coating was necessary for 
ciPTEC-T1 and -T2 to develop a homogeneous cell monolayer on the inserts 
(Figure 2.2a - c). In well plates, confluent ciPTEC monolayers were obtained 
without any additional coatings. 
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Figure 2.1a Flow chart of clone selection. 
Schematic overview of the cell isolation process from kidney tissue upon establishment 
of clonal cell lines. Cells were isolated from three donors and 26 subclones were selected 
in a first round. These subclones were characterized morphologically, but also gene 
expression levels of PTEC specific transporters were investigated. Transduction of 
kidney tissue derived cultures with hTERT solely did not result in suitable cell lines 
as determined by morphology and cell proliferation. Finally, two clones from the 
same donor obtained after combined SV40 and hTERT transductions were chosen for 
detailed characterization (ciPTEC-T1 and -T2), based on PTEC specific morphological 
characteristics and highest gene expression levels of PTEC transporters. 
Figure 2.1b Representative phase contrast images of ciPTEC. 
Proliferating (33°C, 5% (v/v) CO2) and fully matured (7 days at 37°C, 5% (v/v) CO2) 
ciPTEC-U passage 40 (I), -T1 passage 38 (II), and -T2 passage 42 (III) are shown. 
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The tight junction protein zonula occludens-1 (ZO-1) in PTEC is a marker 
for the integrity and polarity of the cell layer. Furthermore, tight junctions 
contain interacting proteins that regulate differentiation, proliferation and 
gene expression, indicating an important role in PTEC functionality (40). 
Cells cultured on Transwell inserts, were stained against ZO-1 and the protein 
expression was examined using confocal microscopy. A clear ZO-1 expression 
was visible for all three cell lines (Figure 2.2a - c). A z-scan depicts the 
fluorescent signal of tight junction expression at the cell boundaries in each 
ciPTEC model, but most abundantly in ciPTEC-U, and confirms polarization 
of the cells. Next to this, we determined cell diameter and observed a larger 
span for matured ciPTEC-T1 (19.4 µm ± 0.8, p<0.001; Figure 2.2b) and -T2 
(21.7 µm ± 0.6, p<0.001; Figure 2.2c) as compared to matured ciPTEC-U (10.9 µm 
± 0.6; Figure 2.2a). Both ciPTEC cell lines isolated from kidney tissue showed 
a larger span compared to ciPTEC-U when cultured in similar uncoated cell 
culture flasks, at both temperatures (Figure 2.1b). This indicates that cell size 
differences were not influenced by a collagen IV coating but may possibly 
source related. 
Cell monolayer tightness was examined further by determination of the 
paracellular permeability of the cell monolayers using the diffusion marker 
inulin (41). CiPTEC cultured on Transwell inserts were basolaterally exposed to 
FITC-inulin. No differences were observed in inulin flux between the ciPTEC-U 
versus kidney tissue derived cell lines, as shown in table 2.2. Furthermore, the 
epithelial barrier integrity was investigated by measuring the transepithelial 
electric resistance (TEER). Cell lines were cultured on Transwell inserts and 
the TEER was measured in matured cells (Table 2.2). CiPTEC-T1 demonstrated 
a higher resistance (140 ± 4 Ω/cm2, p<0.05) as compared to ciPTEC-U 
(124 ± 3 Ω/cm2), whereas no significant differences were observed between 
ciPTEC-T2 (126 ± 4 Ω/cm2) and ciPTEC-U.
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Figure 2.2 Expression of ZO-1 protein in ciPTEC. 
Representative confocal images of ZO-1 (green) in x-y and y-z planes are shown (nuclei 
are stained with DAPI (blue)) in matured (37°C) ciPTEC cultured on Transwell inserts. 
(a-c) The expression of ZO-1 (green fluorescent) was determined at the cell boundaries 
and was most abundantly present in ciPTEC-U (a). Furthermore, the average cell 
diameter was measured, demonstrating a significantly larger cell size of ciPTEC-T1 
and -T2 as compared to ciPTEC-U. Note: ciPTEC-U were cultured on collagen IV coated 
surfaces, whereas ciPTEC-T1 and -T2 were cultured on uncoated Transwell inserts. 
*** = p<0.001, using one-way ANOVA analysis followed by Dunnett’s multiple 
comparison test. 
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Cell line Well plates seeding density
(cells. cm-2)
Transwell inserts seeding density 
(cells. cm-2)
ciPTEC-U 4.8 x 104 1.3 x 105
ciPTEC-T1 1.9 x 104 0.60 x 105
ciPTEC-T2 1.9 x 104 0.60 x 105
Cell line Inulin diffusion (pmol. min-1. cm-2) TEER (Ω/cm2)
ciPTEC-U 9.3 ± 0.4 124 ± 3
ciPTEC-T1 8.0 ± 0.7 140 ± 4*
ciPTEC-T2 9.2 ± 0.5 126 ± 4
ciPTEC cultured at indicated densities resulted in tight monolayer formation upon 
7 days maturation.
Table 2.1 Optimal ciPTEC seeding density in well plates and Transwell inserts 
Table 2.2 Transepithelial barrier functions of ciPTEC
Monolayer integrity was measured using inulin flux and transepithelial electric resis-
tance determination. * = p<0.05, using one-way ANOVA analysis followed by Dunnett’s 
multiple comparison test. Data presented are means of three independent experiments 
and expressed as mean ± SEM.
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Figure 2.3 E-cadherin expression in 
proliferating and matured ciPTEC. 
(a-c) Representative E-cadherin flowcyto-
meter histograms (FL1/Alexa 488 signal – 
Log scale) were shown in the upper panel 
of proliferating (light gray histogram) and 
matured (dark gray histogram) cells in 
the tested models. As a negative control 
(black histogram) ciPTEC were treated 
according to the protocol but the first 
antibody incubation step was excluded. (b 
; lower panel) Upon maturation (black bar), 
ciPTEC-T1 showed a higher geometric mean 
as compared to proliferating ciPTEC-T1 
(white bar). (a - c; upper panel) Nevertheless, 
upon maturation all models clearly showed 
a more heterogeneous population regarding 
E-cadherin expression compared to proli-
ferating cells. Data are shown as mean 
± SEM of three independent experiments. 
* = p<0.05 using an unpaired t test. 
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The cell-cell adhesion protein E-cadherin was clearly present in the models 
tested (Figure 2.3) in proliferating (light gray histogram) as well as in 
matured (dark gray histogram) ciPTEC compared to the negative control 
(black histogram), emphasizing the abundant epithelial characteristics of 
these models. Interestingly, matured ciPTEC showed a more heterogeneous 
population compared to proliferating ciPTEC. Based on geometric mean 
data extracted from these histograms, matured ciPTEC-T1 only showed a 
more abundant prevalence of E-cadherin when compared to proliferating 
ciPTEC-T1. 
To gain more insight in complexes involved in cell development (42,43), the 
presence of ECM genes was investigated. The mRNA expression levels of 
collagen I and –IV αI, fibronectin I and laminin 5 (LAMA5; alpha-5 subunit 
of laminin-10, -11 and -15) were detected in matured ciPTEC-U, -T1 and -T2. 
Interestingly, significant differences were observed between the cell lines. In 
matured ciPTEC-T1 and -T2 a higher expression of collagen I - and IV αI (Figure 
2.4a and b, p<0.001) was observed compared to matured ciPTEC-U. Whereas 
fibronectin I and laminin 5 expression was lower in matured kidney tissue 
derived cell lines (fibronectin I ciPTEC-T1 and -T2: p<0.01, laminin 5 ciPTEC-T2: 
p<0.05, ciPTEC-T1: not significant) compared to ciPTEC-U. In supplemental 
figure S2.1, mRNA expression levels of these genes in proliferating versus 
matured cells are shown. Matured tissue derived cell lines showed an increased 
collagen I αI (supplemental figure S2.1a; p<0.001), fibronectin I (supplemental 
figure S2.1c; p<0.001) and laminin 5 (supplemental figure S2.1d; p<0.05) gene 
expression, whereas matured ciPTEC-U showed a less pronounced genetic 
ECM profile. Interestingly, collagen IV αI (supplemental figure S2.1b) gene 
expression upon maturation was lower (p<0.001) in each cell line compared 
to proliferating cells.
Gene and protein expression levels of PTEC specific 
transporters 
The excretion of endo- and xenobiotics in the proximal tubular system is 
mediated via various important in- and efflux transporters like OCT2, P-gp, 
MRP4 and BCRP (13,14). The presence of these PTEC specific transporters 
was investigated on gene and protein level in matured ciPTEC-U, -T1 and 
-T2. The mRNA expression levels of most transporters (Figure 2.5) were 
comparable between the three matured cell lines, except for OCT2 in 
ciPTEC-T1 (p<0.05) and BCRP in ciPTEC-T2 (p<0.05) which showed a higher 
expression as compared to matured ciPTEC-U. In supplemental figure S2.2, 
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mRNA expression levels of these genes in proliferating versus matured cells 
are shown. Each matured cell line showed an increased OCT2 gene expression 
(supplemental figure S2.2a; ciPTEC-U and -T1 p<0.05, ciPTEC-T2 p<0.001), 
whereas P-gp (supplemental figure S2.2b) and MRP4 (supplemental figure 
S2.2c) gene expressions were more abundantly only in matured tissue-derived 
cell lines (P-gp ciPTEC-T1 p<0.01, ciPTEC-T2 p<0.05; MRP4 ciPTEC-T2 p<0.01). 
Although not significant, the gene expression of BCRP (supplemental figure 
S2.2d) showed less expression upon maturation in each cell line.
Figure 2.4 Expression of extracellular matrix genes in matured ciPTEC models. 
(a and b) Both cell lines derived from kidney tissue showed a higher gene expression 
of collagen I α1 (a) and –IV α1 (b) compared to ciPTEC-U. (c) In ciPTEC-T1 and -T2, 
a lower gene expression of fibronectin I was observed compared to ciPTEC-U. (d) In 
ciPTEC-T2, a lower gene expression of laminin 5 was observed compared to ciPTEC-U. 
Expression levels were corrected for corresponding GAPDH mRNA levels and data are 
expressed as fold change and compared to ciPTEC-U. Data are presented as means of 
three independent experiments ± SEM * = p<0.05, ** = p<0.01, ***= p<0.001, using an 
ANOVA analysis followed by Dunnett’s multiple comparison test.
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Figure 2.5 Expression of proximal tubular specific transporters in matured ciPTEC 
models. 
(a) In ciPTEC-T1 a higher observed compared to ciPTEC-U. Expression levels were 
corrected for corresponding GAPDH mRNA levels and data were expressed as fold 
change and compared to ciPTEC-U. Data are presented as means of three independent 
experiments ± SEM * = p<0.05, ** = p<0.01, using an ANOVA analysis followed by 
Dunnett’s multiple comparison test.OCT2 gene expression was observed compared 
to ciPTEC-U. (b and c) No significant differences in P-gp (b) and MRP4 (c) gene 
expressions were observed between the three cell lines. (d) In ciPTEC-T2 a higher BCRP 
gene expression was. 
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Figure 2.6 Protein expression of OCT2, P-gp, MRP4 and BCRP in membrane 
fractions of ciPTEC-U, -T1 and -T2. 
(a - d) Although not significant, all matured (black bars) ciPTEC showed a slight increased 
OCT2 (a), P-gp (b), MRP4 (c) and BCRP (d) expression compared to proliferating (white 
bars) ciPTEC. Signal intensities were corrected for the corresponding reference protein, 
which was used as a loading control and expression was analyzed semi-quantitative 
by measuring pixel intensity. Note that due to Western blot conditions Na,K-ATPase 
appears in multiple bands (b and c). Hence, for semi-quantification the intensity 
between 100 - 120 kDa was used as a reference. To semi-quantify the OCT2 expression, 
β-actin was used as a reference protein since the molecular mass of β-actin (42 kDa) 
is more within the mass range of OCT2 (60kDa) than Na, K-ATPase (112 kDa). The 
blots presented are representative for protein expression in the ciPTEC models. Data 
are presented as means of three independent experiments ± S.E.M and statistical 
analysis was performed using an ANOVA analysis followed by Dunnett’s multiple 
comparison test.
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In fully differentiated cells, a non-significant but recurrent trend in abundance 
of transport protein expression was observed, which points towards a 
somewhat higher expression of the investigated transporters as compared 
to the corresponding proliferating cells (Figure 2.6). The expression levels 
between the different cell lines in their proliferating or matured state was not 
significantly different. 
Functional transport in ciPTEC
To functionally characterize OCTs, we used a recently established assay based 
on the uptake of the fluorescent marker substrate ASP+ in ciPTEC suspensions 
(25) . All three cell lines showed a clear ASP+ uptake, which was sensitive to 
inhibition by TPA (p<0.001), indicating active OCTs present in each ciPTEC 
model (Figure 2.7a). To compare the activity between the cell lines, the net ASP+ 
uptake was calculated, which was higher in ciPTEC-U (80 ± 8 RFU/1,000 cells) 
compared to ciPTEC-T1 (53 ± 2 RFU/1,000 cells; p<0.05), whereas no difference 
was observed between ciPTEC-U and -T2 (net transport 71 ± 5 RFU/1,000 cells).
The functional expression of P-gp was examined by measuring intracellular 
accumulation of calcein in matured cells, as described earlier (34). The inhibitor 
PSC833 was used to obtain accumulated intracellular fluorescent signals due to 
P-gp inhibition (Figure 2.7b). An increased accumulation was determined in all 
ciPTEC cell lines (p<0.001), indicating functional P-gp present in each ciPTEC 
model. To compare the activity between the cell lines, the net calcein fluorescence 
was determined and a clearly higher calcein accumulation was observed 
in both cell lines established from kidney tissue (ciPTEC-T1 7.3 ± 0.6 RFU x 
103.mg protein-1.cm-2; p<0.01 and ciPTEC-T2 7.2 ± 0.4 RFU x 103.mg protein-1. 
cm-2; p<0.05) compared to ciPTEC-U (5.3 ± 0.4 RFU x 103.mg protein-1.cm-2).
The functional properties of BCRP and MRP4 were investigated by exposing 
matured ciPTEC models to kynurenic acid (Figure 2.7c). The compounds 
MK571 in combination with KO143 were used as MRP4 and BCRP inhibitors, 
respectively (37,38). A higher accumulation was observed in ciPTEC-U in the 
presence of inhibitors (p<0.05). In both tissue derived cell lines, kynurenic 
acid accumulation was slightly increased in presence of the inhibitors but 
this effect was not significant. To investigate and compare the BCRP and 
MRP4 properties between matured ciPTEC models, the net accumulation of 
kynurenic acid was calculated and compared to ciPTEC-U (1.1 ± 0.4 pmol.mg 
protein-1.cm-2), but no differences were observed (ciPTEC-T1 0.7 ± 0.6 pmol.mg 
protein-1.cm-2, ciPTEC-T2 0.9 ± 0.3 pmol.mg protein-1.cm-2). 
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Figure 2.7 Functional in- and efflux proteins in matured ciPTEC.
(a) OCT2 mediated ASP+ uptake was measured in matured ciPTEC in the presence 
(black bars) or absence (white bars) of an inhibitor, TPA (5 mM). All ciPTEC models 
showed ASP+ uptake which was sensitive to inhibition by TPA, confirming specific OCT 
activity. In ciPTEC-T1 the net ASP+ uptake (values without inhibitor subtracted from 
values in presence of TPA) was lower compared to ciPTEC-U. (b) The P-gp activity in 
matured ciPTEC was measured in the presence (black bars) or absence (white bars) 
of a P-gp inhibitor, PSC833. An increased accumulation of calcein was observed in all 
cell lines in the presence of the P-gp inhibitor. Moreover, in ciPTEC-T1 and –T2 the net 
calcein accumulation (values without inhibitor subtracted from values in presence of 
PSC833) was higher as compared to ciPTEC-U. (c) The activity of MRP4 and BCRP in 
matured ciPTEC was detected in the presence (black bars) or absence (white bars) of 
the inhibitors, MK571 and KO143. A significant increased accumulation of kynurenic acid 
was observed in ciPTEC-U in the presence of the inhibitors. Although not significant, 
a slight increase in accumulation of kynurenic acid was detected in ciPTEC-T1 and 
-T2. The net kynurenic acid accumulation (values without subtracted from values 
in presence of both inhibitors) showed no differences between the cell lines. Data are 
presented as means of three independent experiments ± SEM * = p<0.05, *** = p<0.001 
compared to data in the absence of inhibitors per cell line, using an unpaired t test. 
# = p<0.05, ## = p<0.01 compared to net activity in ciPTEC-U, using an ANOVA analysis 
followed by Dunnett’s multiple comparison test.
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Figure 2.8 Essential reabsorption of albumin and phosphate in PTEC. 
(a; upper panel) The albumin reabsorption was detected in matured cells incubated at 4°C 
(blue histogram) and 37°C (red histogram) during experimental processing (15,000 cells 
counted). The signal intensities obtained at 37°C clearly showed specific reabsorption in 
each model. (a; lower panel) The net albumin reabsorption was determined in matured 
ciPTEC and calculated by subtracting a-specific reabsorption data detected at 4°C from 
values determined at 37°C. Significantly increased albumin reabsorption was observed in 
ciPTEC-T2 as compared to ciPTEC-U. (b) The net sodium-dependent phosphate uptake 
was investigated in matured ciPTEC and calculated by subtracting sodium-independent 
uptake data from the uptake determined in presence of sodium. A significantly increased 
sodium-dependent phosphate uptake was detected in ciPTEC-U compared to ciPTEC-T1 
and T2. Data are shown as mean ± SEM of three independent experiments. 
** = p < 0.01, *** = p < 0.001, using one-way ANOVA analysis followed by Dunnett’s 
multiple comparison test.
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In addition to uremic toxin (UT) excretion, proximal tubule cells also play 
an important role in renal reabsorption processes. Wilmer et al. (19) and 
Gorvin et al. (20) previously reported on the presence of megalin in ciPTEC-U 
and specific megalin mediated albumin endocytosis was confirmed with 
the megalin-blocker recombinant receptor-associated protein (RAP). The 
temperature-sensitive reabsorption of albumin was investigated in the three 
cell lines (Figure 2.8a; upper panel). The reabsorption was similar in ciPTEC-T1 
as compared to ciPTEC-U, whereas ciPTEC-T2 demonstrated a higher uptake 
of albumin (Figure 2.8a; lower panel; p<0.001). 
Another PTEC feature concerns sodium-dependent phosphate re-absorption, 
mediated via NaPi-IIa and NaPi-IIc and driven by the free energy provided 
by the electrochemical gradient for Na+. The transporters are located at 
the luminal side of proximal tubular cells (16). The mRNA expression of 
both phosphate transporters was confirmed in proliferating and matured 
cells (supplemental figure S2.3) and uptake in matured ciPTEC-U, -T1 and 
-T2 was studied (Figure 2.8b). Sodium-dependent phosphate uptake was 
found to be lower in ciPTEC-T1 and –T2 (p<0.01) as compared to ciPTEC-U. 
In proliferating cells sodium-dependent phosphate uptake was determined 
as well (supplemental figure S2.4), however, the uptake was clearly higher in 
matured cells as compared to proliferating cells. 
DISCUSSION
In this study, human conditionally immortalized proximal tubular epithelial 
cell lines were successfully developed from kidney tissue. Characterization of 
the newly established human cell lines and comparison with a cell line isolated 
from urine revealed that cells from both sources comparably maintain renal 
physiological properties. A broad range of parameters was endogenously 
present in the three cell lines, including the ability to form tight monolayers, 
ECM deposition and diverse transport activities. On a functional level, the 
cells isolated from kidney tissue were able to compete with the previously 
characterized cell line isolated from urine (ciPTEC-U), while collagen I and 
-IV α1 gene expression was more pronounced in cells derived from renal tissue 
samples.
To maintain homeostatic cell numbers in the epithelium, live cell extrusion 
can take place in epithelial cells into the tubular lumen (27). Although viable 
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cells can be exfoliated in urine, their release might be the result of reduced 
capability to excrete ECM proteins as demonstrated in this study. The cell lines 
derived from kidney tissue showed a more pronounced endogenous expression 
of collagen I and -IV α1 as compared to ciPTEC-U, and monolayer formation 
of the urine derived cell line was clearly improved by collagen IV coating of 
culture material. These findings suggest that despite the more abundant 
gene expression of both fibronectin I and laminin 5 in matured ciPTEC-U, 
lower levels of essential collagen I and IV α1 expression prevents these cells 
from developing tight monolayers. In the kidney, the ECM proteins play an 
important role in intracellular signaling including cell proliferation, survival 
and migration as well in repair (42,43). Therefore, it could be argued, that 
ciPTEC-U has limited properties with respect to ECM and related signaling 
functions. However, based on the functional data and E-cadherin expression 
obtained in this study, ciPTEC-U nicely competes with the cells originally 
derived from kidney tissue. Functionally active OCT2, P-gp, MRP4 and BCRP 
mediated transport was detected in all models tested, and no superior cell 
line with respect to the activity of the investigated transport proteins was 
identified. Furthermore, active albumin reabsorption and sodium-dependent 
phosphate uptake were measured in ciPTEC-U, ciPTEC-T1 and -T2, with only 
small variations between the cell lines. 
Gene and protein expressions of OCT2, P-gp, MRP4 and BCRP transporters 
confirmed the endogenous presence of these proteins in ciPTEC-U, -T1 
and -T2. The small differences between the three cell models most likely 
reflect the biovariability. Importantly, the ciPTEC models showed an 
extensive endogenous expression profile upon maturation, emphasizing the 
differentiation capacity of these human PTEC lines by immortalization using 
the temperature sensitive SV40 tsA58 antigen. In the panel of transporters 
tested, only BCRP was less abundantly present in matured cells as compared 
to proliferating cells (supplemental figure S2.2d). This observation can be 
explained by the role of this efflux pump in kidney regeneration where it has 
a distinct function during cell development and a less prominent expression 
upon maturation (45).
Interestingly, although the gene expression levels of the four transporters 
investigated were lower in matured ciPTEC-U as compared to matured 
ciPTEC-T1 and -T2, their protein expressions and activities were almost equal 
in the three models. These observations might reflect differences in post-
transcriptional or -translational regulation of the transport proteins. The first 
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step from mRNA to protein can be influenced by epigenetic alterations in 
signaling molecules, such as Wnt proteins and DNA-binding factors which 
play a key role in proximal tubular cell development (46). The differences in 
the next step from inactive to a functional and active transport protein can 
possibly be influenced by an altered activity of kinases and/or phosphatases 
responsible for phosphorylation and dephosphorylation, respectively (47). 
Future research directed towards these pathways should reveal how the four 
transporters can be modulated in the cell lines.
Robust transport activity was undoubtedly proven for OCTs and P-gp, while 
the activity of MRP4 and BCRP was less pronounced with the assay used. For 
the latter transporters the combined substrate kynurenic acid (36) was used 
in combination with inhibitors for MRP4 and BCRP. A plausible explanation 
for the limited effect of both inhibitors on kynurenic acid accumulation may 
be the absence of a specific uptake transporter for kynurenic acid. The uremic 
metabolite was proven to be an equally potent substrate for the basolaterally 
expressed organic anion transporters 1 (OAT3) and -3 (OAT3) (48). OAT3 
and OAT3 form important influx transporters in proximal tubular cells 
and determinants in the excretion of a variety of organic anions, including 
waste products from normal metabolism and drugs (49,50). Unfortunately, 
these transporters are absent on gene, protein and functional levels in the 
immortalized cell lines isolated from both urine and kidney tissue (data 
not shown). Although the expression of OATs has been observed in primary 
proximal tubular cells (51), the levels decrease dramatically during the first 
days of culturing and are lost after cell passaging (unpublished observations). 
This phenomenon has already been described in 1990 by J.H. Miller (52) and 
has, as of yet, not been solved. Stable expression of these OATs in renal cell 
lines may not only be of importance for studying regenerative nephrology, 
but may also be of great value for drug development in pharmaceutical 
industry. Next to the OAT transporters, OATP4C1 is another known anion 
uptake transporter expressed at the basal membrane of proximal tubule cells 
(53). The gene expression was studied in these cell lines and the expression 
of OATP4C1 was confirmed in matured cells (an average C(t) value of 27.2 ± 
0.1 was detected). Assays to demonstrate the functionality of this transporter 
are in progress. To study the role of transporters in disposition of new 
pharmaceutical entities and to identify potential drug-drug interactions, a 
need exists for human models predictive for renal drug handling (44,54,55). 
Future research will be directed to further develop and optimize such models. 
Next to the functional basolateral uptake and apical efflux transport, active 
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albumin reabsorption and sodium-dependent phosphate uptake are essential 
processes occurring in human PTEC. Both mechanisms were detected 
in our ciPTEC models, although differences were observed between the 
cell lines. These findings underline the heterogeneity with respect to their 
endocytosis-mediated albumin uptake via megalin, and NaPi-IIa and -IIc 
mediated sodium-dependent phosphate uptake. As described before, post-
transcriptional and -translational differences in these cell lines might explain 
the observed variability.
Isolating functional renal epithelial cells from human urine and applying 
conditional immortalization strategies could be a valuable tool in tissue 
engineering for personalized medicine in patients suffering from renal 
disorders, e.g. in development of a bioartificial kidney, or so called renal 
assist device (RAD)(12). Indications exist that residual renal function in 
CKD represents urine produced by tubular secretion rather than glomerular 
filtration (56). Residual renal function is a predictor of survival in patients 
treated with dialysis (57). Retaining or improving active tubular secretion 
processes may have profound effects on clinical outcome of CKD patients and 
the use bioartificial devices may be a good treatment alternative for this patient 
population (12). However, the amount and the quality of functional cells in 
urine originating from these patients might be questionable. In this study, 
cells from healthy volunteers were transduced using hTERT in combination 
with the temperature sensitive SV40t gene (19,30). Although Wieser et al. 
(58) previously used a single transduction of hTERT only to immortalize 
primary renal cells, in our laboratory this method did not lead to successful 
immortalization and hTERT only transductions resulted in dysmorphic cells. 
A great advantage of using the combined immortalization strategy is that 
cells can remain in their proliferating state at 33°C, thereby providing an 
unlimited cell source. Maturation can be initiated by transferring cells to 37°C, 
upon which the expression of SV40t in ciPTEC decreases (19) and expression 
levels of PTEC specific proteins adequately increases (supplemental figure 
S2.1 – S2.3). These findings support their suitability for studying regenerative 
nephrology. However, the oncogene transductions used require stringent 
biological safety regulation (e.g. filters absorbing eventually disrupted cells) 
before implementing in any clinical application, which is the focus of ongoing 
research and obviously a thorough risk assessment is needed. The use of 
serum-free culture conditions might be favorable to reduce a possible host 
immune response. However, culturing the ciPTEC models using serum-free 
medium for more than 24h induces epithelial-to-mesenchymal transition 
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(EMT) and results in a loss of PTEC-specific characteristics (data not shown). 
Serum-replacement compounds might be an appropriate alternative, but to 
this end comprehensive research is required to study the possible effect in 
these PTEC models prior to implementation. 
In conclusion, the human renal lines established from urine and kidney tissue 
display a comparable variety of functional PTEC specific transporters with 
maintained reabsorption mechanisms. Interestingly, a different ECM profile 
was observed in the cell lines isolated from kidney tissue as compared to the 
cell line isolated from cells exfoliated in urine. The cell models presented 
here could serve as valuable tools to study proximal tubule physiology and 
pharmacology. Furthermore, the availability of inexhaustible sources of 
functional human proximal tubule epithelial cells could allow for further 
development and up scaling of bioartificial kidney devices.
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SUPPLEMENTARY DATA
PTEC transporter gene Catalogue number
OCT-2 (SLC22A2) hs01010723_m1
P-glycoprotein (ABCB1, P-gp) hs01067802_m1
MRP4 (ABCC4) hs00195260_m1
BCRP (ABCG2) hs00184979_m1
NaPi-IIa (SLC34A1) hs00161828_m1
NaPi-IIc (SLC34A3) hs02341448_m1
OATP4C1 (SLCO4C1) hs00698884_m1
GAPDH hs99999905_m1
Table S2.1 Taqman primer-probe sets – PTEC transporter genes.
ECM gene Forward sequence Reverse sequence
collagen I α1 GCCTCAAGGTATTGCTGGAC ACCTTGTTTGCCAGGTTCAC
collagen IV α1 TGGTGACAAAGGACAAGCAG GGTTCACCCTTTGGACCTG
fibronectin I CTGGCCGAAAATACATTGTAAA CCACAGTCGGGTCAGGAG
laminin V GAGGCCCAGGAGCTCAAC GACAGCTCCTGCTTCCTTTG
GAPDH CTGCCGTCTAGAAAAACCTG GTCCAGGGGTCTTACTCCTT
Table S2.2 Primer sequences – Extracellular matrix genes (ECM)
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Figure S2.1, related to figure 2.4.
(a) In mature (black bars) ciPTEC-U, a significantly decreased gene expression of collagen 
I α1 was observed compared to proliferating ciPTEC-U. Both matured cell lines derived 
from kidney tissue showed a significantly increased gene expression of collagen I α1. (b) All 
tested matured cell lines showed a significantly decreased gene expression of collagen IV 
α1 compared to the corresponding proliferating cells. (c and d) In matured ciPTEC-T2, a 
significantly increased gene expression of fibronectin I (c) and laminin 5 (d) was observed 
compared to proliferating ciPTEC-T2. Expression levels were corrected for corresponding 
GAPDH mRNA levels and data were expressed as fold change and compared to 
proliferating ciPTEC per cell line. Data are means of three independent experiments and 
presented as mean ± S.E.M. * = p<0.05, ***= p<0.001, using an unpaired t test. 
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Figure S2.2, related to figure 2.5.
(a) In all matured (black bars) ciPTEC a significantly increased OCT-2 gene 
expression was observed compared to the corresponding proliferating (white bars) 
ciPTEC. (b) In matured ciPTEC-T1 and -T2, a significantly increased gene expression 
of P-gp was observed. (c) In matured ciPTEC-T2 a significantly increased MRP4 
gene expression was detected. (d) No significant differences in gene expression 
levels of BCRP were observed between matured and proliferating ciPTEC. 
Expression levels were corrected for corresponding GAPDH mRNA levels and data 
were expressed as fold change and compared to proliferating ciPTEC per cell line. 
Data are means of three independent experiments and presented as mean ± S.E.M. 
* = p<0.05, ** = p<0.01, ***= p<0.001, using an unpaired t test. 
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Figure S2.3, related to figure 2.8b.
(a) In ciPTEC-T1 a higher NaPi-IIa gene expression was observed compared to 
ciPTEC-U. (b) No significant differences in NaPi-IIc gene expression were observed 
between the three cell lines. (c) In matured ciPTEC-T1 (black bar) a significantly 
increased gene expression of NaPi-IIa was observed compared to the corresponding 
proliferating ciPTEC (white bar). Although not significant, ciPTEC-U and -T2 showed a 
trend of increased NaPi-IIa gene expression upon maturation. (d) In matured ciPTEC-U 
significantly less NaPi-IIc gene expression was observed compared to proliferating 
ciPTEC-U. No significant differences in gene expression levels of NaPi-IIc were observed 
between matured and proliferating ciPTEC-T1 and -T2. Expression levels were corrected 
for corresponding GAPDH mRNA levels. Data were expressed as fold change and 
compared to ciPTEC-U (a - b) or compared to the corresponding proliferating ciPTEC 
model (c - d). Data are presented as means of three independent experiments ± S.E.M. 
* = p<0.05 using an ANOVA analysis followed by Dunnett’s multiple comparison test 
(a - b). * = p<0.05, ** = p<0.01 using an unpaired t test (c - d).
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Figure S2.4, related to figure 2.8b.
The net sodium-dependent phosphate uptake was investigated in proliferating 
(white bars) and matured (black bars) ciPTEC and calculated by subtracting sodium-
independent uptake data from the uptake determined in presence of sodium. A 
significantly increased sodium-dependent phosphate uptake was detected upon 
maturation in each ciPTEC model compared to proliferating cells. Data are shown as 
mean ± S.E.M. of three independent experiments. * = p<0.05 using an unpaired t test.
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ABSTRACT 
Patients suffering from septic acute kidney injury (AKI) demonstrate poor 
survival rates and often require renal replacement therapy. Glucocorticoids 
may protect the kidneys during sepsis by stimulating mitochondrial function. 
Here, we studied the beneficial mitochondrial effects of dexamethasone 
in an experimental inflammatory proximal tubule epithelial cell model. 
Lipopolysaccharide (LPS) treatment of cells led to increased cytokine 
excretion rates, higher cellular ROS levels, and a reduced mitochondrial 
membrane potential and respiratory capacity, which were all attenuated 
by dexamethasone. OXPHOS complex V (CV) activity was enhanced upon 
dexamethasone treatment, whereas the other complex activities remained 
unchanged. This could not be explained by an increase in mitochondrial 
mass or the expression of its major regulator PPARγ coactivator-1α (PGC-
1α). However, dexamethasone specifically induced CV and not CIV expression. 
Finally, we demonstrated that dexamethasone acidified the intracellular milieu 
and consequently reversed the LPS-induced alkalisation. Dexamethasone 
restores mitochondrial function under inflammatory conditions by decreasing 
the cellular pH and increasing CV expression to correct for the inhibitory 
effect of the acidified environment on this complex. Besides the mechanistic 
insights into the beneficial effects of dexamethasone during renal cellular 
inflammation, our work also supports a key role for mitochondria in this 
process and, hence, provides novel therapeutic avenues for the treatment of 
patients suffering from septic AKI.
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INTRODUCTION
The prevalence of acute kidney injury (AKI) in critically ill patients has rapidly 
increased over the past two decades and puts a high burden on healthcare 
worldwide (1). AKI occurs in approximately 30 - 40% of patients admitted to 
the intensive care unit (ICU) (2), and is associated with 20% of all hospitalised 
adults worldwide (3). Though depending on AKI severity, the average mortality 
rate in these patients is over 50% and even less severe manifestations are 
associated with profound short- and long-term adverse effects, such as chronic 
kidney disease (4). The pathogenesis of AKI is highly complex and often 
multi-causal, but the septic form provoked by endotoxins originating from 
gram-negative bacteria is the most common cause of disease onset. Research 
spanning several decades illustrated beneficial effects of many different agents 
(e.g. approved drugs, natural compounds, hormones and peptides), which are 
also based on a wide variety of renal protective mechanisms (e.g. antioxidant, 
anti-inflammatory, or anti-apoptotic effects, or the activation of autophagy) 
(5). Still, most of these strategies have not yet reached clinical studies, and 
none are applied in a clinical setting (5). Treatment with alkaline phosphatase 
(AP) might, however, pave ways towards successful AKI treatment, as two 
phase-II trials demonstrated improved renal function in critically ill patients 
with sepsis-associated acute kidney injury treated with the enzyme alkaline 
phosphatase (AP) (6). Moreover, the molecular mechanism of AP was partially 
unravelled and showed that dephosphorylation of LPS-induced extracellular 
ADP and ATP might be key in the renal protective effect (7). Likewise, further 
clinical validation should demonstrate the efficacy and efficiency of AP prior 
to clinical implementation. As future renal replacement therapy, bioartificial 
kidneys containing renal proximal tubule epithelial cells have been suggested 
to exert immunomodulatory effects in animals models and patients with 
AKI, though controlled randomised multi-centre human studies have not yet 
shown conclusive beneficial evidence (8-10). As effective treatment modalities 
are not available yet, renal function can only partially be replaced using 
haemodialysis (1).
Recently, treatment of cardiac surgery patients with the glucocorticoid 
dexamethasone has been proposed as a new strategy to attenuate AKI 
(11, 12). The potency of dexamethasone to reduce septic AKI was also 
demonstrated in rodent in vivo studies and renal epithelial cells exposed to 
the E.coli endotoxin lipopolysaccharide (LPS) (13-15). Encouraging results were 
obtained with respect to attenuated cytokine levels, improved glomerular 
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filtration rate (GFR), suppressed pro-apoptotic proteins and reduced renal 
mitochondrial injury. Furthermore, Johannes and Tsao et al., demonstrated 
that dexamethasone inhibited inducible NO synthase (iNOS) activity, 
prevented hypoxic injury and improved fluid balance in rat kidneys (16,17). 
In addition, it has been shown that dexamethasone exerts nephroprotective 
effects via stimulation of multi drug resistance protein-2 (MRP2) via non-
genomic stimulation involving multiple kinases. This renal efflux transporter 
is expressed in the apical membrane of proximal tubule epithelial cells and 
has an important detoxification function through the excretion of endo- and 
xenobiotics into the pro-urine (18).
The postulated beneficial effects of dexamethasone in septic-induced AKI 
are promising, however, the exact molecular mechanism of action has not 
been unravelled. Increasing evidence points towards the role of mitochondria 
in the pathophysiology of AKI (3, 15, 19). Mitochondria are responsible for 
ATP production via the oxidative phosphorylation system (OXPHOS) and 
are highly dense in the proximal as well as in the distal segment of the 
nephron (20). During septic conditions, mitochondrial injury was observed 
in human proximal tubule epithelial cells (PTECs), HK-2. The suppression of 
cytochrome c oxidase (COX; complex IV in OXPHOS) expression, most likely 
under the regulation of increased expression of Bcl-2 pro-apoptotic proteins, 
may contribute to mitochondrial dysfunction (15). Consequently, elevated 
reactive oxygen species (ROS) will affect renal tubular function, thereby 
initiating the development of AKI. COX and Bcl-2 protein expression were 
partially restored upon dexamethasone treatment, suggesting a possible 
mitochondrial target (15). Peroxisome proliferator-activated receptor gamma 
(PPARγ) coactivator - 1α (PGC-1α), a known key regulator of mitochondrial 
biogenesis and predominantly expressed in proximal tubules, was also 
suppressed (19, 21). Upon recovery, PGC-1α was restored indicating another 
possible mitochondrial target for therapeutic intervention to treat or prevent 
AKI. Such a protective role of PGC-1α was recently associated with the 
regulation of nicotinamide adenine dinucleotide (NAD) biosynthesis and 
subsequent alteration of the cellular oxidative status (22). However, further 
elucidation of the targets by which dexamethasone influences mitochondrial 
homeostasis pathways during AKI is required.
In this study, human conditionally immortalised proximal tubule epithelial 
cells (ciPTEC, (23)) were used to unravel the molecular mechanism of action 
of dexamethasone to attenuate septic AKI. This model was extensively 
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characterised in our laboratory and demonstrated a broad range of PTEC-
specific transport and metabolic functions (23). Cells were challenged 
with LPS to mimic septic AKI and were co-incubated with dexamethasone 
to induce metabolic recovery. We demonstrate improved mitochondrial 
respiration, OXPHOS complex activity, membrane potential, attenuated ROS 
production. These effects of dexamethasone were not mediated via PGC-1α 
induced mitochondrial biogenesis, but could be associated with a restoration 
of cellular pH.
MATERIALS AND METHODS
Chemicals and cell culture materials
Chemicals were purchased from Sigma-Aldrich (Zwijndrecht, The Nether-
lands) unless stated otherwise. Cell culture plates were purchased from 
Greiner Bio-One (Monroe, NC, United States of America).
Cell culture and experimental design
Human conditionally immortalised PTEC isolated from kidney tissue 
(ciPTEC-T1 (24)) were cultured in phenol-red free DMEM-HAM’s F12 medium 
(Lonza, Basel, Switzerland) containing 10% (v/v) FCS (Greiner Bio-One, 
Monroe, NC, United States of America), 5 µg/ml insulin, 5 µg/ml transferrin, 
5 ng/ml selenium, 36 ng/ml hydrocortisone, 10 ng/ml EGF and 40 pg/ml tri-
iodothyronine (complete PTEC medium (23)). In all experiments, cells were 
seeded using a density of 25,000 cells/cm2 on uncoated surfaces, unless stated 
otherwise. Cells were cultured for 24 hours at 33°C, 5% (v/v) CO2, to proliferate 
and subsequently transferred to 37°C, 5% (v/v) CO2 for 7 days to mature. On 
day 6, cells were exposed to control medium (complete PTEC medium) or 
medium supplemented with LPS (10 µg/ml, (39)) for 24 hours at 37°C, 5% (v/v) 
CO2 to induce endotoxemia (see also Figure 3.2A). After 20 hours incubation, 
control or LPS-treated cells were co-incubated in the presence or absence of 
dexamethasone (10 µM). Subsequently, various parameters were investigated 
following the experimental protocols described below.
Enzyme-linked Immuno Sorbent Assay
The cytokine production of Interleukin-6 (IL-6; #DY206, R&D systems, 
Abingdon, UK) and -8 (IL-8; #DY208, R&D systems) in ciPTEC under control 
or inflammatory conditions in the presence or absence of dexamethasone 
was quantified using Enzyme-linked Immuno Sorbent Assays (ELISAs) as 
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previously described by Schophuizen et al. (40). The optical density of each 
well was measured using the iMark Microplate reader (BioRad, Veenendaal, 
The Netherlands) set to 460 nm and were background corrected using 
readings obtained at 540 nm.
High-resolution respirometry
Cellular and mitochondrial respiration was measured at 37°C using a two-
chamber Oxygraph equipped with Datlab 5 recording and analysis software 
(Oroboros Instruments, Innsbruck, Austria), as previously described previously 
(41-43). Briefly, exposed cells were harvested and approximately 1.5×106 cells 
were resuspended in mitochondrial respiration medium MiR05 (Oroboros 
Instruments, Innsbruck, Austria). To determine the P:O ratio we slightly 
modified the previously described approach (43, 44). Routine respiration 
was recorded followed by digitonin permeabilisation (10 µg/ 1·106 cells) of the 
cell membrane. Next, malate (2 mM) and glutamate (10 mM) were added 
to determine the STATE 4 respiration. STATE 3 respiration was obtained by 
the addition of ADP (220 nM), after which the oxygen consumption rate was 
allowed to decrease to the level of STATE 4 respiration, indicating a complete 
conversion of ADP in ATP. The P:O ratio was calculated dividing the amount 
of ADP used by the amount of oxygen used by the mitochondria to use all the 
ADP. Next, the mitochondrial complex-specific respiration was determined 
using complex-specific substrates and ADP (4 mM). Glutamate (10 mM) and 
malate (2 mM) were used as CI substrates, succinate (10 mM) for CII and 
ascorbate (2 mM) plus TMPD (0.5 mM) as CIV substrates. The glycerol-3-
phosphate dyhydrogenase (G3PDH) respiration was measured in the presence 
of glycerophosphate (20 mM) and flavine adenine dinucleotide (10 µM) and was 
terminated by antimycin A (2.5 µM). To inhibit CI and CII, rotenone (0.5 µM) 
and atpenin A5 (50 nM, Enzo Life Sciences, Raamdonksveer, The Netherlands) 
were added, respectively. Finally, the integrity of the mitochondrial outer 
membrane was tested using 10 µM cytochrome c (respiratory rate increase 
should be less than 10%) (45). 
Mitochondrial membrane potential analysis
Cells were seeded in 35 mm Fluorodishes (World Precision Instruments 
GmbH, Berlin, Germany) and cultured accordingly. Exposed cells were loaded 
with tetramethylrhodamine methyl ester (100nM) (TMRM, Thermo Fisher 
Scientific, Bleiswijk, The Netherlands) for 25 minutes at 37°C, 5% (v/v) CO2. 
Next, cells were washed once using krebs-henseleit buffer supplemented with 
Hepes (10 mM, KHH) (pH 7.4), and images were captured using a temperature-
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controlled chamber connected to an inverted microscope (Axiovert 200M, 
Carl Zeiss, Sliedrecht, The Netherlands) using a x63, 1.25 NA Plan NeoFluor 
oil immersion objective. As a positive control, the known uncoupling agent 
carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP) was used at 
the end of each measurement. Images were corrected for background and 
uneven illumination followed by analysis where images were masked with a 
binarised image for mitochondrial morphology using Image Pro Plus software 
(version 6.3, Media Cybernetics, Silver Spring, MD, United States of America) 
as previously described (46). 
Reactive oxygen species generation analysis
To measure cellular reactive oxygen species (ROS), ciPTEC-T1 were seeded 
in flat bottom 96-well black/clear plates (Corning, Badhoevedorp, The 
Netherlands). Exposed cells were loaded with 5-(and-6)-chloromethyl-2′,7′-
dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA, 10 µM, 
Thermo Fisher Scientific, Bleiswijk, The Netherlands) in KHH buffer for 20 
minutes at 37°C, 5% (v/v) CO2 to measure cellular reactive oxygen species. 
Mitochondrial ROS production was detected using the redox-sensitive 
and cell-permeant probe hydroethidium (10 µM, Thermo Fisher Scientific, 
Bleiswijk, The Netherlands) in exposed ciPTEC. Subsequently, cells were 
washed twice using KHH buffer and imaging was performed using a BD 
Pathway 855 high-throughput microscope (Becton Dickinson, Drachten, The 
Netherlands). Images were background corrected and average CM-DCF or 
hydroethidium intensity per cellular pixel was determined Image Pro Plus 
software (version 6.3, Media Cybernetics, Silver Spring, MD, United States of 
America). 
OXPHOS complex and citrate synthase activities
Approximately 6×106 exposed ciPTEC-T1 cells were harvested and resuspended 
in Tris-HCl buffer (10 mM). Next, samples were pottered in the presence of 
sucrose (215 mM) to obtain a homogenous fraction. Samples were centrifuged 
for 10 minutes at 600 g to remove cellular debris. The supernatant containing 
mitochondria was centrifuged for 10 minutes at 14,000 g. The pellet was 
resuspended in Tris-HCl buffer (pH 7.6), snap frozen in liquid N2 and stored 
at -80°C until usage. The catalytic capacity of the OXPHOS complexes was 
measured using a spectrophotometric method, as previously described 
(47). Citrate synthase activity was determined simultaneously as described 
previously (48). The catalytic activity of CI - IV and citrate synthase were 
corrected for mg cellular protein.
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Cytosolic pH measurements
ciPTEC-T1 were seeded in 35 mm Fluorodishes (World Precision Instruments 
GmbH, Berlin, Germany) and cultured accordingly. Exposed cells were loaded 
with the cytosolic pH-sensitive reporter molecule BCECF-AM (5 µM, 2’,7’-Bis-
(2-Carboxyethyl)-5-(and-6)-Carboxyfluorescein acetoxy methyl ester form) 
(Thermo Fisher Scientific, Bleiswijk, The Netherlands) in KHH buffer and 
incubated for 15 minutes at 37°C. Cells were washed three times using KHH 
buffer and imaging was performed using an inverted microscope (Axiovert 
200M, Carl Zeiss, Sliedrecht, The Netherlands). BCECF fluorescence was 
sequentially excited at the isosbestic point (440 nm) (100 ms) and at the 
H+-sensitive wavelength (490 nm) (100 ms). Fluorescent images were captured 
at 530 nm emission wavelength. Images were analysed using Image Pro Plus 
software (version 6.3, Media Cybernetics, Silver Spring, MD, United States of 
America). After background correction the 490/440 emission ratio was used to 
quantify cellular pH (43, 49). 
Immunocytochemistry
ciPTEC were cultured on human collagen IV coated (50 µg/ml in Hank’s 
Balanced Salt Solution (HBSS), Thermo Fisher Scientific, Bleiswijk, The 
Netherlands) µ-slide 8 well chambers (Ibidi GmbH, Martinsried, Germany). 
As controls, cells were exposed to resveratrol (10 µM) for 48 hours at 37°C, 5% 
(v/v) CO2 to induce the expression of PCG-1α, COX and complex V, whereas 
rapamycin (500 nM) was used for 48 hours to attenuate the expression of the 
proteins of interest as it is a known mTOR-dependent mitophagy inducer. 
First, exposed ciPTEC were incubated using mitotracker red (400nM, Thermo 
Fisher Scientific, Bleiswijk, The Netherlands) for 30 minutes at 37°C, 5% 
(v/v) CO2. Next, cells were fixed using 2% (w/v) paraformaldehyde in HBSS 
supplemented with 2% (w/v) sucrose for 5 minutes and permeabilised using 
0.3% (v/v) Triton X-100 in HBSS for 10 minutes, all at room temperature 
(rT). To prevent a-specific binding of antibodies, cells were blocked using 2% 
FCS (v/v), 2% (w/v) BSA fraction V (Roche, Woerden, The Netherlands) and 
0.1% (v/v) Tween-20 in HBSS for 30 minutes. Next, cells were incubated against 
PCG-1α (1:50 dilution in block solution; clone 3G6; Cell Signaling Technology, 
Leiden, The Netherlands), COX (1:100 dilution in block solution; ab14705, 
Abcam, Cambridge, United Kingdom) and CV (1:100 dilution in block solution; 
clone 7H10BD4F9, Mitosciences, Abcam, Cambridge, United Kingdom) for 
1 hour at rT. Subsequently, cells were incubated with goat-anti-rabbit- or 
goat-anti-mouse-Alexa488 conjugate (1:200, Abcam, Cambridge, United 
Kingdom) and finally nuclei were stained using DAPI (300 nM, Thermo 
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Fisher Scientific, Bleiswijk, The Netherlands) for 5 minutes at rT. Images were 
captured using the Olympus FV1000 Confocal Laser Scanning Microscope 
(Olympus, Tokyo, Japan) and the Olympus software FV10-ASW version 1.7. 
Images were analysed using Image Pro Plus software (version 6.3, Media 
Cybernetics, Silver Spring, MD, United States of America). For both the 
COX and CV images, background was subtracted and subsequently a 
mitochondrial binary mask was created using the mitotracker red images. 
Next, the mitochondrial mask was combined with the COX or CV images 
and the intensity per mitochondrial pixel was quantified. The PGC-1a images 
were combined with a nuclear binary mask instead of a mitochondrial mask, 
which was made using the DAPI images. 
Data analysis
All data are expressed as mean ± S.E.M of multiple independent replicates as 
indicated. Statistical analysis was performed using GraphPad Prism version 
5.02 (La Jolla, CA, United States of America). A one-way or two-way ANOVA 
analysis was performed followed by the appropriate post-hoc analysis as 
indicated. A p-value of <0.05 was considered significant. 
RESULTS
Dexamethasone attenuates LPS-induced endotoxemia 
associated mitochondrial dysfunction
Production of IL-6 and IL-8 in renal cells was clearly stimulated upon twenty-
four hour LPS treatment (42 ± 7 ng×ml-1, p<0.01 vs. 37 ± 9 ng×ml-1, p<0.05, 
respectively) (Fig. 3.1A and 1B), thereby mimicking the human responses in our 
model. In addition, Peters et al., also demonstrated recently that LPS treatment 
of ciPTEC provides a valid model to study sepsis-induced endotoxemia (7). 
Upon co-treatment with dexamethasone the IL-6 production tended to be 
decreased as compared to LPS treatment (Fig. 3.1A), where the significant IL-8 
production was vanished (Fig. 3.1B). 
Here, we further investigated the cellular responses to LPS by evaluating the 
generation of reactive oxygen species (ROS). Exposure of ciPTEC to LPS for 
24 hours led to increased ROS levels (123 ± 6%, p< 0.001), as determined by 
the general ROS indicator 5-(and-6)-chloromethyl-2′,7′-dichlorofluorescein 
CM-DCF (Fig. 3.2B). However, increased ROS production was not observed 
when mitochondrial superoxide anions were measured (Fig. 3.2C). The latter 
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could probably be explained by the versatility of superoxide anions, which 
are rapidly degraded into hydrogen peroxide, which is quickly detoxified 
either enzymatically by catalase or via the reduction of glutathione (GSH) 
(Fig. 3.2D). A brief 4 hours co-treatment of the cells with dexamethasone 
was sufficient to reverse the observed LPS-induced ROS generation 
(Fig 3.2A and B), and respiratory inhibition by increasing OXPHOS CI- 
(25 ± 9%, p< 0.05) and CII-driven respiration (38 ± 11%, p< 0.01) compared 
to control LPS-treated cells (Fig 3.3A-C). Of note, CIV-driven respiration 
was not reduced after LPS treatment, which could be explained by the 
auto-oxidative potential of the substrates used (i.e. ascorbate and TMPD) 
leading to a decreased sensitivity (Fig. 3.3C). Importantly, respiratory inhibition 
by LPS was only apparent upon maximal stimulation of the respiratory 
chain in permeabilised cells, as observed for the CI- (32 ± 13%, p< 0.001), CII- 
(27 ± 13%, p< 0.001), and glycerophosphate dehydrogenase (G3PDH; 34 ± 16%, 
p< 0.01)-driven respiration, but not under basal conditions (Fig. 3.3B and C). 
Figure 3.1 Dexamethasone co-treatment reduced IL-6 and IL-8 cytokine production 
in LPS-induced endotoxemia.
To induce endotoxemia ciPTEC proximal tubule cells were exposed to 10 mg/mL 
lipopolysacharide (LPS) for 20 hours. Subsequently, the cells were co-treated with 
dexamethasone (10 mM, DEX) for 4 hours, as indicated in figure 3.2A, and (a) IL-6 and 
(b) IL-8 cytokine excretion into the culture medium was measured by ELISA. Statistical 
analysis: one-way ANOVA with Tukey’s post-hoc analysis: *p<0.05, **p<0.01, ***p<0.001. 
Mean ± SEM, n = 5 independent experiments.
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Figure 3.2 LPS-induced endotoxemia is characterised by ROS generation and is 
attenuated by dexamethasone treatment.
(a) To induce endotoxemia ciPTEC proximal tubule cells were exposed to 10 mg/mL 
lipopolysacharide (LPS) for 20 hours. Subsequently, the cells were co-treated with 
dexamethasone (10 mM, DEX) for 4 hours. (b,c) After dexamethasone and/or LPS exposure 
the generation of reactive oxygen species (ROS) is examined using (B) CM-DCF or (c) 
hydroethidium for the detection of general cellular ROS species or superoxide anions 
(O2·-), respectively. Values were normalised to control (CT): CM-DCF (766 ± 64 arbitrary 
intensity units), hydroethidium (343 ± 64 arbitrary intensity units). (d) Cellular fate 
of superoxide anions into reactive nitrogen species (NO·-, ONOO·-), hydroxyl radicals 
(OH·-) and hydrogen peroxide (H2O2). Statistical analysis: one-way ANOVA with Tukey’s 
post-hoc analysis: *p<0.05, ***p<0.001. Mean ± SEM, n = 3 independent experiments. 
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Such a specific pattern points to a decreased mitochondrial respiratory reserve 
capacity, which can be explained by a decreased mitochondrial membrane 
potential or a decreased substrate availability. The ATP produced per oxygen 
atom reduced by the OXPHOS system (i.e. P:O ratio), provides an indication 
for the mitochondrial coupling of both processes. The observed tendency of 
LPS to increase the P:O is in line with the idea that coupling was decreased 
(Fig. 3.3D), which was confirmed after measuring the mitochondrial membrane 
potential using TMRM (Fig. 3.3E). Dexamethasone co-exposure corrected the 
LPS-induced depolarisation of the mitochondrial membrane potential, which 
corroborates the other beneficial effects on mitochondrial function, and even 
showed hyperpolarisation (Fig. 3.3E; 124 ± 5%, p< 0.001). 
Dexamethasone increases OXPHOS complex V activity 
and its expression
Respiratory inhibition combined with a decreased mitochondrial membrane 
potential after LPS exposure could potentially be explained by a direct 
inhibition of one of the OXPHOS complexes. We could, however, not 
detect inhibition of LPS on the enzyme activity of the individual CI to CV 
activities (Fig. 3.4). Surprisingly, CV enzyme activity was enhanced upon 
dexamethasone treatment (123 ± 10%, p< 0.05), and also, but not significantly, 
when cells were exposed to LPS (Fig. 3.4). Moreover, increased CV activity 
could provide an explanation for the increased mitochondrial membrane 
potential, when the complex runs into reverse mode (e.g. pumps electrons 
Figure 3.3 LPS-induced endotoxemia leads to severe mitochondrial dysfunction 
which is restored by dexamethasone treatment.
(a) Cells were treated with LPS and dexamethasone (DEX) as described in detail in figure 
3.2A. (b) Next, cells were harvested and transferred to the chambers of the respirometer 
to determine routine oxygen consumption. (c) After permeabilisation of the plasma 
membrane, OXPHOS complex I (CI)-, CII-, glycerol-3-phosphate dehydrogenase 
(G3PDH)-, and CIV-driven oxygen consumption rates were measured. (d) The 
mitochondrial coupling was determined using the P:O ratio, before the measurement 
of the complex-specific respiratory rates, and calculated dividing the amount of ADP 
used by the amount of oxygen used by the mitochondria to use all the ADP (220 nM). (e) 
Alternatively, mitochondrial coupling was determined by measuring the mitochondrial 
membrane potential using the cationic dye tetramethylrhodamine methyl ester 
(TMRM). Values were normalised to control (CT): 158 ± 22 arbitrary intensity units. 
Statistical analysis: one-way ANOVA with Tukey’s post-hoc analysis: *p<0.05, **p<0.01, 
***p<0.001. Mean ± SEM, n = 3 independent experiments. 
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from the mitochondrial matrix to the inner membrane space at the expense 
of ATP). Besides an increase in the intrinsic enzyme activity, induction could 
also be due to an enhanced complex V expression. However, citrate synthase 
activity, a marker of mitochondrial mass, did not change upon dexamethasone 
or LPS exposure (Fig. 3.5A). To exclude a role of mitochondrial biogenesis 
the expression of PGC-1α was investigated, which is a master regulator of 
mitochondrial biogenesis (Fig. 3.5B) (24). Although the positive regulator 
of mitochondrial mass, resveratrol, induced nuclear PGC-1α expression, 
no significant changes were found after 4 hours dexamethasone treatment 
(Fig. 3.5C). Using immunocytochemistry, we could confirm that CV expression 
per mitochondrial pixel was increased (Fig. 3.6; 140 ± 6%, p< 0.001), which 
was reduced by rapamycin, an mTOR-dependent mitophagy inducer. To 
investigate whether the increased CV expression was specific for this complex, 
we also determined CIV expression (Fig. 3.7), which was up regulated by 
resveratrol but not by dexamethasone (Fig. 3.7B).
Figure 3.4 Dexamethasone leads to an increased enzyme activity of OXPHOS 
complex V without affecting the activity of complex I-IV.
Cells were treated with LPS and dexamethasone (DEX) as described in detail in figure 
3.2A. Next, cells were harvested and complex I-V enzyme activity was measured 
spectrophotometrically. Values were corrected for cellular protein and normalised to 
control (CT): complex I (160 ± 9 U×mg protein-1), complex II (220 ± 7 U×mg protein-1), 
complex III (202 ± 6 U×mg protein-1), complex IV (183 ± 10 U×mg protein-1), complex V 
(282 ± 87 U×mg protein-1). Statistical analysis: two-way ANOVA with Bonferroni’s post-
hoc analysis: *p<0.05, ***p<0.001. Mean ± SEM, n = 3 independent experiments.
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Figure 3.5 Mitochondrial mass and PGC-1a expression are not affected by 
dexamethasone.
(a) Cells were treated with LPS and dexamethasone (DEX), as described in detail in 
figure 3.2A. Next, cells were harvested and citrate synthase activity was measured 
spectrophotometrically as a measure of mitochondrial mass. Values were corrected for 
cellular protein and normalised to control (CT): 362 ± 28 U×mg protein-1. Statistical 
analysis: one-way ANOVA with Tukey’s post-hoc analysis: no statistical differences 
were observed. Mean ± SEM, n = 3 independent experiments. (b) The expression 
of PGC-1a, a master regulator of mitochondrial biogenesis, was measured using 
immunocytochemistry after 4 hours dexamethasone treatment (10 µM, DEX). In 
addition, cells were incubated for 48 hours with rapamycin (500 nM) or resveratrol 
(10 µM) as known negative and positive regulators of PGC-1a and mitochondrial mass 
(scale: 20 µm) (c) The nuclear PGC-1a expression was quantified using a nuclear mask 
based on DAPI staining. Values were normalised to control (CT): 15900 ± 370 arbitrary 
intensity units. Statistical analysis: one-way ANOVA with Dunnett’s post-hoc analysis: 
***p<0.001. Mean ± SEM, n ≥ 253 individual cells analysed in n = 3 independent 
experiments.
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Figure 3.6 Dexamethasone increases OXPHOS complex V expression.
(a) The expression of OXPHOS complex V was measured using immunocytochemistry 
after 4 hours dexamethasone treatment (10 µM, DEX). In addition, cells were incubated 
for 48 hours with rapamycin (500 nM) or resveratrol (10 µM) as known negative and 
positive regulators of mitochondrial mass. Mitochondria were stained with mitotracker 
red and nuclei with DAPI to determine the cellular localisation (scale: 20 µm). (b) 
The mitochondrial complex V expression was quantified using a mitochondrial mask 
based on the mitotracker red staining. Values were normalised to control (CT): 40.4 ± 
1.1 arbitrary intensity units/ mitochondrial pixel. Statistical analysis: one-way ANOVA 
with Dunnett’s post-hoc analysis: ***p<0.001. Mean ± SEM, n ≥ 89 individual cells 
analysed in n = 3 independent experiments.
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Figure 3.7 Dexamethasone does not affect the OXPHOS complex IV expression.
(a) The expression of OXPHOS complex IV was measured using immunocytochemistry 
after 4 hours dexamethasone treatment (10 µM, DEX). In addition, cells were incubated 
for 48 hours with rapamycin (500 nM) or resveratrol (10 µM) as known negative and 
positive regulators of mitochondrial mass. Mitochondria were stained with mitotracker 
red and nuclei with DAPI to determine the cellular localisation (scale: 20 µm). (b) The 
mitochondrial complex IV expression was quantified using a mitochondrial mask based 
on the mitotracker red staining. Values were normalised to control (CT): 33.2 ± 1.5 
arbitrary intensity units/ mitochondrial pixel. Statistical analysis: one-way ANOVA with 
Dunnett’s post-hoc analysis: ***p<0.001. Mean ± SEM, n ≥ 89 individual cells analysed in 
n = 3 independent experiments.
Figure 3.8. LPS-induced endotoxemia alkalisation of the intracellular pH is reversed 
by dexamethasone co-treatment.
(a) Cells were treated with LPS and dexamethasone (DEX) as described in detail in 
figure 3.2A. After exposure, intracellular pH was measured using the ratiometric probe 
BCECF. pH levels were determined using ratio images which were obtained by dividing 
the 490 nm by the 440 nm image, (b) and quantified on a single cell level. Statistical 
analysis: one-way ANOVA with Tukey’s post-hoc analysis: *p<0.05, **p<0.01, ***p<0.001. 
Mean ± SEM, n ≥ 77 individual cells analysed in n = 3 independent experiments. 
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Dexamethasone reverses LPS-induced cellular 
alkalisation 
The increased CV expression could potentially be explained as a compensatory 
mechanism of the reduced intracellular pH upon dexamethasone treatment, 
as an acidified milieu is known to inhibit activity of the complex (25, 26). 
Indeed, we observed that the BCECF ratio, providing a measure of the cellular 
pH, increased after LPS exposure, indicative of an intracellular alkalisation 
(Fig. 3.8A and B; 114 ± 2%, p<0.001). Such an increased intracellular pH is 
also in line with the observed decreased mitochondrial membrane potential 
(Fig. 3.3E), which depends on the ΔpH between the matrix (~ 7.8) and inner 
membrane space (~7.0). The mitochondrial outer membrane is permeable 
for protons, thus the pH of the inner membrane space will be equal to the 
cytosolic pH. A raise in intracellular pH will therefore cause dissipation of the 
ΔpH and as a consequence the mitochondrial membrane potential. When co-
exposed to dexamethasone the BCECF ratio decreased indicative of a slight 
but significant cellular acidification (Fig. 3.8B; 87 ± 2%, p< 0.05). As mentioned, 
this will result in a minor inhibition of complex V, which could explain its 
increased expression as a compensatory response, further contributing to the 
restoration of the LPS-induced decrease in mitochondrial function.
DISCUSSION
AKI is characterised by high mortality rates in patients admitted to the ICU, 
as efficient treatment modalities are absent. Maintaining renal mitochondrial 
function is considered to be essential for a better outcome of AKI, therefore, 
these organelles could be of interest as therapeutic targets (3). In this study, 
we confirmed the importance of mitochondrial function in human PTEC 
during experimental inflammatory conditions and we demonstrated 
mechanistic insights into the beneficial effects of dexamethasone treatment. 
We showed that dexamethasone attenuates the LPS-induced inflammatory 
response, illustrated by a reduced cytokine excretion. These findings 
were corroborated by a small but significant dexamethasone-mediated 
intracellular acidification and, as a consequence, an attenuation of the 
LPS-induced mitochondrial dysfunction. LPS-induced endotoxemia 
resulted in a decreased mitochondrial respiration, decreased mitochondrial 
membrane potential and increased ROS generation, which is explained by 
alkalisation of the intracellular milieu. These data are compatible with the 
postulated central role of mitochondria in sepsis-induced AKI in patients. 
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In addition, we demonstrated a possible new mechanism contributing to 
the development of inflammatory conditions. Previously, AKI-associated 
mitochondrial mechanisms were predominantly attributed to a decreased 
metabolic capacity, such as an increased ROS generation, decreased 
mitochondrial biogenesis and mitochondrial permeability pore opening, 
leading to apoptosis (3, 19). 
Although the dexamethasone-induced changes in intracellular pH have 
not been associated earlier with the beneficial effects in AKI, it has been 
reported previously that the glucocorticoid leads to intracellular acidification 
in proximal tubule cells. This acidification was explained by the stimulating 
effect of dexamethasone on the basolatoral sodium-bicarbonate (Na+:HCO3-) 
co-transporter (NBC1) and the sodium-proton (Na+,H+) exchanger (NHE3) 
at the luminal side (27, 28), which together with Na+,K+-ATPase activity 
are responsible for the renal bicarbonate reabsorption under physiological 
conditions (29). Although the activity of both transporters was enhanced by 
dexamethasone, only the NBC1 expression was found to be increased (27). 
Combined with an efflux stoichiometry of 1:3 for the Na+:HCO3- efflux, the net 
effect of dexamethasone causes a drop in the intracellular HCO3- concentration 
and consequently in the pH (27, 28, 30). However, NHE3 expression has been 
demonstrated to increase upon LPS exposure in monocytes (31) and leads 
to an extracellular acidification in proximal tubule cells (32). The latter also 
being characteristic for inflammatory conditions, which has been associated 
with decreased cytokine production rates in epithelial cells (33), indicating 
the complex interplay of the different pathways affected by LPS and 
dexamethasone. 
The drop in intracellular pH after co-treatment with dexamethasone 
does, however, provides an explanation for the observed up-regulation of 
mitochondrial complex V expression, as the slightly acidified environment 
is known to inhibit the mitochondrial F1Fo ATP synthase (CV)(25, 26). Such 
an induction of the complex V expression can also be observed in iron- 
and ethanol-induced mitochondrial dysfunction, and could be considered 
as a more general response to mitochondrial damage (34, 35). In addition, 
our results provide an explanation for the previously observed increased 
expression of the mitochondrial F1Fo ATP synthase and the adenine nucleotide 
translocator (36), as both are inhibited by a low intracellular pH (25, 26). The 
latter also emphasizes the important role of the cellular pH in the observed 
mitochondrial responses after LPS and dexamethasone treatment. 
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Besides restoration of the intracellular pH and mitochondrial function, 
dexamethasone is also expected to have other beneficial effects on the 
progression of AKI. Dexamethasone has been demonstrated to increase 
the renal microvascular oxygenation, which is also expected to improve the 
respiratory capacity resulting from a decreased oxygen availability (17). In 
addition, dexamethasone is known to inhibit iNOS and thereby to decrease 
the formation of NO, which has a vasodilatory action and can form nitrogen 
radicals. Previous studies did illustrate that iNOS expression is indeed 
decreased upon dexamethasone treatment, however, the NO levels were not 
fully reversed or were even unchanged (16, 17). This gives rise to the idea that 
not all NO-mediated oxidative stress originates from iNOS, which is in line 
with a central role of mitochondrial dysfunction in the AKI pathogenesis. 
Although our work confirms such a role and supports previous results showing 
mitochondrial CIII as a major ROS generation site (37), we cannot exclude 
other effects of dexamethasone. For example, dexamethasone appeared to be 
an inhibitor of NADPH oxidase (NOX)-2-dependent ROS generation as well 
(38).
Until now almost all in vivo and patient studies showed beneficial effects 
of dexamethasone in a prophylactic setting (11, 14, 16, 19). This warrants 
further investigation of the potential beneficial effects of dexamethasone 
treatment at the manifestation of AKI in animal models and patients. 
However, dexamethasone intervention, in general, is limited by its narrow 
therapeutic window. This is probably also the main reason for the equivocal 
effects observed in clinical trials, whereas low-dose treatments show 
beneficial effects opposed to no or detrimental effects of high-dose regimens 
(11, 12, 16, 17). Future research should provide better insight into the balance 
between efficacy and safety of dexamethasone treatment. Alternatively, novel 
pharmaceutical interventions could be investigated, which also target the 
cellular pH without impacting the adverse mechanisms activated upon high-
dose dexamethasone treatment.
In conclusion, we provide mechanistic insights into the observed beneficial 
effects of dexamethasone in AKI and emphasize a key role of mitochondria 
in the disease. The striking effects on intracellular pH, hence, provide novel 
therapeutic avenues for effective treatment of patients suffering from septic 
AKI.
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Innovation
AKI is associated with more than 20% of all adult hospitalisations 
worldwide, has a poor prognosis, and the underlying mechanism remains 
poorly understood. Although a key role for mitochondrial damage has 
been recognised, its aetiology remains elusive. Our results demonstrate 
that cellular alkalisation could be the initiating event underlying LPS-
induced mitochondrial dysfunction in a human proximal tubule epithelial 
cell model. Moreover, we provide a rationale for the beneficial effects of 
the glucocorticoid dexamethasone in AKI, as it corrects cellular pH and, 
consequently, mitochondrial function. Eventually this will provide novel 
therapeutic avenues for the treatment of septic AKI.
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ABSTRACT 
With the world-wide increase of patients with renal failure, the development 
of functional renal replacement therapies have gained significant interest 
and novel technologies are rapidly evolving. Currently used renal replacement 
therapies insufficiently remove accumulating waste products, resulting in the 
uremic syndrome. A more preferred treatment option is kidney transplantation, 
but the shortage of donor organs and the increasing number of patients 
waiting for a transplant warrant the development of novel technologies. 
The bioartificial kidney (BAK) is such promising biotechnological approach 
to replace essential renal functions together with the active secretion of 
waste products. The development of the BAK requires a multidisciplinary 
approach and evolves at the intersection of regenerative medicine and renal 
replacement therapy. Here we provide a concise review embracing a compact 
historical overview of bioartificial kidney development and highlighting the 
current state-of-the-art, including implementation of living-membranes and 
the relevance of extracellular matrices. We focus further on the choice of 
relevant renal epithelial cell lines versus the use of stem cells and co-cultures 
that need to be implemented in a suitable device. Moreover, the future of the 
BAK in regenerative nephrology is discussed. 
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INTRODUCTION
The need for novel renal replacement therapies
The kidneys play a crucial role in the health balance of organisms by the 
excretion of waste products, the reabsorption of essential compounds and 
its endocrine and metabolic activities (1-5). The complex organ contains 
functional components, the nephrons, consisting of numerous cell types to 
fulfill its vital tasks (figure 4.1). Onset of acute kidney injury (AKI) or chronic 
kidney disease (CKD), can be multifactorial and caused by eg. hypertension, 
aging, obesity, diabetes mellitus, auto-immune disease or drug-induced 
nephrotoxicity (6-11). In CKD the retention and accumulation of a variety 
of endogenous metabolites is a hallmark, associated with a broad range of 
pathologies constituting the uremic syndrome. Patients undergoing chronic 
hemodialysis (3-4 times weekly) or peritioneal dialysis have a markedly reduced 
survival attributable to cardiovascular disease, hypertension, bone disorders 
and reduced cognitive function. Progression of renal disease through fibrosis 
can eventually lead to anuria (12-16). 
Current dialysis therapies only partly replace renal excretion, suggesting 
that the waste products (putative uremic toxins) are actively being secreted 
by the kidneys rather than filtered. Vanholder and colleagues pioneered in 
establishing the European Uremic Toxin Workgroup Database (EUTox; http://
www.uremic-toxins.org), and defined a list of over 150 compounds divided 
in three classes: 1) small water-soluble compounds (< 500 Da) that readily 
pass dialysis membranes, 2) middle molecules (>500 Da) for which filtration 
is limited due to size and charge, and 3) the protein-bound solutes which 
are a class of compounds difficult to clear by current dialysis modalities. 
The removal of the latter group depends on active tubular secretion shifting 
protein binding to the free fraction. For this, the renal proximal tubule cells 
of the kidneys are equipped with multiple transporters with overlapping 
substrate specificities that vigorously cooperate in basolateral uptake and 
luminal (urinary) excretion (17). In addition to the limited clearance capacity 
of the current renal replacement therapies, the lack of metabolic and 
endocrine functions contribute further to disease progression, morbidity and 
mortality (18). Best treatment option is organ transplantation but a major 
shortage of donor organs (in Europe and the United States, the waiting list 
for a new patient nowadays is 4 years (19)), as well as complications related to 
immunosuppressive therapy after transplantation warrant novel approaches 
such as BAK development (7, 8, 20). 
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Historical overview of the BAK
The BAK is a promising biotechnological approach to replace essential renal 
functions, including excretory, metabolic and endocrine pathways. Although 
major developmental progress has been made over the last decades, a 
clinically applicable system has, as of yet, not been realized. The development 
of BAKs evolves at the intersection of regenerative medicine and renal 
replacement therapy. As shown in figure 4.2, BAKs combine a haemofilter 
used in conventional dialysis with a bioreactor unit containing renal proximal 
tubule epithelial cells (PTEC), termed a renal assist device (RAD) (21). 
An historical overview of pioneering studies in the field of artificial and 
bioartificial kidney engineering is presented in figure 4.3, and started in June 
1947 with the presentation of the rotating drum dialyzer at the Scientific 
Session of the Annual Meeting of the American Medical Association by Drs. 
Kolff, Fishman and Kroop (22). Forty years later, Aebischer et al. proposed 
the combination of an ultrafiltration device with an exchanger whose semi 
permeable hollow fibers are covered with renal epithelial cells as a design 
for a BAK (23). Aebischer and co-workers demonstrated that continuous 
ultrafiltration can be maintained for relatively long periods in the absence 
of anticoagulation, using non-human kidney epithelial cells (dog or porcine 
derived) (23). 
In 1999, Humes et al. enriched and adapted the BAK concept, utilizing porcine 
renal proximal tubule cells (LLC-PK1) cultured on semipermeable polysulfone 
(PSF) hollow fiber membranes upon which extracellular matrix (pronectin-L) 
was layered to enhance cells attachment and growth (24). They successfully 
achieved tissue engineering of a bioartificial tubule as a confluent monolayer 
in a single hollow fiber bioreactor system. In the same year, Humes et al. 
successfully scaled-up from a single-fiber system to a multifiber bioreactor, 
which also allowed active vectorial transport of sodium, bicarbonate, glucose 
and organic anions, enabling functional maintenance. Moreover, it was 
demonstrated that the cells in the device were metabolically active, and capable 
of ammoniagenesis, glutathione metabolism and 1,25-dihydroxyvitamin D3 
synthesis (25). 
Five years later they started applying renal cell therapy in the treatment of 
patients with acute and chronic renal failure. For these studies, the BAK 
comprised of a continuous venovenous haemofiltration circuit connected to 
a synthetic haemofiltration cartridge and the RAD. Despite demonstrated 
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metabolic activity and systemic effects, the RAD treatment was discontinued 
for safety reasons because platelet count levels reached a lower limit of 35,000 
per mm3 (26, 27). 
In 2011, Ni et al. extended the BAK concept with the characterization of the 
membrane materials and coatings adapted in bioreactor units (28). The BAK 
bioreactor unit consisted of different porous membranes (Polyethersulfone/
polyvinylpyrrolidone (PES/PVP), polysulfone/polyvinylpyrrolidone (PSF/PVP) 
and PSF only)) seeded with human primary PTEC. For clinical applications, 
it is mandatory that PTEC remain a tight differentiated epithelium on 
membranes. In vitro results demonstrated that human derived PTEC showed 
unsatisfactory adhesion and proliferation on a variety of polymeric membranes 
or a combination of PSF/PVP materials, which was used in the bioreactor 
unit after coating with an extracellular matrix (ECM). In concert, single ECM 
molecule coating showed insufficient improvement of cell performance on 
non-PTEC-compatible membrane materials either. On the other hand, a 
double coating with 3,4-dihydroxy-L-phenylalanine (L-DOPA) and an ECM 
molecule (collagen IV) markedly improved PTEC performance and resulted in 
the formation of differentiated epithelia on PSF/PVP membranes (28).
In 2012, Buffington et al. introduced the Bioartificial Renal Epithelial 
Cell System (BRECS). This is a regular cell bioreactor designed to be fully 
cryopreservable at -80°C or -140°C. This unique design allowed for long-term 
storage and on-demand use for acute clinical applications. The BRECS was 
designed to maintain a dense population of adult human renal epithelial cells 
grown on porous, niobium-coated carbon disks within the system. After the 
cells reach an optimal density, the BRECS can be cryopreserved, transported, 
and stored, thereby alleviating many practical limitations previously 
encountered by cell-based therapies (29). This design represented the newest 
technology in conservation of human renal epithelial cells.
One year later, Oo et al. introduced a novel model of BAK with improved 
cell performance and haemocompatibility for large animal studies (30). It 
was demonstrated that PTEC performance was improved on the outer non-
haemocompatible polyarylethersulfone surfaces. Moreover, under these 
conditions membrane coatings were not required (30). This new BAK design 
greatly improved haemocompatibility and safety, and allowed the bloodline 
to discontinue to the bioreactor rapidly in case of problems.
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All the devices proposed here have the promise to be combined to produce 
a wearable or implantable BAK for renal replacement therapy that may 
significantly diminish morbidity and mortality in patients with acute or 
chronic kidney disease. However, those systems have, as of yet, not shown to 
fully embrace the ability to excrete protein-bound uremic retention solutes.
REQUIREMENTS FOR RENAL CELL MODELS
Characteristics of proximal tubular epithelial cells
For optimal urinary excretion of endo- en xenobiotics, the renal tubular 
epithelium is equipped with an organic anion and an organic cation system. 
These systems comprise of transporters belonging to the solute carrier 
family (SLC; e.g. Organic Cation Transporter 2 (OCT2; SLC22A2), Organic 
Anion Transporter 1 and 3 (OAT1/3; SLC22A6 and SLC22A8), Organic Anion 
Transporting Polypeptide 4C1 (OATP4C1; SLCO4C1), the Multidrug and 
Toxin Extrusion proteins (MATEs; SLC47A1/2)) and the ATP-binding cassette 
transporter family (P-glycoprotein (P-gp also termed MDR1; ABCB1), 
Multidrug Resistance Proteins 2 and 4 (MRP2/4; ABCC2/4), and Breast Cancer 
Resistance Protein (BCRP; ABCG2)), as schematically depicted in figure 4.1 
(17, 31, 32). Roughly distinguished, basolateral uptake of organic anions is 
mediated by OAT1 and OAT3 and their urinary efflux by MRP2, MRP4. For 
organic cations, OCT2 is the predominant carrier for facilitated transport 
into renal proximal tubule cells and MATE1, MATE2K and P-gp mediate their 
urinary efflux. BCRP and OATP4C1 might handle both organic anions and 
cations in renal proximal tubule epithelial cells (17). 
Renal cell culture models
Diverse cell lines and primary renal PTEC cultures have been used to study 
BAK engineering as a potent therapeutic approach (26, 28, 30, 33-38). Various 
research groups applied the porcine derived LLC-PK1 cell model for BAK 
engineering (23, 30). The functionality of the cationic influx transporter 
OCT2 in LLC-PK1 was confirmed by unidirectional transport of creatinine 
and tetraethylammonium using regular cell culture techniques (39, 40). 
However, limited expression and function of other transporters, such as the 
efflux pumps BCRP and P-gp, was demonstrated (41, 42). In addition, its non-
human origin limits the suitability of LLC-PK1 for BAK approaches.
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For clinical applications, human origin of the cells is highly preferred but 
very few models are available. Human primary tubular cell cultures (HPTC) 
reflect most closely the physiological demands and functionally express 
various organic anion plus cation transporters essential for uremic retention 
solutes excretion. Moreover, essential reabsorptive mechanisms, such as 
phosphate and albumin endocytosis, were demonstrated to be present (43-
45). Nevertheless, HPTC application is hampered by the large batch-to-batch 
variability in quality and function. Most transport systems were found to 
be down-regulated upon cell culturing. Moreover, the isolation and culture 
of a sufficient number of primary cells required for a BAK with maintained 
epithelial characteristics, is highly challenging. 
To overcome these hurdles, (conditionally) immortalized PTEC of human 
origin have been developed, including HK-2 (46) and ciPTEC (47, 48). The 
immortalization strategies allow for sufficient cell numbers, and cells remain 
stable in expression and function of essential proteins upon prolonged 
culturing (47). A variety of functional SLC and ABC-transporters, known to be 
involved in protein-bound uremic toxin excretion, have proven to be present. 
In 1994, HK-2 was successfully established by Ryan et al. by transduction of 
renal epithelial cells using recombinant retrovirus containing the human 
papillomavirus type 16 E6/E7 genes. This cell line has been widely distributed 
and applied for studying renal pharmacology and physiology, although the 
lack of OCTs, OATs and BCRP was demonstrated (49-53). In contrast to HK-
2, ciPTEC displays specific functional influx and efflux systems in line with 
primary HPTC (47, 48, 54). A potential uremic toxin influx transporter is OCT2, 
which was demonstrated to be present and found predictive for human renal 
organic cation handling (54). The interaction between several anionic uremic 
toxins and two important efflux pumps present at the apical membrane of 
the proximal tubule, MRP4 and BCRP, was demonstrated as well. Moreover, 
the interaction of the uremic toxins with an important class of metabolism 
enzymes, namely UDP-glucuronosyltransferases (UGT), and mitochondrial 
succinate dehydrogenase activity was confirmed (55). The latter results 
presented a novel pathway via which uremic retention solutes affect the 
metabolic capacity of the kidney and might affect drug disposition during 
CKD. This functionality in ciPTEC is a great breakthrough which allows us to 
have a translational model predictive for studying renal excretory function 
through the transport machinery. One drawback of all renal cell lines is the 
lack of OAT1 and OAT3 expression on gene, protein and functional level. 
Although the expression of OATs has been observed in primary HPTC (43), 
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the levels decrease dramatically during the first days of culturing and are lost 
after cell passaging. This phenomenon has already been described in 1992 by 
Miller et al. (56) and has, as of yet, not been solved. 
MEMBRANES AND MATRIX BIOLOGY:  
HOW TO MAINTAIN FUNCTIONALITY
Bioactive membranes
Nowadays, the development of synthetic biomaterials rapidly progresses and 
their applications depend on their controlled, well-characterized composition, 
degradation and physical properties (57, 58). PSF describes a family of 
thermoplastic polymers and are known for their toughness and stability 
at high temperatures. In addition, PSFs are used in specific applications 
and often are a superior replacement of polycarbonates. PSF allows easy 
manufacturing of membranes with reproducible properties and controllable 
pore size, explaining their current use in hemodialysis (59). PES is derived 
from PSF with low protein retention and, when combined with PVP, an ideal 
balance can be realized between hydrophilicity and biocompatibility due to 
PES’ hydrophilic nature. Their asymmetric pore structure offers a perfect 
balance between highly selective filtration characteristics and high fluxes 
with minimized flux barriers (60).
Mimicking the basement membrane including a native extracellular matrix 
(ECM) with its fiber-like morphology and display of bioactive signals is a 
prerequisite for optimal epithelial cell function in vitro. However Nur, E.K.A., 
et al. and Schindler, M., et al. demonstrated the cells did not respond to 
specific bioactive signals, but were only influenced by the topology provided 
by the fiber-like structure (61, 62). Moreover, Dankers et al. (38) developed 
a membrane more suitable for BAK systems. Promising results with respect 
to cell viability, brush border enzyme activities, tight cell monolayer 
formation and the expression of various transporters and ECM proteins were 
observed when cultured in static conditions in HPTC cultures on bioactive 
supramolecular membranes. These characteristics were improved further in 
perfusion conditions (38). The benefits of this membrane was contributed 
to the unique properties of the supramolecular polymer used. The electro-
spun microfibers resemble the structure of the ECM, composed of nanofibers 
formed by stacking of ureido-pyrimidinone (UPy)  dimers in the lateral 
direction assisted by additional urea functionalities (38, 57). Furthermore, 
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Khan et al. provided a clear insight on the attachment of bioactive peptides 
and proteins to self-assembled peptide amphiphile nanofibers via a chemo-
selective native chemical ligation reaction. This allowed functional peptides 
integration in order to design an optimal biomaterial for cell attachment, 
creating a ‘living membrane’ (58).
The extracellular matrix 
The native ECM is a key factor in inter- and intracellular signaling, regeneration 
and support, and forms a depot for growth factors. The ECM composition 
can be divided into two major components: the basement membrane (BM) 
and the stromal matrix (SM; figure 4.4). The BM is a sheet-like scaffold for 
tissue’s peripheral cells, including the vasculature as a scaffold for endothelial 
cells. The SM is made up of larger, fibrous structures, which provide much 
of the structural support of the ECM. Glycosaminoglycans (GAGs) are most 
representative ECM molecules, and are long unbranched polysaccharides 
consisting of repeating sugar dimers. GAGs can be divided in heparan 
sulfates, chondroitin sulfates and hyaluronic acid. Hyaluronic acid is the only 
GAG that is not bound to core proteins. When a GAG is covalently bound 
to a core protein, it is named a proteoglycan (PG) (63). The major biological 
function of proteoglycans is to provide hydration and swelling pressure to 
the tissue giving the resistance to compression forces (64). Proteoglycans and 
GAGs, also known as the proteoglycan glycomatrix, play an important role in 
the modulation of the innate immune system, as well as in tissue remodeling 
during inflammatory disease processes (65).
Fibers are other important ECM components. Type I collagen is the 
predominant component of the SM and of the ECM. Native collagen I is 
porous, adhesive to many cell types, and provides a strong scaffold upon which 
cells can attach and grow. Collagen IV is a non-fibrillar collagen and exists in 
small sheets as a predominant component of the BM. Collagen IV is known to 
be able to augment smooth muscle cell differentiation from various stem cell 
populations (63). It has been localized also to the dermal-epidermal junction, 
in capillaries, and beneath endothelial cells in larger vessels. Ultrastructurally 
it has been shown to be a specific component of the lamina densa (66). ECM 
also constitutes of other molecules, including fibronectin,  which is a high 
molecular glycoprotein present in blood, connective tissue and at the cell 
surface. It is believed to be involved in cells attachment to the surrounding 
ECM, collagen and GAGs (67). 
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Figure 4.4 Essential extracellular matrix components.
The native ECM is a key factor in inter- and intracellular signaling, regeneration, support 
and is a depot for growth factors, indicating its high relevance in cell maintenance. The 
cell-ECM adhesion and signaling is mediated by integrins, which are transmembrane 
receptors located in the PTEC plasmamembrane. The ECM composition can be divided 
into two major components: the basement membrane (BM) and the stromal matrix 
(SM). The BM is a sheet-like scaffold and is mainly characterized by fibronectin, 
proteoglycans, laminin and collagen IV. The SM is made up of larger, fibrous structures, 
which provide the major structural support of the ECM. Collagen I, proteoglycans and 
GAGs belong to this strate. 
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Most BMs are rich in α1 and α2 chains, suggesting that these chains may 
be required for embryonic development. The α3-α6 (IV) chains, however, 
are selectively expressed in small subsets of BMs and are expressed  late in 
development. Thus, their loss might be expected to cause tissue-specific 
defects. Mutations of the α3-5 (collagen IV) genes in humans have been 
associated with Alport syndrome, a hereditary glomerulonephritis that leads 
to end-stage renal disease (68). 
Cell adhesion to extracellular components can occur either by focal adhesions, 
connecting the ECM to actin filaments of the cell, or hemidesmosomes, 
connecting the ECM to intermediate filaments, such as keratin. This cell-to-
ECM adhesion is regulated by specific cell-surface cellular adhesion molecules 
known as integrins. Integrins bind cells to ECM structures, including 
fibronectin and laminin, and also to integrin proteins on the surface of other 
cells (63).
Taken together, the constant interchange between cells and the ECM 
determines cell fate and triggers the shift from proliferation to structure 
formation (69). Integrating core ECM components into cyto- and hemo-
compatible biomaterials will contribute to maintaining renal epithelial cell 
functionality upon prolonged appliance.
HK-2 and Human PTEC growth on bioactive 
membranes
Optimal renal cell performance on biomaterials is dependent on the presence 
of an appropriate ECM. In vivo, the native ECM is a key factor in inter- and 
intracellular signaling, support and regeneration. To advance cell attachment, 
supportive membranes can be coated using ECM components, i.e. bioactivating 
the membrane. In the past few years some research groups tested different ECM 
compounds as BAK coating (table 4.1 and 4.2) using a cell line (HK-2) or HPTC. 
In general, a ECM coating is applied to the BAK membranes for 1-2 hours (34), 
prior to seeding the renal epithelial cells onto the membranes. The ECM coating 
stimulates cell adhesion and differentiation; successful cell differentiation 
causes ECM production by the epithelium (47) eventually increasing their 
adherence and phenotype on the membrane with prolonged durability. Zhang 
et al. demonstrated that after 2-3 weeks with a maximum of 4 weeks (34), the 
cell monolayer is still viable and intact on the BAK membrane. The monolayer 
integrity is in relation with the ECM coating combination used (collagen IV was 
always present in those successful combinations).
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Table 4.1 – Successful ECM coating used in HK-2 monolayer formation
Coating type and 
concentration
Source Surface material Seeding density 
(cells/cm2)
Monolayer formation: 
ZO-1
Ref.
Laminin
(100 µg/ml)
Human 24-wells plate
polystyrene
1.4x105 2 (34)
Gelatin (1 mg/ml) Porcine 24-wells plate
polystyrene
1.4x105 2 (34)
Matrigel (70x diluted) Mouse 24-wells plate
polystyrene
1.4x105 2 (34)
3,4-Dihydroxy-L-pheny-
lalanine (DOPA)
NM PES/PVP mem-
branes
1x105 5 (28)
Optimal monolayer formation and cell attachment can be studied by the ZO-1 staining 
using a scoring system ranging from 1 to 5, accordance to Zhang et al. (28) The ZO-1 
pattern scores are reported in relation with different ECM coatings and surface 
materials used until now. NM= not mentioned
Table 4.2 – Successful ECM coating used in HPTC monolayer formation
Coating type and 
concentration
Source Surface material Seeding density 
(cells/cm2)
Monolayer formation: 
ZO-1
Ref.
Collagen IV (150 µg/ml) Human 24-wells plate
polystyrene
1.4x105 4-5 (34)
Laminin (100 µg/ml) Human 24-wells plate
polystyrene
1.4x105 4-5 (34)
Gelatin (1mg/ml) Porcine 24-wells plate
polystyrene
1.4x105 2-3 (34)
collagen IV (150 µg/
ml) +
3,4-Dihydroxy-Lpheny-
lalanine (DOPA)
Human PES/PVP mem-
branes
5 x104 3 (28)
Collagen IV (150 µg/ml ) Human PET 1x105 4 (28)
Collagen IV (150 µg/ml ) human tissue culture 
polystyrene (TCPS)
1x105 4 (28)
Optimal monolayer formation and cell attachment can be studied by the ZO-1 staining 
using a scoring system ranging from 1 to 5, accordance to Zhang et al. (28) The ZO-1 
pattern scores are reported in relation with different ECM coatings and surface 
materials used until now. 
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Collagen IV appeared to be one of the best ECM coatings in both PES/PVP and 
PET membranes. Interestingly, optimal results were obtained when collagen 
IV was coated after a first layer of L-DOPA (28). L-DOPA is the catecholamine’s 
precursor (dopamine, noradrenaline, and adrenaline) obtained via tyrosinase 
biosynthesis from the amino acid L-tyrosine and shown to be involved in the 
formation of mussels adhesive proteins (70). L-DOPA is negatively charged, 
and the combination with collagen IV, positively charged, create the optimal 
condition, up to now, for attachment and differentiation (table 4.1 and 4.2) 
(28). Apart from that combination, other ECM molecules combinations 
showed no cells attachment superiority. Although collagen IV itself may play 
an optimal role for HPTC attachment (table 4.2), stressing the fact that a 
more “biological” ECM coating is needed instead of a synthetic one.
Optimal monolayer formation and cell attachment can be studied by the tight 
junction protein zonula occludens-1 (ZO-1) staining using a scoring system 
ranging from 1 to 5, accordance to Zhang et al. ((34), table 4.1 and 4.2). Few 
studies were conducted using different cell models, but in tables 4.1 and 4.2 we 
show only the studies related to cells from human origin (HPTC and HK-2). 
In particular, we focused on optimal cells attachment using varying surface 
materials and ECM coatings. Less favorable ECM coatings data were collected 
as well and shown in supplementary table S4.1. The application of these 
coatings, including pronectin F, Poly-D-Lysine, Poly-L-Lysine and collagen I, 
resulted in poor monolayer formation and no positive ZO-1 staining (28, 34).
RENAL EPITHELIUM IMPROVEMENT USING 
CO-CULTURE AND STEM CELL APPROACHES
Co-culture applications
BAK engineering could be improved further by applying more than one renal 
cell type within a device. This requires a more comprehensive approach, 
but might enable to maintain differentiated epithelium during prolonged 
application. In vivo, paracellular pathways across the leaky proximal tubular 
epithelium are mediated along the tight junction proteins of the cells in 
order to reabsorb solutes and water (71). The combination of proximal 
tubular cells with endothelial cells or epithelial cells from down-stream 
nephron segments might be favorable in order to improve monolayer 
tightness and maintain or even enhance transport and metabolic activity. 
Finally, this might result in improved resistance against uremic conditions 
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and enhanced PTEC functionality in BAK. In table 4.3 relevant co-culture 
studies are summarized for HK-2 or HPTCs combined with various cell lines 
and growth factors. Aydin et al. (72), showed the co-culture of HK-2 and 
HPTCs with endothelial cells (HMEC-1; a human dermal microvasculature 
cell line) and HK-2 cells cultured on HMEC-1 extracellular matrix conditioned 
filters, which resulted in monolayer integrity improvement as measured by 
transepithelial resistance and paracellular leakage of inulin. In total, 99 genes 
were found to be up- or downregulated in co-culture which are involved in 
various cellular pathways, such as extracellular matrix signal transduction, 
cell-cell communications (i.e. through release of the cytokines IL-6 and IL-1β). 
No enhanced effects on monolayer integrity was observed when HK-2 was 
co-cultured in HMEC-1 conditioned medium  (72). In addition, as described 
by Tasnim et al., an increased mRNA expression level of drug transporters, 
such as OAT1, OAT3 and OCT, as well as increased activity of the metabolic 
enzyme, γ-glutamyltransferase (GGT), was found when HPTC were co-
cultured with HUVEC (73). In addition, as studied by Bertocchi et al., the 
co-culture of HK-2 with EA.hy 926 cells (Human Umbilical Vein Endothelial 
Cells (HUVECs) fused with a bronchial carcinoma cell line) showed a positive 
effect on cell integrity and viability when nitric oxide (NO) was inhibited, 
suggesting a cytoprotective effect caused by epithelial and endothelial 
cross-talk (74). Inducible NO synthase (iNOS) is constitutively expressed in 
the kidney tubular epithelium and is involved in the maintenance of diverse 
physiological processes, but upon induction involved in renal pathologies (75). 
Ameliorated but also attenuated NO levels contribute to various disorders, 
such as cardiovascular disease and acute or chronic kidney disease. Culturing 
epithelial cells in more physiological conditions using bilayer formation with 
endothelial cells resulted in improved monolayer integrity. As shown by 
Miya et al.,  next to the co-culture using HUVEC cells, hepathocyte growth 
factor (HGF), solely or accompanied by HUVEC cells, appeared to play an 
exclusive and cumulative role in cell proliferation, invasion, migration and 
tubulogenesis (i.e. the formation of tubules in epithelial or endothelial cells) of 
primary cells cultured in Matrigel. This gel is a rich ECM culture environment 
stimulating the development of 3D cellular structures (76). Particularly 
enhanced proliferation and migration properties detected in these co-culture 
applications revealed interesting characteristics that could be favorable in 
BAK approaches. For example, recovery of cells in uremic conditions might be 
enhanced in the presence of HGF to enable proliferation and, as a consequence, 
prolong functional BAK platforms. Obviously, the animal-derived Matrigel as 
a potential HFM coating strategy is not compatible with human treatment 
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Proximal tubule 
line
Cell Lines/  
growth factors
Results Comments Ref.
HK-2 cells (ATCC,  
Rockville, MD)
Human dermal 
microvascular 
endothelial cell 
(HMEC-1)
↑TEER  and ↓ inulin leakage 
99 altered gene expression 
levels
Exclusive role for 
endothelium-derived ECM 
Altered genes related to 
cell-cell communication, ECM 
proteins, transport proteins.
(72)
Human primary 
proximal tubular 
cells (HPT)
Primary glomerular 
microvasular 
endothelial cells 
(GMEC)
↑TEER and ↓ Inulin leakage (72)
HK-2 cells (ATCC, 
Rockville, MD)
EA.hy 926 (HUVEC 
fused with bronchial 
carcinoma cell line )
↑Monolayer integrity and 
vitality
Injurious effects of nitric oxide 
synthase inhibited
(74)
Primary human 
renal PTEC (Lonza, 
Walkersville, MD)
HUVEC +/- HGF (20 
ng/ml)
↑ tubular structure 
↑ cell proliferation 
↑ cell invasion and migration
Cumulative effect of HUVEC 
and HGF
(76)
HPTC (ScienCell 
Research 
Laboratories, 
Carlsbad, CA)
HUVEC and HRGEC ↑ mRNA of GGT, CD13, AQP1, 
OAT1, OAT3, OCT1, GLUT5, 
NA+/K+ ATPase, NBC1 and 
SGLT2 transporters
↑GGT activity
↑ cell proliferation
Altered mRNA expression 
levels  in co-cultured HUVEC 
of VEGF, FGF-2, HGF, TGF-β1, 
PDGF-A, A2M, DCN, FST, FSTL-
3 and FGFR-2 HUVECs. 
(73)
Table 4.3: Monolayer integrity and maintenance effects of HK-2 and human primary 
tubule epithelial cells in co-culture 
HK-2: human kidney cell line -2; TEER: transepithelial electric resistance; ECM: extracellular 
matrix; HUVEC: Human umbilical vein endothelial cells; HGF: hepathocyte growth factor; 
HRGEC: human renal glomerular endothelial cells; GGT: γ-glutamyltransferase; CD13: 
aminopeptidase-N; AQP1: aquaporin 1; OAT1: organic anion transporter - 1; OAT3: organic 
anion transporter - 3; OCT1: organic cation transporter - 1; GLUT5: glucose transport 
protein - 5; NBC1: Na+/HCO3- cotransporter - 1; SGLT2: sodium/ glucose cotransporter - 2; 
VEGF: vascular endothelial growth factor; FGF-2: fibroblast growth factor - 2; TGF-β1: 
transforming growth factor - beta 1; PDGF-A: platelet-derived growth factor alpha chain; 
A2M: alpha-2-macroglobulin; DCN: decorin: FST: follistatin; FSTL-3: follistatin-like 3; 
FGFR-2: fibroblast growth factor receptor 2.
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approaches and should be replaced by appropriate surface modifications (e.g. 
L-DOPA in combination with collagen IV (28)). To date, the effect of uremic 
conditions in co-culture approaches has not been studied. Interestingly, the 
favorable co-culture effects observed in monolayer integrity, cell metabolism 
and transport capacity as reviewed here might indicate oppurtunities for 
BAK applications to maintain or even enhance proximal tubule epithelial 
characteristics upon prolonged usage when exposed to uremic conditions. 
Therefore, future research is required to study protein-bound uremic toxins 
effects on PTEC monoculture versus co-culture of PTEC combined with, for 
example, cells from up- or down-stream nephron segments or specific growth 
factors. 
Renal regeneration using stem cells
In the past few years, various research groups developed and characterized 
CD133+ multipotent cells isolated from human kidney able to differentiate 
into renal epithelial cells  (29, 77, 78). These cells are capable of high expansion 
of at least 108 cells in perfusion culture and high viability, glucose transport and 
glutathione metabolism were established. Moreover, after lipopolysaccharide 
stimulation of these cells, active 1,25-di-hydroxyvitamin D3 derivative was 
found confirming endocrine function (29, 77). Furthermore, its immunologic 
activity was demonstrated by IL-8 production (29, 37), signifying the relevance 
of these cells for BAK applications. Moreover, it was shown that extrarenal stem 
cells, including embryonic stem cells (ESCs), bone marrow-derived stem cells 
and amniotic fluid-derived stem cells, are capable of differentiating in renal 
epithelial cells using specific nephrogenic factors (79-83). For BAK purposes, 
Narayanan et al. demonstrated functional differentiated hESC (i.e. GGT activity 
and intracellular cAMP response to parathyroid hormone) when cultured in 
perfusion bioreactors, indicating opportunities for hESC in BAK development 
(82). Though ESCs and BMDCs showed promising regenerative capacities, 
ethical concerns, mainly for ESCs, and tumor formation risk hamper a short-
term application. In contrast, amniotic fluid-derived stem cells are relatively 
easy to get to from routine clinical amniocentesis specimens, and phenotypic 
and genotypic characteristics upon prolonged culturing were shown to be 
maintained as well as self-renewal properties (84). Renal regeneration and 
survival in AKI mice was enhanced after amniotic fluid-derived stem cell 
treatment, indicating a promising avenue in future research (81). In addition, 
the use of induced pluripotent stem cells (iPSCs) as a source for cells restoring 
tubule epithelium is a relatively new era. The application of human iPSC is 
potentially a powerful tool in regenerative medicine and toxicology screening 
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programs (85-88), but their use in regenerative nephrology has, as of yet, to be 
demonstrated. iPSC can be generated from cells exfoliated in urine followed 
by reprogramming cell cultures (89), indicating high suitability for autologous 
BAK development or for establishment of appropriate disease models.
PRECLINICAL AND CLINICAL BAK 
APPLICATIONS IN AKI PATIENTS 
In a preclinical study, HPTCs were cultured in a RAD and ex vivo performance 
was successfully applied in acutely uremic dogs (37). Next, the FDA approved 
Phase I/II clinical evaluation was performed, in which the effect of RAD 
treatment for 24h in ten patients suffering from AKI and multiorgan failure 
with predicted hospitality mortality rates above 85%, was studied (27). Five 
out of ten critically ill patients were able to complete 24h RAD treatment and 
encouraging results were obtained which reflected, for example, ameliorated 
endocrine functions whereas proinflammatory cytokines (i.e. IL-6, G-CSF) 
and plasma creatinine levels diminished after treatment. A promising feature 
should be stated regarding the device itself as well. The cell viability, integrity 
and metabolic functions were still retained after 24h of use and cell loss 
during therapy appeared to be less than 0.01%. However, 40% of the patient 
group passed away in the post-RAD treatment period due to comorbidities 
within 30 days. To investigate safety and efficacy of RAD treatment in greater 
detail, more multicenter clinical studies were performed in ICU patients 
suffering from AKI and multiorgan failure (90-92). In these trials, ameliorated 
kidney function and reduced cytokine levels were observed resulting in 
reduced mortality. Interestingly, an altered inflammatory response was 
also observed in a selective cytopheretic inhibitory device (without cells) 
indicating possible immunomodulatory effects of this synthetic membrane 
on circulating leucocytes in patients suffering from sepsis and multiorgan 
failure (90). A follow-up study has been designed to specifically address the 
latter phenomenon (93).
CONCLUSION AND FUTURE PERSPECTIVES
Concluding remarks
The development of a BAK requires a complex interaction of functional cells 
and a fine-tuned ECM coating on cyto- and hemocompatible biomaterials. 
Here, we concisely described the current status of BAK engineering with 
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an overview of key factors. In the field of regenerative nephrology, the need 
for stable cell models that remain functional upon prolonged culturing 
time is still present. Although primary renal epithelial cells (29) or stem cell 
applications might embrace the possibility of high cell expansions, stable 
expression and maintained functionality of waste eliminating transporters is 
still challenging. The application of primary proximal tubular cells in a BAK 
system is hampered by their limited availability as human kidney material is 
sparse. Even when cell proliferation can be stimulated by optimal application 
of growth factors, a high batch-to-batch variability in expression and function 
of primary renal epithelial cells is a major drawback for primary cells in BAK 
development. Future research needs to be directed towards the elucidation of 
optimal surface modifications using a well defined ECM complex to enhance 
proliferation and allow stable expression of relevant proteins in primary renal 
epithelial cells (94). On the other hand,  using primary renal epithelial cells 
permits to isolate autologous cells from kidney biopsies, paving the way to 
develop a valuable tool in personalized medicine. However, the number of 
cells isolated from a kidney biopsy will be limited and a direct obstacle to 
develop a fully functional BAK device. A solution to overcome this hurdle, is 
to immortalize cells using transduction strategies. Obviously, an application 
containing immortalized cells cannot longer be classified as an autologous 
approach. From an autologous point of view, hESC or iPSC applications might 
offer suitable alternatives in future BAK development (82, 88). To overcome 
current limitations of renal primary epithelial cells, implementation of human 
ciPTEC, which showed stable functionality of PTEC specific transporters 
(47, 48, 54), might be favorable in BAK devices. To date, transcellular transport in 
ciPTEC of uremic cationic and anionic uremic toxins in 2D and 3D approaches 
is in progress and interesting data have been obtained ((47) and unpublished 
data). In addition to BAK applications, such models are potentially predictive 
for renal drug handling by studying the role of transporters in disposition of 
new pharmaceutical entities, to identify possible drug-drug interactions and 
potential (drug-induced) nephrotoxicity (95). Obviously, the application of 
immortalized cell lines, with a potential risk of provoking oncogenic responses 
upon disruption, will require extensive research to eventually establish a safe 
and solid device. Consequently, detailed risk assessments prior to any clinical 
trial will be crucial.
The improvement of renal replacement therapy using BAK systems seemed to 
be promising in uremic animals, but also in patients suffering from AKI (27, 
36, 37, 90-92, 96). Multicenter randomized clinical trials are currently ongoing 
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in AKI patient groups and outcomes will be analyzed thoroughly (93), prior 
to any further assessment in CKD or end-stage renal disease patients BAK 
treatment. A major difference between AKI and CKD or end-stage renal 
disease treatment is related to the inflammatory status of the patient. In AKI 
patients, a BAK device appeared to result in increased survival rate due to 
immunomodulation (26). In CKD or ESRD patients the inflammatory response 
will influence disease progression, which is related to the accumulation of 
protein-bound uremic retention solutes as well (14, 15, 97). Therefore, cells 
applied in a BAK should actively secrete retention solutes and, in the end, 
induce clearance of protein-bound uremic retention solutes below a certain 
threshold to diminish disease progression. Maintenance of the functional 
capacity of cells upon prolonged BAK application is the ultimate prerequisite. 
A more long-term objective is to reduce the BAK size without affecting its 
functionality. The implantable bio-artificial kidney hypothesis has been drawn 
up in the last few years (98, 99). Up to now, the bioartificial hemofilter devices 
implantation has been performed in small animal studies. The main problem 
encountered in these studies was cells long-term viability in the system. 
Eventhough it will be a valuable perspective for clinical purposes as this might 
improve patients physiological condition because current dialysis treatment 
is not sufficient for that purpose. Moreover, implanting a bio-artificial kidney 
will ultimately decrease the burden of wearing an extra-corporal renal device 
improving further patients quality of life (98-100).
An optimal ECM surface is favorable to support and maintain proximal 
epithelial cell proliferation and differentiation when cultured in 2D and 
3D applications. So far, maintaining a tight functional renal epithelium in 
vitro is highly challenging and is a hurdle to overcome   prior to enabling 
a stable functional BAK. For future research, synthetic biomaterials are of 
high interest to enable prolonged renal epithelial cell functionality in a BAK. 
This type of ECM mimics a comprehensive and dynamic environment in 
comparison to more straightforward and commonly used collagen, laminin 
and gelatin coatings. In the end, decellularized ECM surfaces might result in 
enhanced differentiation and maintenance of PTEC characteristics and might 
even be a more dynamic environment compared to synthetic biomaterials. 
Decellularization of whole organs, is commonly used to facilitate the 
constructive remodeling of a variety of tissues (101). The procedure is 
characterized by the perfusion of the whole organ with a detergent, mainly 
SDS, which completely remove the nuclear material leaving the ECM construct 
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intact that can be used as a biological scaffold (102-107). In kidney regeneration 
studies, this approach was recently described and applied in various animal 
studies (102-105). The main focus was to obtain an ECM construct reflecting 
the native membrane in order to stimulate cellular adhesion and functional 
renal properties when recellularized using embryonic stem cells (102, 
107). A successful cell attachment and hematopoietic differentiation was 
demonstrated in these studies. Translating this decellularization technique 
into a human BAK system would be a major breakthrough and could further 
enhance cell viability and functionality when cultured on bio-compatible 
membranes. Yet, such approach is highly elaborative and definitely requires 
more research.
Moreover, combining endothelial or other epithelial cells from downstream 
nephron segments with PTECs resulted in improved cell monolayer integrity 
(72-74, 76) and may possibly enhance resistance against uremic conditions. 
Obviously, elucidating optimal combinations of cell types is of high interest 
and further research is required. Based on recent studies reviewed here, this is 
a promising avenue for BAK platforms as well. 
Interestingly, Kusuba et al. (108) and Smeets et al. (109) demonstrated that 
almost any proximal tubular cell is able to dedifferentiate upon injury to 
stimulate tubular repair and this characteristic is not restricted to a fixed 
CD133+ progenitor stem cell population within the kidney. This finding 
is a promising aspect to aid BAK engineering and regeneration. For future 
applications, if renal progenitor cells express a stable and broad range 
of proximal tubule specific transporters, then the implementation and 
maintenance of autologous cells in a bioartificial cell system device might 
be possible. However, invasive techniques are required to extract cells from a 
patient’s kidney, which implies obvious restrictions. Moreover, the feasibility 
of autologous cell applications  depends on the condition of a patient’s kidney 
and may not be applicable in patients suffering from AKI. An appropriate, 
and favorable, alternative for autologous cell procedures in a BAK to treat 
CKD patients might be the use of pluripotent stem cells isolated from urine 
samples (89). Human iPCs isolated from urine samples showed multi-
differentiation properties, potentially indicating valuable autologous cell 
sources for application in regenerative medicine. The immunologic response 
will probably not be triggered upon regular autologous cell device treatment 
compared to non-autologous cell approaches, improving health conditions in 
patients suffering from renal disorders.  
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Future perspectives
For future applications the translation towards a wearable BAK for CKD 
patients would be highly favorable and will remarkably increase the quality 
of life. A sophisticated but efficient and non-invasive treatment might 
result in a substantial reintegration in professional and social environment. 
Although the development of appropriate BAK devices is expensive, the rapid 
development currently seen in up-scaling and automation techniques for cell 
therapy purposes indicates that current cost estimates may well be outdated 
in few years’ time. Obviously, a thorough evaluation should be applied based 
on FDA guidelines to investigate the potency of a BAK in public health care 
(110). Other applications, such as disease modeling, drug discovery and drug 
development, may also contribute to the final economic value of a BAK. 
To date, encouraging BAK results were obtained by various outstanding 
research groups (29, 30, 96). However, the implementation of BAK in public 
healthcare on short-term is challenging and not yet foreseen. Limiting aspects 
of BAK development are related to restricted cell sources and functional 
transcellular transport properties in 3D approaches, as reviewed here. Insight 
in current approaches contribute to comprehensive future research in order 
to stimulate the development of stable and functional BAK devices for 
prolonged applications in various patients groups.
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SUPPLEMENTARY DATA
Table S4.1  – Unsuccessful ECM coating used with HK-2 and HPTC
Optimal monolayer formation and cell attachment can be studied by the ZO-1 staining 
using a scoring system ranging from 1 to 5, accordance to Zhang et al. (28) The ZO-1 
pattern scores are here reported in relation with different ECM coatings and surface 
materials used until now. 
Coating type and concentration Cells 
used
source Surface material Seeding density 
(cells/cm2)
ZO-1 Ref.
Poly-D-Lysine (100 µg/ml) HK-2 NM 24-wells plate
polystyrene
1.4 . 105 2 (34)
Poly-L-Lysine (10 µg/ml) HPTC NM 24-wells plate
polystyrene
1.4 . 105 1 (34)
Pronectin F (NM) HPTC NM 24-wells plate
polystyrene
1.4 . 105 - (34)
Collagen I (750 µg/ml) HPTC murine PES/PVP 1x105 cultivated for 
up to four weeks
- (28)
Collagen IV (150 µg/ml ) HPTC human PES/PVP 1x105 cultivated for 
up to four weeks
- (28)
Collagen IV (150 µg/ml )+ Laminin
(100 mg/ml)
HPTC human PES/PVP 1x105 cultivated for 
up to four weeks
- (28)
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ABSTRACT 
The need for improved renal replacement therapies is a stimulance for 
innovative research for the development of a cell based bioartificial kidney, 
or so called Renal Assist Device (RAD). A key requirement for such device 
is the formation of a “living membrane” consisting of a tight kidney cell 
monolayer with preserved functional organic ion transporters, on suitable 
artificial membrane surfaces. In this work, we applied a unique conditionally 
immortalized proximal tubule epithelial cell (ciPTEC) line with an optimized 
coating strategy on polyethersulfone (PES) membranes to develop a “living 
membrane” with a functional proximal tubule epithelial cell layer. PES 
membranes were coated with combinations of 3,4-dihydroxy-L-phenylalanine 
and human Collagen IV (Coll IV). The optimal coating time and concentrations 
were determined to achieve retention of vital blood components while 
preserving high water transport and optimal ciPTEC adhesion. The ciPTEC 
monolayers obtained were examined through immunocytochemistry to detect 
zona occludens-1 (ZO-1) tight junction proteins. Reproducible monolayers 
were formed when using a combination of 2 mg/ml L-DOPA (4 min coating, 1 
h dissolution) and 25 μg/ml Coll IV (4 min coating). The successful transport 
of 14C-creatinine through the developed “living membrane” system was used 
as an indication for organic cation transporter functionality. Addition of 
metformin or cimetidine significantly reduced the creatinine transepithelial 
flux, indicating active creatinine uptake in ciPTEC, most likely mediated by 
the organic cation transporter, OCT2 (SLC22A2).
In conclusion, this study shows the successful development of a “living 
membrane” consisting of a reproducible ciPTEC monolayer on PES membranes, 
an important step towards the development of a bioartificial kidney.
133
5
INTRODUCTION
The number of patients with end-stage renal disease (ESRD) is progressively 
increasing and the need for renal replacements therapies is rising (1). Worldwide, 
over 2 million patients suffer from ESRD and each year that number grows by 
5%. Since transplant options are limited (2), approximately 70% of patients 
receive (hemodialysis or peritoneal) dialysis treatment. While dialysis therapy 
has already prolonged many ESRD patients’ lives, the treatment cannot 
completely replace renal function. Mortality (15-20% per year) and morbidity 
of these patients remain high, whereas their quality of life is generally low. 
Hemodialysis (HD) therapy removes mainly small, unbound substances from 
the circulation, while leaving large, compartmentalized and protein-bound 
uremic retention solutes untouched (3). Although the introduction of high-
flux (HF) or hemodiafiltration (HDF) therapy promotes enhanced removal 
of middle molecular weight solutes, the removal of protein-bound retention 
solutes remains limited (4,5). 
Since renal secretion of such protein-bound compounds is predominantly 
mediated by the proximal tubule epithelial cells (PTEC) (6,7), the need for 
improved renal replacement therapy has stimulated innovative research into 
the development of a bioartificial kidney, or so called Renal Assist Devices 
(RAD) (8). These innovative devices aim to complement the hemodialysis 
treatment, by coupling artificial membranes with functional kidney cells. 
To achieve efficient clearance of uremic retention solutes, proximal tubular 
epithelial cells need to be seeded on the inner surface of hollow fiber 
membranes. This situation is comparable to the native tubule, where the 
basement membrane separates proximal tubule cells from the circulation. 
While the patients’ blood flows over the outer surface, the uremic retention 
solutes can bind to the transport proteins present on the basolateral surface 
of human PTEC, facilitating their subsequent secretion into the hemodialysis 
filtrate. This approach could provide a means to further diminish the systemic 
accumulation of uremic retention solutes, reduce the incidence of secondary 
morbidities in patients, and shorten dialysis duration or frequency, thereby 
improving the quality of life in ESRD.
The development of a RAD brings along very specific biotechnological 
challenges, as was recently reviewed by Jansen et al. 2014 (9). First of 
all, an important challenge in the development of a RAD is the limited 
availability of reliable and well characterized human proximal tubule cells 
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capable of transepithelial excretion of uremic retention solutes. This “living 
membrane” should consist of tight cellular monolayers maintaining their 
typical polarity and functionality. Second, one side of the membrane to be 
used in a RAD needs to be suitable for blood contact (low cell adhesion), 
whilst the other side should facilitate cellular adhesion. Surface topography 
was identified as an important feature affecting cell adhesion and membrane 
hemocompatibility, the two properties being favored by higher surface 
roughness and smoothness, respectively (10). Several studies, which attempted 
to create “living membranes” with renal epithelial cells, have used existing 
membranes (mostly hollow fibers) used in dialysis and / or blood purification. 
Polyethersulfone (PES), polysulfone (PSF), polyacrylonitrile (PAN) and 
cellulose acetate membranes, were evaluated for their ability to support 
monolayer growth of renal epithelial cells (11-13). Since these membranes 
are designed for low cell adhesion, and maximum hemocompatibility during 
blood filtration, it is necessary to apply a coating consisting of extracellular 
matrix components. This actually describes the third challenge in RAD 
development; the optimization of coating conditions. In some cases, coatings 
have been reported to improve the attachment of renal tubule epithelial cells, 
but often coatings failed to maintain trans-monolayer transport activity and 
monolayer integrity (14-18). Human collagen type IV (Coll IV) based coatings 
are promising for attachment and functional culture of proximal tubule cells 
(15), since Coll IV is endogenously present in the basal lamina and promotes 
mesenchymal cell differentiation towards the epithelial lineage (19). However, 
it is necessary to improve its adhesion to the artificial membrane. The 
treatment of polymeric surfaces with biomolecules via covalent reactions is 
generally inconvenient given the susceptibility of different activated groups 
to hydrolysis, which can lead to low efficiency of surface biofunctionalization 
(20). An easy two-step water based biofunctionalization method has been 
proposed that promotes the formation of a thin adherent polydopamine 
(PDA) film (10,17,21) using self-polymerizing 3,4-dihydroxy-L-phenylalanine 
(L-DOPA); and exploits the reactivity of the PDA film to covalently bind 
the biomolecule Coll IV on the membrane surface (10,20). However, in these 
earlier studies, the application of the coatings was not optimized with regard 
to membrane transport characteristics (high water permeance and retention 
of vital proteins such as BSA and IgG). 
The selection of renal cell lines suitable for RAD application poses another 
challenge. The use of animal cell models, such as porcine (primary or LLC-PK1), 
monkey (JTC-12) and canine (MDCK) renal epithelial cells, provides insight in 
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the functionality of a RAD, both in-vitro as well as in-vivo (13,16,22-25). However, 
their clinical application is highly restricted. Moreover, species differences in 
renal proximal tubule physiology are in favor of a renal cell line of human 
origin (26,27). Studies using freshly isolated primary human proximal tubule 
cells in a RAD have shown promising results (10,28,29). However, their limited 
availability, low proliferative capacity, and donor-to-donor variation, severely 
restrict the use of these cells. The utilization of a functional human proximal 
tubule epithelial cell line overcomes these drawbacks. Previously, some of the 
co-authors of this study have developed a human conditionally immortalized 
proximal tubule epithelial cell (ciPTEC) line, with intact proximal tubular 
characteristics and endogenous expression of various functional transport 
proteins (30,31). Among the advantages of this cell line is the switch between 
a proliferative state at 33 °C to a differentiation state at 37 °C, permitted by 
transduction with the temperature sensitive Simian virus 40 (SV40) large T 
antigen. The genetic switch allows for cell proliferation arrest when the cells 
are confluent and fully differentiated, promoting the formation of tight and 
functional monolayers (30). 
In this work, we show for the first time the development of a stable, functional 
“living membrane” by culturing ciPTEC on PES based membranes with 
a molecular weight cut off 50 kDa. This cut off prevents albumin leakage, 
blocks possible immunoglobulin transfer, and avoids the loss of vital blood 
component in case of cell monolayer integrity failure. The membranes 
were coated with a double coating consisting of L-DOPA and Coll IV on 
the more porous rough membrane side to maximize the beneficial effect of 
both membrane topography and coating on cell adhesion. This coating was 
carefully optimized to preserve high membrane permeability and create a 
tight cell monolayer. The selective active transport of creatinine through the 
“living membranes” was investigated in the presence and absence of specific 
inhibitors, and compared to a commercially available polyester Transwell® 
system. 
MATERIALS AND METHODS
Membrane coatings
Flat polyethersulfone membranes (Sartorius, Goettingen, Germany), which 
showed good hemocompatibility properties (32), with a molecular weight 
cut off of 50 kDa (indicated, as PES - 50) were coated with a double layer 
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of 3,4-dihydroxyl-L-phenylalanine (L-DOPA) (D9628, Sigma Aldrich, 
Zwijndrecht, The Netherlands) and human collagen IV (Coll IV, C6745, 
Sigma Aldrich, Zwijndrecht, The Netherlands) L-DOPA solutions with 
concentrations ranging from 1 to 2 mg/ml in Tris buffer 10 mM (pH 8.5) were 
prepared and dissolved at 37°C. Complete dissolution was obtained after 1 
h, followed by filter sterilization. Subsequently, the L-DOPA solution was 
used to either coat the membranes immediately after powder dissolution, 
with minimum polymerization degree (referred to as L-DOPA (1 h)), or left 
to polymerize for 2 more hours (referred to as L-DOPA (3 h)) before coating 
the membranes. For the sake of simplicity, we defined the dissolution time as 
the time that the L-DOPA is kept in solution before coating the membrane. 
The membranes were first pre-incubated in Hanks’  balanced salt solution 
(HBSS; Life Technologies, Bleiswijk, the Netherlands) for 10 min. Next, the 
L-DOPA solutions were applied to the membrane surface. The solution 
was aspirated, and the membranes were left to dry for 5 min. Then, a Coll 
IV solution (25 µg/ml or 50 µg/ml) in HBSS was used for the second step of 
the coating. After fluid aspiration and drying, the membranes were washed 
three times in HBSS to remove any remaining solvent or unbound compound. 
Diverse L-DOPA dissolution times (1 and 3h) and coating times of membranes 
(1 and 4 min) were tested and their effects on membranes properties were 
evaluated in terms of membrane morphology and pure water permeance. An 
overview of the coating conditions tested is given in Figure 5.1. The PES-50 
membrane has an asymmetric structure: one membrane side is denser (and 
therefore determines the transport properties) and smooth, while the other 
membrane side is more porous and rough. The double coating was performed 
on the more porous membrane side, under static conditions, by contacting 
the coating solution with the membrane surface. To obtain single sided 
coating of the flat PES membranes, the coating solution was first poured 
in glass Petri dishes and the membrane was gently placed on the top of the 
solutions with the porous side in contact with the liquid. The selection of final 
concentrations, dissolution times and coating times for both the L-DOPA and 
the Coll IV solution was based on cell adhesion, cell monolayer formation and 
tight junction expression. Reproducibility of the coating was investigated in 
terms of water and protein transport properties. For cell culturing, polyester 
Corning (Corning Costar, NY, USA) custom Transwell® supports were used. 
In these Transwells (12mm in diameter), the polyester cell membrane was 
replaced by PES - 50 membrane used for the double coating development. 
Here, membrane coating was performed on one side of the membrane 
by applying the solutions to the apical (cell-facing) side of the Transwell®. 
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Since the PES membrane is sealed on the perimeter to the plastic holder, the 
basolateral side of the membrane did not come into direct contact with the 
coating solution. Supplemental figure 5.A1 provides a schematic overview of 
a coated Transwell® membrane. As a reference, we employed double-coated 
(positive control) polyester Transwell® membranes, which are frequently used 
for in-vitro PTEC culture (30,33).
Membrane morphological and surface composition 
analysis 
Membrane morphology was determined by scanning electron microscopy 
(FEI/Philips XL30 FEG ESEM). Surface samples were prepared and kept 
overnight at 30°C and gold sputtered before examination by SEM at a voltage 
of 5 kV. The membrane surface chemical structures and composition of 
the coated and uncoated PES-50 were characterized using an Attenuated 
total reflection-Fourier transform infrared spectra (ATR-FTIR) (Spectrum 
two,, Perkin Elmer, Waltham, USA) instrument. Elementary analysis of the 
membrane composition was performed by Energy Dispersive Spectroscopy 
analysis (EDS -EDAX Apollo X for ESEM, New Jersey, USA).
Membrane transport properties
Pure water, bovine serum albumin (BSA, A2153, Sigma Aldrich, Zwijndrecht, 
the Netherlands) and immunoglobulin G (IgG, I9640, Sigma Aldrich, 
Zwijndrecht, the Netherlands) solution permeance was determined using an 
air-pressurized dead end ‘Amicon type’ ultrafiltration cell (hosting 4 cm Ø 
membrane samples) and ultrapure water. The flux (J) of water and protein 
solution through the membranes at each pressure was determined by 
collecting the mass of the permeated liquid over time and correlating it to the 
membrane unit surface area. The permeance (L, in L m-2 h-1 bar-1) of water or 
protein solution was estimated by normalizing the water or protein solution 
flux (J, in L m-2 h-1) by the applied transmembrane pressure (ΔP, in bar). The 
permeance is, in fact, calculated from the slope of the linear part of the flux 
vs. transmembrane pressure relationship:
 (1)
Clean water permeation tests were performed by using ultrapure water (MilliQ 
18 MΩ.cm, Millipore; Billerica, MA, U.S.A) solutions inside stirred Amicon 
cells (Millipore; Billerica, MA, U.S.A), where the membranes were placed with 
the thin layer facing the feed solution. Automatic collection of permeate mass 
𝐿𝐿 =
𝐽𝐽
𝛥𝛥𝛥𝛥
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during time was performed by means of a Labview based software, the mass 
was converted to volume given the water density equal to 998 kg. m-3 at 20°C 
(34). Uncoated flat membranes were tested after immersing them in pure water 
for 1 hour to remove preservatives added during the manufacturing process. 
Membranes double coated with L-DOPA and Coll IV were immersed in HBSS 
buffer for 30 min before they were used. Subsequently, the membranes were 
subject to a flushing step with ultrapure water at the highest working pressure 
(0.75 bar). Then, down to up pressure cycles were applied to each membrane. 
The extent of protein transport through the membrane was evaluated by 
estimating the apparent sieving coefficient (SCa). 
 (2)
Where Cp is the protein concentration in the permeate and Cb is the protein 
concentration in the feed protein solution. SCa=1 means that the protein 
passes freely through the membrane, while SCa=0 means that the membrane 
rejects the protein completely.
Phosphate buffered saline (PBS) containing BSA or IgG, were used at a 
concentration of 1 mg/ml and 0.02 mg/ml, respectively. Three different 
pressures (0.25, 0.50, 0.75 bar) were applied and sample collection occurred 
every 15 minutes for 1 hour. The protein solution was continuously mixed at 
the top of the membrane surface to prevent polarization concentration effect 
and delay membrane fouling. BSA and IgG concentration was evaluated by 
spectrophotometric analysis in quartz cuvettes at 280 nm. 
Cell culture 
A previously developed ciPTEC cell line (30) was used for functional testing 
of the coated membranes. In short, this immortal cell line was developed by 
transducing primary human proximal tubule epithelial cells, obtained from 
urine samples of healthy volunteers, with a SV40t, and hTERT gene. SV40t 
stimulates cellular proliferation at 33°C, while it is silenced by culturing the 
cells in a 37°C environment. As a consequence, at 37°C the cells are able 
differentiate and form a tight monolayer. The hTERT ensures the cellular 
quality, by keeping the length of the telomeres intact during proliferation. 
We have previously evaluated the characteristics of this cell line, on a 
morphological and functional level (7,31). CiPTEC were cultured in Dulbecco’s 
modified eagle medium DMEM-HAM’s F12 (Lonza; Basel, Switzerland) 
𝑆𝑆𝑆𝑆! =
𝐶𝐶!
𝐶𝐶!
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containing 10% v/v fetal calf serum (FCS) (Greiner Bio-One; Alphen a/d Rijn, 
the Netherlands), 5 μg/ml insulin, 5 μg/ml transferrin, 5 ng/ml selenium, 
36 ng/ml hydrocortisone, 10 ng/ml epidermal growth factor and 40 pg/ml 
tri-iodothyronine, all purchased from Sigma-Aldrich Co. (Zwijndrecht, the 
Netherlands). Culture media were phenol-red and antibiotic free. To prevent 
de-differentiation of ciPTEC during regular culturing, cells were used in 
experiments up to a maximum of 40 passages, during which proximal tubular 
characteristics remained unaltered (30). Proliferating ciPTEC were seeded 
onto the polyester or PES membrane Transwell® inserts at a density of 133.000 
cells/cm2. To promote initial cellular attachment and proliferation, ciPTEC 
were cultured for 24 h at 33°C 5% (v/v) CO2 and after this time period the 
temperature was changed to 37°C for 7 days to promote the formation of a 
differentiated monolayer. 
Immunocytochemistry 
To investigate morphological characteristics and monolayer integrity of 
matured ciPTEC cultured on polyester (30,33) and PES-50 Transwell® inserts, 
immunocytochemistry was performed and after 7 days the expression of the 
tight junction protein, ZO-1 (zonula occludens – 1), was studied. Matured 
ciPTEC were fixed using 2% (w/v) paraformaldehyde in HBSS supplemented 
with 2% (w/v) sucrose for 5 min and permeabilized in 0.3% (v/v) Triton X-100 
in HBSS for 10 min. To prevent non-specific binding of antibodies, cells were 
exposed to block solution containing 2% (w/v) bovine serum albumin fraction 
V (Roche, Woerden, the Netherlands) and 0.1% (v/v) Tween-20 in HBSS for 30 
min. Cells were incubated with antibodies diluted in block solution against 
the tight junction protein zonula occludens 1 (ZO-1, 1:50 dilution, Invitrogen, 
Carlsbad, CA) for 1 h, followed by incubation with goat-anti-rabbit-Alexa488 
conjugate (1:200, Life Technologies Europe BV, Bleiswijk, the Netherlands) for 
30 min. Finally, DAPI nuclei staining (300 nM, Life Technologies Europe BV) 
was performed for 5 min. Protein expression and localization were examined 
using the Olympus FV1000 Confocal Laser Scanning Microscope (Olympus, 
Tokyo, Japan) and images were captured using the Olympus software FV10-
ASW version 1.7. To semi-quantify the fluorescent staining of ZO-1, a grid 
of 8.5 µm2 was placed on top of the confocal images using ImageJ software 
(ImageJ 1.46r, NIH, USA) (35). The number of intersections between the grid 
and the ZO-1 signal was determined for each condition. 
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Transepithelial transport measurements
Transepithelial transport of (14C)-creatinine by matured ciPTEC monolayers 
cultured on either polyester or PES Transwell® inserts was measured using 
a Transwell® culture system. A schematic overview of the set-up, is provided 
in the supplemental file (Figure 5.A1). Polyester Transwells® (diameter 12mm, 
pore size 0,4µm) were coated with L-Dopa alone or in combination with Coll 
IV (25 mg/ml, for 2 hours), and compared to double coated polyester or PES-50 
Transwells®. Mature cell monolayers were washed in modified Krebs-Henseleit 
buffer (Sigma-Aldrich, Zwijndrecht, The Netherlands) including 10mM Hepes 
(pH 7.4). Subsequently, all membranes tested were pre-incubated for 2 h at 
37°C, 5% (v/v) CO2 in Krebs-Henseleit-Hepes buffer (0.5 mL apically, 1.5 mL 
basolaterally). Transport was initiated by the basolateral addition of either 
(14C)-creatinine (0.75 µM, 2 μCi/ml) or (3 H)-inulin (0.45 µM, 20 μCi/ml) with or 
without cimetidine (100 µM) or metformin (100 µM) as competitors for OCT2 
transport (Sigma-Aldrich Co., Zwijndrecht, the Netherlands). At the start of 
the measurement, a 20 μL reference sample was taken from the basolateral 
exposure compartment. After 30 min of incubation with gentle agitation at 
37°C a 200 μL sample was removed from the apical chamber. The activity of 
(3H) and (14C) in the samples was determined by liquid scintillation counting 
(Beckman). Fluxes of (14C)-creatinine or (3H)-inulin were determined for each 
separate Transwell®. The flux of (3H)-inulin was used as an internal leakage 
marker. The basolateral to apical flux (J) was calculated with:
 (3)
Where dQ = amount transported (pmol); dt = duration of transport (minutes); 
S = surface area (cm2). 
Data analysis 
Water, BSA and IgG transport measurements in each experiment were 
performed at least in triplicates (N≥3 for each coating condition). Results are 
presented as mean ± standard deviation. Statistical analysis was performed 
with the Microsoft Excel® software (Microsoft Corporation, Seattle, USA) 
using a one-way ANOVA or a Student’s T-test when appropriate. 
Quantification of ZO-1 staining on Transwell® polyester or PES membranes 
was performed in triplicates for each coating condition. The results are 
presented as mean ± sem. Results were normalized by taking the double 
coated Polyester Transwell® as 100% reference. One-way ANOVA followed by 
𝐽𝐽 =
𝑑𝑑𝑑𝑑
𝑆𝑆 ∗ 𝑑𝑑𝑑𝑑
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a Dunnett’s post-test, was performed using GraphPad Prism version 6.00 for 
Windows, (GraphPad Software, La Jolla California USA). 
For basolateral creatinine transport experiments in the commercially available 
polyester Transwells® the experiments were performed at least in triplicate in 
three independent experiments. The custom PES Transwells® were tested in 
duplicate in three independent experiments. Results are presented as mean 
± sem. Statistical analysis was performed with GraphPad Prism, using a two 
way ANOVA combined with a Bonferroni’s post-test. 
RESULTS – DISCUSSION
The biofunctionalization strategy of flat PES-50 membranes was optimized 
first to develop functional ciPTEC monolayers. Artificial membranes should 
provide a solid base for cells to form tight monolayers and facilitate active 
transepithelial solute transport. In the nephron, the proximal tubule is 
responsible for the reabsorption of 65% of all the water filtered by the 
glomerulus; the very high permeability of the tissue was estimated to be 
about 1x105 L m-2 h-1 bar-1 (36). The hydraulic permeability of native PES-50 
membrane is 2 orders of magnitude lower than the value reported for natural 
tissue, the membrane was chosen on the base of its capacity to retain vital 
blood components, consistent with other research in the field (22). For this 
reason, water transport through the coated membranes was one of the main 
parameters to optimize, in order to preserve the highest permeance possible.
A recent study proposed the application of an overnight double coating (10). 
However, when we applied such a coating, a significant decrease in membrane 
water permeance, (39 ± 23 L m-2 h-1 bar-1) was detected in comparison to 
uncoated membranes (738 ± 110 L m-2 h-1 bar-1). Further reduction of the 
permeance was expected when applying the second coating layer consisting 
of Coll IV. To avoid significant transport limitations, we investigated shorter 
L-DOPA dissolution times. In a first attempt, L-DOPA was used for the 
coating immediately after the dissolution step (L-DOPA (1 h)). The average 
value of water permeance did not change significantly (654 ± 70 L m-2 h-1 bar-1) 
with respect to uncoated membrane values (Figure 5.1, I). After applying the 
Coll IV coating on top of the L-DOPA layer (Figure 5.1, II), the average value of 
water permeance decreased to 347± 151 L m-2 h-1 bar-1. 
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Figure 5.1 Schematic overview of the coating 
conditions evaluated for their membrane 
properties and cell adhesion.
See text for further details and abbreviations.
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However, the high coefficient of variation (0.44) indicated a non-reproducible 
coating. These results indicate that short coating times do not cause 
significant changes, whilst overnight coating results in a dramatic reduction 
in membrane transport properties. Since the variable “time” plays a central 
role in the macroscopic transport properties of the coated membrane, we 
compared the effects of prolongation of the L-DOPA dissolution time (Figure 
5.1; II, III and IV), to prolongation of the coating time to L-DOPA and Coll IV 
from 1 to 4 min (Figure 5.1; II, V).
When applying L-DOPA coating alone, prolongation of the L-DOPA 
dissolution time slightly increases the average membrane water permeance, 
although this effect was not significantly different from the non-coated PES-
50 membranes (dark symbols, Figure 5.2a). Literature reports that L- DOPA 
coating can increase the membrane hydrophilicity due to the coexistence 
of carboxylic and amino groups in the L- DOPA molecule (37). In fact, the 
effect of L-DOPA coating on hydrophilization of different materials has been 
shown by the reduction of water contact angle under the same experimental 
conditions used in the present study (pH, Tris buffer molarity and L-DOPA 
concentration) (21,37,38) we therefore expect that our membranes are slightly 
hydrophilized, too. Nevertheless, the application of L-DOPA to porous 
membranes can reduce the membrane transport properties. This decrease 
mostly occurs to UF membranes where the pore dimensions allow migration 
of L-DOPA monomers and oligomers inside the membrane structure with 
consequent reduction or blockage of the inner porosity (39,40). The transport 
properties of reverse osmosis (RO) and microfiltration (MF) membranes was 
reported to be less affected by L-DOPA coatings, due to the different pore 
size (40). Since we used PES-50 UF membranes, the coating time as well 
as the L-DOPA dissolution time required optimization to avoid complete 
suppression of the membrane permeance. 
The Coll IV coating on top of the L-DOPA layer (Figure 5.1, conditions I – 
IV) decreased the membrane water permeance significantly (open symbols in 
Figure 5.2a). The permeance for the double coated membranes with L-DOPA 
(3 h) and Coll IV for 1 min was 194 ± 35 L m-2 h-1 bar-1, which is significantly 
lower than the uncoated membranes. However, when compared to overnight 
L-DOPA coating (Figure 5.1; VI), the membrane permeance improved 
markedly. Furthermore, prolongation of L-DOPA dissolution to 3 h enhanced 
the coating reproducibility, as demonstrated by the low standard deviation 
of the permeance values. Figure 5.2b presents the optimization procedure 
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of the double coating using different coating times of L-DOPA (1h) (Figure 
5.1; II, V and VI). The water permeance for double-coated membranes with 4 
min coating was A 2.7 fold higher (146 ± 10 L m-2 h-1 bar-1) than for overnight 
L-DOPA (only) coating. Prolongation of coating time to 4 min also improved 
the double coating reproducibility, as demonstrated by the low standard 
deviation of the permeance results. These results indicate that optimization 
of the L-DOPA dissolution, and coating times significantly improves the 
membrane permeance and coating reproducibility, when compared to 
overnight coating.
The progressive reduction of membrane water permeance correlated with the 
observed morphological changes at the porous side of the membrane surface 
where the double coating was applied. Figure 5.3 presents SEM images of 
uncoated, only L-DOPA and double coated membranes surfaces. The single 
L-DOPA coating slightly affected the porous layer morphology (data not 
shown). After application of L-DOPA (3h), an estimated 40% reduction in the 
macroporosity visible at the upper surface of the flat membranes could be 
observed compared with the original membranes (Figure 5.3b). Application of 
Coll IV to the L-DOPA coating resulted in complete occlusion of membrane 
surface pores as compared to membranes coated with L-DOPA only, for all 
L-DOPA dissolution times tested (Figure 5.3c). The lack of visible differences 
in surface morphology in the presence of the single L-DOPA coating in 
comparison with native membranes was consistent with the average rate 
of PDA layer deposition (2 nm/h) reported in previous studies for the same 
experimental conditions (L-DOPA concentration, temperature, pH and 
Tris buffer molarity) (21,41). The analysis of membrane surface chemical 
composition confirmed that the thickness of the coating was in the nm range, 
as the beam penetration for both EDAX and FT-IR analysis was deeper than 
the single or double coating applied. In fact for both the FT-IR spectrum and 
the elementary composition, the underlying PES material is still dominant 
(Figure 5.4). Dopamine monomers and small oligomers have previously been 
demonstrated to play a primary role in the initiation of the PDA deposition 
and its consequent polymerization at the membrane surface (21,40,41). In 
these studies, maximal monomer deposition rate was observed during the first 
hours after L-DOPA dissolution. This finding may explain why, in our case, a 
short coating time was sufficient to modify the PES-50 membranes, providing 
good collagen IV adhesion and reproducibility of transport properties. 
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Figure 5.2 Pure water permeance of PES-50 membranes coated with L-DOPA 
(2 mg/ml) and Coll IV (25 µg/ml) as a function of: a) L-DOPA dissolution time for PES 
membranes coated for 1 min with L-DOPA solution only (  ), or L-DOPA followed by 
Coll IV (□); b) double coating with L-DOPA followed by Coll IV with varying coating 
times (○), or L-DOPA solution after overnight coating (●). Data are presented as mean 
± standard error, * p<0.05; ** p<0.01; ***p<0.005; N≥3 for each experimental point.
Figure 5.3 Representative Scanning Electron Microscopy analysis of PES-50 
membranes porous side surface morphology with L-DOPA (2 mg/ml) and Coll IV 
(25 µg/ml) with different L-DOPA dissolution times: a) uncoated; b) 1 min coating with 
L-DOPA (3h) only; c) 4 min coating with L-DOPA (1h) and Coll IV. Magnification 100X. 
At least three independent membranes were examined for each condition.
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The optimized coatings were tested further for optimal cell monolayer 
formation by ZO-1 tight junction protein expression, a marker that indicates 
monolayer integrity and polarity of epithelial cells. The tested coating 
conditions are described schematically in Figure 5.1, under the cellular 
adhesion heading (Figure 5.1; conditions VII-XII). Standard double coated 
polyester Transwell® inserts, were used as a positive control (Figure 5.5a). 
Uncoated PES-50 membranes provided poor cell adhesion of ciPTEC (Figure 
5.5b) while single coating with Coll IV (25mg/ml) or L-DOPA (2mg/ml) did not 
improve this (Figure 5.5c,d). After application of the double coating, cellular 
adhesion and the expression of ZO-1 improved (Figure 5.5e-f). The observed 
clear ZO-1 expression indicates polarization of the monolayer, improving 
epithelial characteristics (42) and limits paracellular leakage. No significant 
difference in monolayer formation and ZO-1 expression was detected between 
conditions XI and XII (Figure 5.5e,f), which varied either the coating or 
dissolution time. Furthermore, quantification of the ZO-1 has indicated that 
ciPTEC expressed ZO-1 protein in a similar fashion on both double coated 
PES-50 as on polyester Transwells®, which are considered the golden standard 
in ciPTEC transepithelial studies (Figure 5.5g). Lowering the concentration of 
L-DOPA reduced the reproducibility of cellular adhesion, even in the presence 
of a higher Coll IV concentration, thus suggesting the importance of a good 
L-DOPA layer to foster Coll IV membrane coating. Furthermore, increasing 
the Coll IV concentration to 50 µg/ml after 2 mg/ml L-DOPA coating did not 
improve monolayer quality with respect to 25 µg/ml Coll IV (supplemental 
Figure 5.A2).
The coatings were investigated further in terms of protein rejection and 
fouling phenomena during protein solution permeance. Table 5.1 shows 
a comparison of transport properties of uncoated and membranes with 
optimized coatings (Figure 5.1; conditions I, IV and V). The permeance of IgG 
and BSA solutions for the uncoated PES-50 membranes is 53 ± 11 and 57 ± 7 L 
m-2 h-1 bar-1, respectively, about 96% lower than the water permeance through 
the same membranes (P<0.05). There was no significant difference in protein 
solution permeance for the coated membranes, as values ranged from 37 ± 27 
L m-2 h-1 bar-1 to 65 ± 24 L m-2 h-1 bar-1. Both BSA (66 kDa) and IgG (150 kDa) 
were almost completely rejected by both uncoated and coated membranes: 
the SC < 0.1, consistently to what is expected for a 50 kDa membrane. 
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Figure 5.4 Surface chemical composition of PES-50 membranes uncoated and coated 
with L-DOPA (2 mg/ml) and Coll IV (25 µg/ml).
Above ATR-FTIR spectra for: purple) uncoated PES-50; green) 4 min coating with 
L-DOPA (1h) only; yellow) 4 min coating with L-DOPA (1h) and Coll IV. Below EDAX 
analysis of (from left to right: uncoated PES-50; 4 min coating with L-DOPA (1h) only; 1 
min coating with L-DOPA (3h) only; 1 min coating with L-DOPA (3h) and Coll IV; 4 min 
coating with L-DOPA (1h) and Coll IV.
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Figure 5.5 Representative images of immunocytochemical analysis of the ZO-1 
tight junction protein (green) and nuclei (blue) in ciPTEC monolayers cultured on 
membranes with varying coating times.
a) L-DOPA (2 mg/ml) and Coll IV (25 μg/ml) double coated Polyester Transwell® inserts; 
b) uncoated PES - 50 Transwell® insert; c) Coll IV (25 μg/ml) coated PES-50 Transwell® 
inserts d) L-DOPA (2 mg/ml) coated PES - 50 insert; e) PES-50 Transwell® inserts coated 
for 4 min with L-DOPA (1h) and Coll IV; f) PES-50 Transwell® inserts coated for 1 min 
with L-DOPA (3h) and Coll IV. G) ZO-1 abundance in ciPTEC monolayers compared 
to double coated Polyester Transwell® inserts. At least three independent membranes 
were examined for each condition. ***p<0.005 Magnification 60x.
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Given the similarity between the transport properties and the similar cell 
behavior for the membranes with the optimized coatings, the transport of 
inulin and creatinine was measured on membranes coated with the coating 
which required the shortest experimental time: L-DOPA (1h) with a coating 
time of 4 min for both L-DOPA and Coll IV (Figure 5.1, XII). Transepithelial 
transport of (14C)-creatinine was measured in presence and absence of 
transporters substrates, acting as competitors to inhibit uptake. In the 
kidney, approximately 20% of creatinine is actively transported by organic 
cation transport proteins (43). The functionality of the basolateral cation 
uptake by organic cation transporters (OCTs) in ciPTEC has previously been 
demonstrated (7). Here, Figure 5.6 presents the transmembrane flux of (14C)-
creatinine (0.75 µM, Figure 5.6 a, b, c) and (3H)-inulin (0.45 µM, Figure 5.6 d, 
e, f ) by ciPTEC cell monolayers, cultured on double coated PES-50, polyester 
Transwell® membranes or Coll IV coated polyester Transwell® membranes. 
The paracellular leakage of (3H)-inulin across the monolayer was used as 
an indicator of passive diffusion, hence, monolayer tightness, since active 
transcellular transport has not been reported for this compound (44). In all 
cases, the inulin leakage was very low, indicating that a tight monolayer was 
achieved. The observed average leakage of 0.8 ± 0.1 pmol min-1 cm-2 (0.1% of 
the total inulin amount) is comparable to observations made in previous 
studies that utilized MDCK or LCC-PK cells (45). In accordance, the organic 
cation transport inhibitors, metformin and cimetidine, did not affect inulin 
transport across the cell monolayers. The creatinine flux through the double-
coated “living” PES-50 membranes (2.8 ± 0.1 pmol min-1 cm-2) was 3.5 times 
Uncoated 1 min l-DOPA 
(3 h) + 1 min Coll IV
4 min l-DOPA 
(1 h) + 4 min Coll IV
Pure water permeance (L m−2 h−1 bar−1) 738 ± 110 194 ± 35 146 ± 10
BSA solution permeance (L m−2 h−1 bar−1) 57 ± 7 44 ± 8 37 ± 27
IgG solution permeance (L m−2 h−1 bar−1) 53 ± 11 65 ± 24 51 ± 12
BSA SCa = CP/Cb (–) 0.03 ± 0.01 0.06 ± 0.02 0.02 ± 0.01
IgG SCa = CP/Cb (–) 0.02 ± 0.01 0.05 ± 0.03 0.04 ± 0.03
Table 5.1 Comparison of the transport properties of uncoated PES-50 membrane and 
coated with L-DOPA (2 mg/ml) and Coll IV (25 µg/ml) with two approaches: 1) 1 min 
coating with L-DOPA (3h) and 1 min Coll IV; 2) 4 min coating with L-DOPA (1h) and 
4 min Coll IV.
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higher than the inulin flux (0.8 ± 0.03 pmol min-1 cm-2). Importantly, the 
creatinine flux was significantly decreased by the inhibitors, metformin (24 ± 
6% decrease, P<0.05) and cimetidine (18 ± 0.2% decrease, P<0.05), indicating 
that the developed “living” membrane actively secretes creatinine. The results 
of the “living” PES-50 membranes were comparable to those obtained for cells 
cultured on the golden standard Polyester - Coll IV Transwell® system (see 
Figure 5.6 and supplemental Figure 5.A3 which compare the permeance of 
inulin and creatinine through the various membranes). 
Various studies have used cellular over-expression models to demonstrate 
transepithelial creatinine transport. We currently show this trans-epithelial 
secretory pathway is endogenously present and functional in ciPTEC. Limited 
data are available for creatinine fluxes in human renal cells. Brown et al. 2008 
reported transepithelial creatinine fluxes for primary human proximal tubule 
epithelial cells (46). Although we observed lower creatinine fluxes in ciPTEC, 
the transport capacity is maintained for up to 40 passages (unpublished data). 
This underscores the robustness of this model and its potential application 
in a RAD. The use of an immortal cell line provides unlimited proliferative 
capacity, providing the option to expand the surface area of the living 
membrane necessary to reach the required clearance levels.
Previous studies have shown that the proximal tubule cell can take up free 
L-DOPA through the organic cation transport system, thereby influencing 
cellular processes (47,48). However, since the L-DOPA coating was fully 
polymerized before application of Coll IV, and several additional pre-culture 
washing steps had been applied, no free L-DOPA is expected to be present 
when culturing the cells. This is supported by the finding that no detrimental 
effect of the coating was observed for either transepithelial 14C-creatinine 
transport or for the morphology of ciPTEC.
Although we focused here on creatinine transport as a marker for endogenous 
secretion processes in ciPTEC, creatinine is not the only substance that has to 
be cleared from the blood. Many cationic and anionic waste products, including 
indoxyl sulfate, hippuric-acid, kynurenic acid, polyamines and guanidines, are 
retained in patients suffering from uremia (49). Previously, we reported that 
ciPTEC functionally express various membrane transport proteins that are 
involved in the uptake and excretion of uremic toxins (UTs) (7,30,50). Therefore 
a device based on cultured monolayers of ciPTEC grown on modified PES-
50 surfaces could provide the ideal tool in the removal of these compounds. 
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Figure 5.6 Basolateral to apical fluxes of (a,b,c) (14C)-creatinine (0.75 μM) and (d,e,f) 
(3 h)-inulin (0.45 μM) across ciPTEC monolayers. Measurements were performed in 
the presence or absence of the inhibitors metformin (100 µM) or cimetidine (100 µM). 
Depicted are ciPTEC monolayers cultured on: (a,d) PES-50 Transwell® inserts coated 
with L-DOPA(1h) and Coll IV; (b,e) Polyester Transwell® membranes coated with 
L-DOPA(1h) and Coll IV; (c,f) Polyester Transwell® membranes coated with Coll IV only. 
All coatings were applied for 4 minutes at the following concentration: L-Dopa 2mg/ml, 
Coll IV 25mg/mL. Data are presented as mean ± standard error, N=3 *P<0.05. 
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The use of sophisticated bioanalysis techniques such as LC-MS/MS might 
provide more opportunities for the transepithelial transport measurements 
of these toxic compounds by ciPTEC monolayers (51). As a next step in RAD 
development, long term stability and preservation of functionality in ciPTEC 
monolayers should be evaluated. Furthermore, the introduction of dynamic 
culture conditions could improve both the formation of tight junctions and 
cellular transport properties (52). Recent work suggests beneficial effects 
of shear stress on renal epithelia, leading to increased endocytosis (45) and 
sodium reabsorption by the NHE3 receptor (53,54). Evaluation of the shear 
stress on the functionality of a transporting ciPTEC monolayer would provide 
valuable information for the development of a bioartificial device. 
Conclusions - outlook
In this study, we showed the proof of concept for creating a “living 
membrane” by combining functional ciPTEC with PES-50 membranes coated 
with L-DOPA and Coll IV. The coating was optimized to achieve retention 
of vital blood components whilst preserving high water permeance and 
optimal cell monolayer formation. The transport of creatinine through the 
developed “living membrane” was comparable to golden standard systems 
for studying transepithelial transport across proximal tubule monolayers 
in-vitro. The results reported here are promising for the development of a 
bioartificial kidney. Further investigations are required to establish the long-
term stability of these functional renal cell monolayers. Future studies will be 
directed towards producing “living membranes” on hollow fiber PES-based 
membranes and to evaluate up-scaling in a bioreactor system to develop a 
clinically relevant device. 
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Figure 5.A3 basolateral to apical creatinine transport.
The basolateral to apical Inulin diffusion, and creatinine apparent permeability (Papp) 
was calculated with the following equation:
Where J = flux; Cb = initial concentration in the basolateral compartment; Ca = initial 
concentration in the apical compartment. For the double coated PES-50 and polyester 
membranes the transepithelial transport levels were 2.2 ± 0.4 and 1.97 ± 0.3 μL cm-2 
min-1, respectively. For the standard polyester Transwells® coated with Coll IV this 
value was 1.8 ± 0.3 μL cm-2 min-1. Data are presented as mean ± standard error, N=3 in 
duplicates, *P<0.05 **P<0.01 ***P<0.001
𝑃𝑃app =
𝐽𝐽
𝐶𝐶b − 𝐶𝐶a
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ABSTRACT 
The bioartificial kidney (BAK) aims at improving dialysis by developing ‘living 
membranes’ for cells-aided removal of uremic metabolites. Here, unique 
human conditionally immortalized proximal tubule epithelial cell (ciPTEC) 
monolayers were cultured on biofunctionalized MicroPES (polyethersulfone) 
hollow fiber membranes (HFM) and functionally tested using microfluidics. 
Tight monolayer formation was demonstrated by abundant zonula 
occludens-1 (ZO-1) protein expression along the tight junctions of matured 
ciPTEC on HFM. A clear barrier function of the monolayer was confirmed by 
limited diffusion of FITC-inulin. The activity of the organic cation transporter 
2 (OCT2) in ciPTEC was evaluated in real-time using a perfusion system by 
confocal microscopy using 4-(4-(dimethylamino)styryl)-N-methylpyridinium 
iodide (ASP+) as a fluorescent substrate. Initial ASP+ uptake was inhibited 
by a cationic uremic metabolites mixture and by the histamine H2-receptor 
antagonist, cimetidine. In conclusion, a ‘living membrane’ of renal epithelial 
cells on MicroPES HFM with demonstrated active organic cation transport 
was successfully established as a first step in BAK engineering.
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BACKGROUND
The development of biotechnological platforms to aid uremic syndrome 
treatment is of high interest world-wide. Current treatment strategies, such 
as hemo- or peritoneal dialysis, demonstrate a poor clearance of small lipid 
soluble and protein-bound uremic metabolites and the mortality rate in 
patients suffering from renal disease remains high (1). The uremic syndrome is 
characterized by the retention of metabolites due to an attenuated filtration 
capacity of the glomerulus and a loss of function of proximal tubule epithelial 
cells (PTEC), which are responsible for active metabolite secretion. Elevated 
levels of retention solutes contribute to competitive inhibition of drug 
transporters and thereby alter the metabolic environment as well as drug 
disposition in the kidney (2, 3). The accumulation of uremic metabolites (i.e. 
uremic toxins) in the human body may contribute to further progression of 
renal disease and the association of chronic kidney disease with cardiovascular 
morbidity (4-6). 
A cell-aided device containing stable living membranes, which enable active 
transport of uremic metabolites would be a major breakthrough in the field of 
regenerative nephrology. Nowadays, various research groups are focussed on 
the development of a bioartificial kidney (BAK), containing PTEC to improve 
current treatment strategies (7-9). In uremic animals and patients suffering 
from acute kidney injury (AKI) encouraging results have been obtained 
with respect to enhanced survival in BAK treated subjects by reduction of 
the inflammatory status, but further extensive research is required to obtain 
stable and functional cell-aided devices for chronic use (9-13). A crucial step in 
the development of functional devices relates to advanced functionalization 
of the hollow fiber membranes (HFM) to stimulate monolayer formation. 
In vivo, the extracellular matrix (ECM) is key in inter- and intracellular signaling, 
regeneration, and support (14, 15). Mimicking this complex matrix to obtain 
well-differentiated PTEC monolayers in vitro is essential in BAK engineering. 
Successful PTEC monolayer formation was obtained using combinations 
of laminin, gelatin, matrigel, collagen IV and L-3,4-dihydroxydiphenylala- 
nine (L-DOPA) ECM coatings on biomaterials (16-18). However, active 
transport of uremic metabolites mediated by PTEC specific transporters on 
hollow fiber membranes to aid renal replacement therapy has, as of yet, not 
been demonstrated. 
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In addition to glomerular filtration, the renal excretion of endo- and 
xenobiotics is advanced by active tubular secretion, a process mediated by 
PTEC, which are equipped with a broad range of transporters. One of the 
main PTEC transporters involved in the uptake of cationic uremic metabolites 
and drugs, such as cimetidine, metformin and cisplatin (19-21), is the 
basolateral organic cation transporter - 2 (OCT2; SLC22A2). Various cationic 
uremic metabolites, including guanidino compounds and polyamines, were 
found to interact with this transporter as well (30). Guanidino compounds are 
derived from the arginine metabolism and are small, water-soluble cations 
and not bound to proteins (4). However, the effective removal of guanidines 
is hampered in uremic conditions particularly due to their large distribution 
volume (22). Guanidines are known neurotoxins (23), but more recently the 
pro-inflammatory effects on the expression of leukocyte surface molecules and 
thus the possible interference of leukocytes with endothelial cells resulting in 
cardiovascular events was demonstrated as well (24, 25). Polyamines, derived 
from cellular lysine, arginine or ornithine catabolism, were identified in the 
late ‘70s as putative cationic uremic metabolites by Campbell et al. (26). More 
recent work elucidated further that the polyamines cadaverine, putrescine, 
spermine, spermidine and their breakdown product acrolein accumulate in 
uremic patients and are associated with cytotoxicity, through damage to 
proteins, DNA and other cellular components (27-29). 
In our laboratory, a unique conditionally immortalized PTEC model (ciPTEC) 
derived from human urine was established and thoroughly characterized (31, 
32). These cells contain the temperature sensitive vector SV40tsA58, allowing 
proliferation at 33°C and differentiation in mature PTEC at 37°C. In addition, 
cells were transfected with human telomerase (hTERT) limiting replicative 
senescence by telomere length maintenance, improving further the unlimited 
availability of ciPTEC. This model presents a broad range of PTEC-specific 
functions, including the transporters associated with uremic toxin secretion 
along with drug metabolism enzymes (30, 31, 47). In the present study, ciPTEC 
monolayer function when cultured on MicroPES HFM was investigated as a 
crucial element of a renal assist device. To this end, permeability properties 
of (biofunctionalized) membranes, monolayer formation and epithelial 
functional characteristics were investigated. The latter included OCT2 activity 
assessment using a microfluidic system with real-life imaging in the presence 
or absence of OCT2 inhibitors as well as a cationic uremic metabolites mixture 
of guanidines and polyamines. 
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METHODS
Brief methods are given. For details, the reader is referred to Supplementary 
information.
Chemicals and cell culture materials
Chemicals were purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands) 
unless stated otherwise. MicroPES type TF10 hollow fiber capillary membranes 
(wall thickness 100 µm, inner diameter 300 µm, max pore size 0.5 µm) were 
obtained from Membrana GmbH (Wuppertal, Germany). Cell culture plates 
were purchased from Greiner Bio-One (Monroe, NC).
Hollow fiber sterilization and double coating
MicroPES (polyethersulfone) hollow fiber membranes were sterilized using 
70% (v/v) EtOH incubation for 30 min. The primary coating component 
L-DOPA (L-3,4-dihydroxyphenylalanine, 2 mg.ml-1) was dissolved in 10 mM 
Tris buffer (pH 8.5), as described previously by Ni et al. (16), at 37°C for 45 min. 
Next, the solution was filter sterilized prior to incubation of the horizontally 
placed fibers for 5 hours at 37°C. The L-DOPA coated fibers were exposed 
to the second coating component human collagen IV (C6745-1ml, 25 µg.ml-1) 
for 1 hour at 37°C. The collagen IV solution was aspirated afterwards and the 
fibers were washed thoroughly in HBSS buffer prior to cell seeding. 
Scanning electron microscopy of cell-free hollow fiber 
membranes
Membrane topography of uncoated and coated HFM was determined 
using scanning electron microscopy (SEM) analysis (Philips XL-30 ESEM, 
Amsterdam, the Netherlands). In short, HFM were prepared using liquid 
nitrogen fracture to enable cross section analysis. Samples were incubated 
at 37°C overnight and gold sputtered before examination by SEM (3 kV and 
5 kV).
Transport properties of cell-free hollow fibers 
membranes
The transport of pure water (Merck MilliPore, Billerica, MA), bovine serum 
albumin (BSA) and immunoglobulin G (IgG) solutions through the uncoated 
and coated cell-free HFMs were measured at various transmembrane 
pressures using a KrosFlo Research IIi Tangential Flow Filtration system 
(Spectrum laboratories, Wurzburg, Germany). The membrane permeability 
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of H2O was plotted as the slope of the flux versus the transmembrane 
pressure. The membrane sieving coefficient (SC) was calculated by dividing 
the concentration of the BSA and IgG in the permeate by the concentration 
of the feed protein solution. 
Culture of ciPTEC on double coated hollow fiber 
membranes
Proliferating ciPTEC (32) were seeded on double-coated fibers (length 2cm) 
using 1.5 x 106 cells per 1.5 ml. The cell suspension was added to an eppendorf 
tube containing the fiber and incubated at 33°C, 5% (v/v) CO2, for 4 hours. 
Every hour the tube was turned 90° in order to stimulate cell adhesion to 
the whole surface. Next, fibers with adhered cells were removed from the 
suspension and transferred to a 6 well plate with PTEC culture medium and 
were cultured as previously described by Jansen et al. (31).
Immunocytochemistry
The expression of OCT2, zonula occludens-1 (ZO-1) and the ECM component 
collagen IV in ciPTEC monolayers on hollow fibers were investigated using the 
immunocytochemistry methodology as previously described by Jansen et al. 
(31). The expression and localization of the proteins of interest were examined 
using the Olympus FV1000 Confocal Laser Scanning Microscope (Olympus, 
Tokyo, Japan) and images were captured using the Olympus software FV10-
ASW version 1.7.
Transmission- and scanning electron microscopy
The morphology of ciPTEC and its organelles was investigated using 
transmission electron microscopy (TEM) and SEM. In short for TEM, cells 
were fixed and dehydrated using series of chemical solutions and finally 
embedded in Epon and polymerized at 60°C. After ultrathin sectioning and 
contrasting with uranyl acetate and lead citrate, sections were analyzed 
using a transmission electron microscope JEOL JEM 1010 (Jeol, Akishima 
Tokyo, Japan). For SEM purposes, cells were fixed and dehydrated using 
various chemical solutions and finally critical point dried. Samples were gold 
sputtered prior to SEM analysis (JEOL JSM-6340F, Tokyo, Japan).
Transepithelial barrier function
Paracellular permeability was determined in the living membrane by endpoint 
quantification of inulin-fluorescein isothiocyanate (FITC) (0.1 mg.ml-1 in 
Krebs-Henseleit buffer) supplemented with HEPES (10 mM; KHH buffer)) 
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diffusion when perfused (6 ml.h-1, in close agreement with previously applied 
flow rates (8)) using a custom-made microfluidic system (supplemental figure 
S6.1) connected to a syringe pump (Terumo STC-521, Terumo Europe N.V., 
Leuven, Belgium) for 13 min at 37°C. As a control, the inulin-FITC diffusion 
in coated HFM in the absence of cells was investigated in similar conditions. 
Fluorescence was detected by measuring samples and a standard range (0.0005 
– 0.1 mg/ml, including a final blank sample (KHH buffer) 100 µl) at excitation 
wavelength 485 nm and emission wavelength 535 nm, using a VictorTM X3 
multilabel platereader (Perkin-Elmer, Groningen, The Netherlands). Blank 
data were subtracted from all arbitrary fluorescence units measured and the 
corrected AFU data of the standard range were used to calculate the inulin-
FITC concentration of the samples (mg/ml). Next, the flux (J) was calculated 
according to:
J = ((((C / Mw) * V) *109) / t) / A = pmol · min-1 · cm-2
Where C is the calculated concentration (mg/ml), Mw the average inulin-FITC 
molar mass in mg/mmol (4500 mg/mmol), V the volume present in the apical 
compartment of the perfusion chamber (0.3 ml), t the perfusion time (13 min) 
and A the fiber surface (0.13 cm2). 
Functional organic cation transport
The activity of OCT2 in ciPTEC cultured on HFM was examined real-time by 
perfusing the hollow fiber basolaterally (inner HFM, (6 ml.h-1, (8))) with the 
fluorescent OCT2 substrate 4-(4-(dimethylamino)styryl)-N-methylpyridinium 
iodide (ASP+, 10 µM) in KHH buffer, when assembled in a microfluidic system. 
The assay was performed in the presence or absence of a cationic uremic toxin 
mix (UTmix; 10 times uremic plasma concentrations reported in literature - 
spermidine 6.7 μM, spermine 0.9 μM, cadaverine 2.1 μM, putrescine 8.8 μM, 
acrolein 14.2 μM, guanidine 21.8 μM and methylguanidine 76.6 μM) (30) or 
cimetidine (100 µM), for 13 min at 37°C, 5% (v/v) CO2. Imaging was performed 
using the Zeiss LSM510 META microscope (Zeiss, Oberkochen, Germany). 
Semi-quantification of real-time data was performed using Image J software 
(version 1.40g). Of each fiber in time spanning 1 - 13 min (800 scans), four cells 
present in the focal plane were used to extract mean ASP+ pixel intensities 
and background was subtracted using pixel intensities form ASP+ perfused 
non-cell double-coated fibers. Next, data were normalized according to:
Yt/xmt * 100
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Where Yt is the pixel intentsity at time point t of a condition (ASP+ only, ASP+ 
+ UTmix or ASP+ + cimetidine) divided by Xmt , which is the average pixel 
intensity (m) of only ASP+ condition at that similar time point (t). This value 
was multiplied by 100 and the obtained relative data were fitted according 
to One-phase exponential association using nonlinear regression analysis. To 
compare ASP+ uptake in different conditions, slopes were extracted from min 
1 - 8 and compared. In detail, of each fiber from min 1 - 8 (428 scans), four cells 
present in the focal plane were used to extract mean ASP+ pixel intensities 
and were background corrected. Average pixel intensities from these four 
cells per fiber were plotted and six slopes derived from six fibers per condition 
were calculated using linear regression analysis and compared to ASP+ uptake 
using two-way ANOVA analysis followed by Bonferroni post-test.  
Data analysis
All data are expressed as mean ± S.E.M of multiple replicates. Nonlinear 
curve fitting and statistical analysis of functional organic cation data were 
performed with GraphPad Prism version 5.02 (La Jolla, CA). A two-way 
ANOVA analysis followed by Bonferroni post-test or, when appropriate, an 
unpaired t test was applied. A p-value of <0.05 was considered significant. 
RESULTS
Modified HFM maintain membrane permeability
The surface of MicroPES HFM was functionalized via a double coating to 
enable tight homogeneous cell monolayer formation. The coating was 
successfully developed in 2D by our group using Transwell® membrane 
supports (18). Here, this was optimized further in 3D. The membrane surface 
and cross sections of uncoated and coated HFM in the absence of cells were 
investigated using SEM (figure 6.1A-B). In agreement with our previous 
study (18), the coatings applied were thin and did not differ between fibers, 
consistent with their transport properties. The coated HFM should facilitate 
transepithelial transport of protein-bound uremic toxins, with retained solute 
permeability. As shown in figure 6.1C, the H2O permeability was preserved in 
double coated HFM ((16.4 ± 0.7) . 103 L m-2 h-1bar-1) compared to uncoated HFM 
((17.0 ± 0.3) . 103 L m-2 h-1bar-1). In addition, both IgG and BSA passed almost 
freely through the membrane as demonstrated by the sieving coefficient (SC) 
close to 1 for both coated (0.90 ± 0.01 and 0.97 ± 0.02, respectively; p<0.01) 
and uncoated HFM (0.97 ± 0.02 and 0.98 ± 0.01, respectively) (figure 6.1D). 
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Obviously, the final composition of coated HFM with a tight cell monolayer 
should form a true barrier and prevent the loss of essential components such 
as IgG and albumin into the dialysate.
Figure 6.1. HFM topography and flux of essential compounds.
(a-b) Representative SEM images of uncoated and coated MicroPES HFM are shown. 
No microscopic differences were observed and topography was preserved in coated 
HFM. (c) The water permeance of uncoated and coated HFM was highly similar 
in both conditions (U: (17.0 ± 0.3) . 103 Lm-2 h-1bar-1) vs. C: (16.4 ± 0.7) . 103 Lm-2 h-1bar-1, 
respectively). (d) The SC of IgG was slightly less in coated HFM (C: 0.90 ± 0.01, p<0.01) 
compared to uncoated HFM (U: 0.97 ± 0.02), whereas BSA passed almost freely through 
the membrane as demonstrated by the SC close to 1 for coated (C: 0.97 ± 0.02) and 
uncoated HFM (U: 0.98 ± 0.01). Data are shown as mean ± S.E.M. of three independent 
experiments performed in duplicate ** = p<0.01 using an unpaired t test. 
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Extracellular matrix, cellular adhesion and paracellular 
permeability
Collagen IV is a non-fibrillar collagen and is known to assist in cell 
differentiation towards renal lineages from various stem cell populations 
(33). The presence of a collagen IV matrix after the coating procedure was 
confirmed, as shown in figure 6.2A and B, though a heterogeneous pattern 
was observed. Interestingly, in the presence of matured ciPTEC, a nice 
homogeneous collagen IV matrix was visible (figure 6.2C and D). Moreover, cell 
adhesion clearly improved upon surface modification, as shown in figure 6.2E, 
suggesting biofunctionalization. Hardly any nuclei (i.e. cells) were detected 
when cultured on uncoated HFM, whereas a uniform distribution of nuclei 
was observed after double coating. Furthermore, the transepithelial barrier 
function was quantified by inulin-FITC diffusion after perfusion of HFM in 
the presence or absence of matured ciPTEC. As shown in figure 6.2F, matured 
ciPTEC formed a true barrier compared to coated HFM in the absence of cells 
(373 ± 42 pmol · min-1 · cm-2; 1200 ± 193 pmol · min-1 · cm-2, respectively, p<0.001). 
In addition, cell adhesion of ciPTEC to PES HFM was found to be related to 
the curvature of the membrane. Similar double coating procedures applied to 
PES HCO 1100 membranes with an inner diameter of 215 µm resulted in poor 
ciPTEC adherence (supplemental figure S6.2), in contrast to double coated 
MicroPES HFM with an inner diameter of 300 µm (figure 6.2). 
Intact cellular organelles and numerous microvilli 
Matured ciPTEC cultured on HFM retained intact cellular organelle 
morphology as observed by TEM (figure 6.3A). The presence of numerous 
mitochondria indicated that the cell monolayer consists of viable and 
Figure 6.2 Extracellular matrix, cellular adhesion and paracellular permeability. 
Representative confocal images of collagen IV (green) in y-z (a and c) and x-y (b and 
d) planes are shown. (a-b) A heterogeneous collagen IV ECM pattern was detected on 
coated HFM without cells. (c-d) Nuclei were stained using DAPI (blue) in matured 
ciPTEC cultured on coated HFM. A homogenous and abundant distribution of collagen 
IV (green) was detected in the presence of matured ciPTEC. (e) Representative images 
of adhered cells (matured ciPTEC) are shown by nuclei staining (dapi; blue). A limited 
number of cells were present when cultured on uncoated HFM whereas numerous 
cells adhered to the coated HFM surface. (f) The transepithelial barrier function was 
examined in the presence or absence of matured ciPTEC by inulin-FITC perfusion and 
the flux across the HFM was quantified. Data are shown as mean ± S.E.M. of three 
independent experiments performed in triplicate or duplicate. *** = p<0.001 using an 
unpaired t test. 
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Figure 6.3 Cellular organelles and surface characteristics.
(a) The morphology of organelles in matured ciPTEC cultured on HFM (H) was 
investigated by transmission electron microscopy and intact cells were detected. Next 
to numerous well-developed mitochondria, the nucleus (N) containing the chromatin 
(Ch), the endoplasmatic reticulum (E), ribosomes (R) and the Golgi apparatus could 
be nicely detected. (b) The surface of matured ciPTEC was visualized using scanning 
electron microscopy. At the apical membrane microvilli were observed, as expected for 
proximal tubule epithelial cells, though a heterogeneous distribution was detected. 
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Figure 6.4 ZO-1 and OCT2 protein expression.
Representative confocal images of ZO-1 (green), OCT-2 (red) and nuclei (blue) in 
matured ciPTEC cultured on HFM are shown in x-y and y-z planes. (a-b-c-e) The 
ZO-1 expression was abundantly present along the cell boundaries within a tight and 
homogenous cell monolayer. (d-e) The endogenous OCT-2 protein expression in ciPTEC 
was observed heterogeneously in the membranes, moreover, some signal was detected 
in the cytoplasm. 
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metabolically active PTEC (34). Moreover, other essential cellular components, 
including the Golgi apparatus, endoplasmatic reticulum, ribosomes, the 
nucleus and its chromatin, could be determined. The brush border membrane 
of ciPTEC is reasonably well-developed, containing many microvilli to enlarge 
the apical surface and to stimulate intensive reabsorption, as observed with 
SEM (figure 6.3B).
Homogenous cell monolayers represent ZO-1 and OCT2 
expression
The presence of the tight junction protein ZO-1 in cell monolayers emphasizes 
cell polarity and monolayer tightness. In addition, tight junction proteins 
contribute to fluid and ion homeostasis mediated by paracellular transport 
(35). A tight homogeneous cell monolayer was observed for ciPTEC on 
HFM with ZO-1 abundantly expressed along the cell boundaries as shown 
in representative z-scans (figure 6.4A and C). Moreover, the endogenous 
expression of the influx transporter OCT2 was demonstrated to be expressed 
basolaterally (figure 6.4D), although some cytoplasmic staining was visible as 
well, suggesting ongoing posttranslational OCT2 modifications as previously 
suggested (53). The OCT2 antibody was validated in paraffin embedded 
Figure 6.5 Functional organic cation transporter - 2 transport.
(a) Representative real-time images and (b) semi-quantification of ASP+ uptake (10 µM, 
green) are shown, a model substrate for OCT-2, in the absence (circle) or presence of 
specific inhibitors (triangle: cationic uremic toxin mix (UTmix), square: cimetidine (100 
µM)) in matured ciPTEC cultured on HFM. Data were normalized against ASP+ uptake in 
the absence of inhibitors and were fitted according to One-phase exponential association 
using nonlinear regression analysis. (a - circle) After 4 min, intracellular ASP+ signal could 
be visualized and further increased until 13 min. (a - triangle) In the presence of UTmix 
the ASP+ uptake was less pronounced during the complete uptake experiment compared 
to perfusion with only ASP+. (a - square) The ASP+ uptake was clearly attenuated in the 
presence of cimetidine and hardly any further increase in fluorescent ASP+ uptake was 
detected after 7 min. (b) Semi-quantification of ASP+ uptake data in the absence (10 µM, 
circle) or presence of specific inhibitors (triangle: cationic uremic toxin mixture (UTmix, 
(10X)), square: cimetidine (100 µM) in matured ciPTEC cultured on HFM are shown. A 
clear fluorescent intracellular signal in ciPTEC indicated an active OCT-2 mediated basal 
ASP+ uptake started at 1 min. Initial uptake was significantly inhibited by the UT mixture 
and cimetidine. Data are shown as mean ± S.E.M. of three independent experiments 
performed in duplicate. Slopes extracted from min 1 - 8 of the ASP+ uptake in different 
conditions were compared and applied for statistical analysis. *** = p<0.001 using two-
way ANOVA analysis followed by Bonferroni post-tests. 
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human kidney tissue using immunohistochemistry and positive staining at 
the basolateral membrane of PTEC was observed (data not shown). 
ciPTEC on HFM show functional OCT2 transport
The activity of basolaterally expressed OCT2 in matured ciPTEC cultured 
on coated HFM was determined by real-time fluorescent ASP+ uptake 
measurements, and shown in figure 6.5. The experiments were performed 
in the presence or absence of a cationic toxin mix or cimetidine, which 
are known inhibitors of OCT2-mediated ASP+ transport (30). In figure 
6.5A, representative real-time uptake images of the various conditions are 
shown for the time frame of 4 - 13 min. In the absence of inhibitors, a clear 
intracellular fluorescent ASP+ signal was visible after 4 min of perfusion, 
which increased up to 13 min. In the presence of the cationic uremic toxin 
mixture of guanidine and polyamine compounds, the basal uptake of ASP+ 
was still detectable and augmented over time, though the uptake was less 
pronounced compared to fiber perfusion in absence of the mixture. In the 
presence of cimetidine, the ASP+ uptake was even further attenuated. Semi-
quantification of these data (figure 6.5B) confirmed the observed differences 
in ASP+ uptake per condition. The slopes from the linear part (min 1 - 8) of 
ASP+ uptake curves in the presence of the cationic toxin mix or cimetidine 
were significantly altered compared to control uptake (25 ± 16%, p<0.001 and 
62 ± 12%, p<0.001, respectively)
DISCUSSION 
In this study, ciPTEC were successfully cultured on optimally coated HFM 
with maintained functionality. The coating and membrane curvature showed 
to be crucial for the formation of a homogenous cell monolayer with a clear 
epithelial barrier function, without affecting transport properties of H2O or 
albumin. Epithelial cell polarity and organelle morphology were retained when 
cultured on HFM. In addition, the epithelial and polarized characteristics 
of ciPTEC were demonstrated further by the expression of ZO-1 and the 
basolaterally expressed OCT2. Transport activity was confirmed by specific 
uptake in ciPTEC monolayers, demonstrating the establishment of a living 
membrane suitable for BAK development.
The MicroPES membranes used in this study are hydrophilized fibers used 
predominantly for plasma separation and have rather large pores allowing the 
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transport of proteins including BSA and IgG. The membranes are designed for 
having low interaction with blood, plasma and proteins. To apply a uniform 
cell monolayer, the outer membrane of HFM had to be biofunctionalized by 
ECM components. The native ECM is a dynamic network consisting of various 
types of collagen, glycosaminoglycans, laminin and fibronectin connected to 
integrins present in the plasma membrane. The ECM is a key factor in cell 
adhesion, differentiation and regeneration, as well as in intercellular signalling 
(14, 15). Oo et al. demonstrated a successful coating on PES membranes 
consisting of the combination of L-DOPA and collagen IV to culture primary 
human renal cells (36). Upon polymerization, when exposed to light and 
oxygen, the L-DOPA layer becomes negatively charged and will attract the 
positively charged collagen IV that is applied subsequently. In our laboratory, 
this coating was first applied on flat PES membranes and optimal conditions 
for ciPTEC adhesion and differentiation were established (18). Maintained 
membrane permeability, as well as homogenous cell monolayers and 
creatinine transport were demonstrated in ciPTEC on double coated PES flat 
membranes. Based on these encouraging results, the coating was adapted for 
HFM biofunctionalization. Both L-DOPA and collagen IV coating times were 
extended to hours instead of minutes to stimulate cell adhesion and tight cell 
monolayer formation. Next to an optimized ECM, the membrane curvature is 
an important parameter for maintaining cellular functions (51). The culture 
of ciPTEC on MicroPES HFM with a slightly lower membrane curvature 
compared to the HCO 1100 HFM had a positive effect on cell adhesion, most 
likely related to a more optimal organization of the cytoskeleton and its 
membrane composition. The almost unrestricted permeability of H2O, IgG 
and albumin in coated MicroPES HFM indicated the need for a tight cell 
monolayer with a true barrier function to avoid significant blood components 
loss from the host. Hence, the free permeability of albumin across coated HFM 
is essential, as a large number of uremic toxins are protein-bound and need to 
be delivered in close proximity to the cells in order to be eliminated. Possible 
immunogenic effects due to contact between the host blood components and 
cell monolayers will be studied thoroughly in future research. 
The morphological characteristics of tight cell monolayers on HFM were 
examined, as well as the epithelial barrier functions. In vivo, the proximal 
tubule epithelium is known as a leaky epithelium and paracellular transport 
is mediated along the tight junctions and lateral inter-cellular spaces (34). The 
reabsorption of glucose, amino acids, H2O and electrolytes is partly facilitated 
by paracellular transport and occurs in a passive manner. The abundant 
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expression of the tight junction protein ZO-1 in the monolayers emphasized 
the epithelial character of the ciPTEC when cultured on HFM. Moreover, the 
epithelial barrier function was confirmed by demonstrating limited inulin-
FITC diffusion. Since technical aspects of fiber handling when placed in 
the perfusion chamber will affect the tightness of the cell layer, the barrier 
restriction measured, as shown here, is most likely an underestimation. To 
prevent monolayer disturbance caused by technical aspects in future research, 
cell culture on HFM could be performed in disposable perfusion chambers. In 
this way, the cells on HFM will mature while already present in the system and 
will be ready-to-use for any perfusion experiment. Vital PTEC possess a high 
number of mitochondria to facilitate active processes (e.g. elimination of waste 
products) and a well-developed brush border membrane containing microvilli 
to enlarge the apical surface (34). The morphology of ciPTEC reflected the 
presence of intact organelles and a substantial number of mitochondria. The 
microvilli at the apical surface were visible when ciPTEC were cultured on 
HFM, but showed a heterogeneous pattern. Further optimization of culture 
conditions in disposable perfusion chambers, including medium flow across 
the apical membrane, could improve the uniformity of the ciPTEC brush 
border membrane (49).
The application of a cell-aided device, such as the BAK, for the removal of 
cationic metabolites can improve current renal replacement therapies. In 
this study, active OCT2 transport was demonstrated in living membranes 
of human PTEC when cultured on HFM for BAK purposes. Uptake via the 
OCT2 transporter is the first step in the renal secretion of various cationic 
endogenous metabolites or other xenobiotics, including drugs (54). Upon 
transport failure, accumulation of cationic metabolites, such as guanidines 
occurs. This is associated with cardiovascular implications, induced by, 
amongst others, activated leukocytes and microinflammation (24, 25). Here, 
OCT2-mediated ASP+ uptake was inhibited in the presence of a polyamine 
and guanidino cationic uremic toxin mixture, as well as in the presence of 
cimetidine, a well-known and extensively studied renal OCT substrate and 
inhibitor (37, 38). These findings indicate functional OCT2 transport in ciPTEC 
on HFM, in concordance with recently described observations by Schophuizen 
et al., where the cationic toxin mixture competed with OCT2-mediated ASP+ 
uptake in a ciPTEC cell suspension (30). In addition, Kimura and Winter et 
al. demonstrated interference of guanidino compounds and putrescine, a 
polyamine, with OCT2 using human embryonic kidney cell line (HEK293) 
overexpressing the transporter (39, 40). The application of functional ciPTEC 
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cultured on HFM opens a promising avenue in the clearance of cationic 
metabolites in patients suffering from renal disorders. Future research is 
required to quantify transepithelial transport of uremic metabolites in 
up-scaled multifiber bioreactors. As (cationic) uremic toxins compete for 
the same system, their accumulation may also hamper efficient removal. 
Therefore, in-depth kinetic studies are needed to investigate the clearance 
capacity of our bioartificial tubule over time, and to predict their performance 
in vivo. In addition, other aspects, such as the balance between the number 
of ciPTEC and the duration per dialysis cycle required for efficient removal of 
waste products in human patients, have to be investigated.
The development of a functional and stable BAK device is a complex interplay 
between advanced biomaterials and renal epithelial cells. Beneficial effects 
were demonstrated in uremic animals and enhanced survival of patients 
suffering from multi-organ failure and AKI in a phase II clinical trial. 
However, a phase IIb clinical trial failed predominantly due to hampered cell 
performance (9-13, 41). In the late ‘90s, Humes et al. cultured porcine proximal 
tubule epithelial cells (LLC-PK1) in a multi-fiber bioreactor and demonstrated 
metabolically active cells, capable of ammoniagenesis, glutathione metabolism 
and 1,25-dihydroxyvitamin D3 synthesis (42). However, next to its non-human 
origin, porcine cells have limited transport functionality (e.g. lack of essential 
transporters (43, 44)) and are not preferred for use in a BAK device. Only a 
few human-derived cell models are available with endogenous transporter 
expression and functional capacity. A well-distributed cell line is HK2, which 
was developed by recombinant retroviral transduction (humanpapillomavirus 
16 E6/E7 genes) of human primary renal cortex cells (45), though a lack 
of functional transporters emphasizes the limitations of this model for 
studying renal transport in pharmacological and physiological studies (46). 
The thoroughly characterized cell model ciPTEC, as used in this study, was 
isolated from human urine and immortalized using retroviral hTERT and SV40 
large T antigen transduction (32). The cell model displays diverse functional 
endogenous in- and efflux transporters relevant in the secretion of endo- and 
xenobiotics (31, 32). In addition, UDP-glucuronosyltransferases (UGT) and 
mitochondrial succinate dehydrogenase enzyme activity was confirmed and 
altered in uremic conditions that might affect drug disposition during CKD 
(47). Similar to HK-2, no organic anion transporter (OAT) expression could be 
detected in ciPTEC, a known phenomenon of immortal renal cells in culture 
and a drawback of renal cell line applications (48). Nevertheless, the stable 
functionality of other relevant transporters and metabolic enzymes in ciPTEC 
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upon prolonged culturing illustrate that these cells may prove a valuable tool 
in regenerative nephrology. Furthermore, this model may serve as a predictive 
model for drug toxicity screening in drug development processes. 
To treat patients suffering from CKD or end-stage renal disease (ESRD), an 
efficient removal of protein-bound uremic toxins by a BAK is a prerequisite 
to diminish systemic disease progression (50). The active transport of 
cationic uremic toxins mediated by ciPTEC, as shown here, is an important 
contribution for future BAK engineering. However, future research is required 
to study the maintenance of functional cationic and anionic toxin transport 
in an up-scaled BAK system, as well as multi-factorial safety aspects, as 
described by the European medicines agency in the European guidelines for 
advanced therapy medicinal products enabling the applications of GMO in 
medicinal products (52). 
In conclusion, a successful cell monolayer formation was established on 
biofunctionalized MicroPES HFM and matured ciPTEC represented clear 
epithelial characteristics with barrier and active transporter function. To the 
best of our knowledge, for the first time active organic cationic transport in 
PTEC monolayers on HFM was demonstrated. The combination of a unique 
human cell model with biofunctionalized MicroPES HFM is a valuable tool in 
regenerative nephrology and further development may contribute in future 
BAK engineering.
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SUPPLEMENTARY INFORMATION
Methods
Hollow fiber sterilization and double coating
MicroPES (polyethersulfone) hollow fiber membranes were sterilized using 
70% (v/v) EtOH incubation for 30 min. Subsequently, membranes were 
washed thoroughly in Hank’s balanced salt solution (HBSS) buffer containing 
CaCl2 (1.26 mM), MgCl (0.49 mM), MgSO4 (0.41 mM), KCl (5.33 mM), KH2PO4 
(0.44 mM), NaHCO3 (4.17 mM), NaCl (137.93 mM), Na2HPO4 (0.34 mM) and 
D-Glucose (5.56 mM). The primary coating component L-DOPA (L-3,4-
dihydroxyphenylalanine, 2 mg.ml-1) was dissolved in 10 mM Tris buffer (pH 8.5), 
as described previously by Ni et al. (16). To dissolve the coating, the solution 
was incubated at 37°C for 45 min. Next, the solution was filter sterilized prior 
to incubation of the horizontally placed fibers for 5 hours at 37°C. Every hour 
the fiber was turned 90°. Next, the L-DOPA solution was aspirated and the 
fibers were washed once with HBSS buffer. The L-DOPA coated fibers were 
exposed to the second coating component human collagen IV (C6745-1ml, 
25 µg.ml-1) for 1 hour at 37°C. After 30 min, the tube was turned 180° and 
incubated for the remaining time. The collagen IV solution was aspirated 
afterwards and the fibers were washed thoroughly in HBSS buffer prior to 
cell seeding.
Transport properties of cell-free hollow fibers membranes
The transport of pure water (Merck MilliPore, Billerica, MA), bovine serum 
albumin (BSA) and immunoglobulin G (IgG) solutions through the uncoated 
and coated cell-free HFMs were measured at various transmembrane 
pressures using a KrosFlo Research IIi Tangential Flow Filtration system 
(Spectrum laboratories, Wurzburg, Germany). Prior to the experiment, 
HFMs were incubated at 37°C in phosphate buffered saline, (PBS, pH 7.4; 
Life technologies, Breda, The Netherlands) for 1 hour. Next, the HFMs were 
assembled in one-membrane module using bi-component polyurethane 
potting glue (Intercol BV, Ede, The Netherlands), push-in fittings (Festo, 
Brussels, Belgium) and polyethylene tubing (Festo, Brussels, Belgium). 
The BSA and IgG were dissolved in PBS at concentrations of 1 mg.ml-1 and 
0.02 mg.ml-1, respectively (feed solutions). The pressure (0.10, 0.15 and 0.20 
bar) was applied from the luminal side towards the abluminal side of the 
HFM. As described previously by Schophuizen et al. (18), the flux through 
the HFM at each pressure was determined by collecting the mass of the 
permeated liquid over time correlated to the HFM surface area. BSA and 
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IgG samples were collected at each pressure after 15 min and concentrations 
were determined by spectrophotometric analysis (Cary 300 UV-Vis system, 
Agilent Technologies, Amstelveen, The Netherlands) at 280 nm and 276 nm 
wavelengths, respectively. 
Culture of ciPTEC on double coated hollow fiber membranes
Proliferating ciPTEC (32) were seeded on double-coated fibers (length 2cm) 
using 1.5 x 106 cells per 1.5 ml. The cell suspension was added to an eppendorf 
tube containing the fiber and incubated at 33°C, 5% (v/v) CO2, for 4 hours. 
Every hour the tube was turned 90° in order to stimulate cell adhesion to 
the whole surface. Next, fibers with adhered cells were removed from the 
suspension and transferred to a 6 well plate with PTEC culture medium: 
phenol-red free DMEM-HAM’s F12 medium (catalogue number 11039, Lonza, 
Basel, Switzerland) containing 10% (v/v) FCS (Greiner Bio-One, Monroe, NC), 
5 µg/ml insulin, 5 µg/ml transferrin, 5 ng/ml selenium, 36 ng/ml hydrocortisone, 
10 ng/ml EGF and 40 pg/ml tri-iodothyronine. The incubation period was 
prolonged at 33°C, 5% (v/v) CO2, for additional 48 hours. Subsequently, the 
proliferating cells on fibers were transferred to 37°C, 5% (v/v) CO2 to mature 
for 7 days. Cells upon passage 42 were applied in this study.
Immunocytochemistry 
The expression of OCT2 and zonula occludens-1 (ZO-1) in ciPTEC monolayers 
on hollow fibers were investigated using the immunocytochemistry 
methodology as previously described by Jansen et al. (31). The ZO-1 
(Invitrogen, Carlsbad, CA) and OCT2 primary antibodies were diluted (1:50) 
in block solution (HBSS buffer supplemented with 2% (w/v) BSA, 2% (v/v) 
fetal calf serum and 0.001% (v/v) Tween-20 to prevent aspecific binding), 
followed by incubation with goat-anti-mouse-Alexa488 conjugate or goat-
anti-rabbit-Alexa568 conjugate (1:200, Life Technologies), respectively. The 
expression of the ECM component collagen IV was investigated using the 
primary anti-type IV collagen antibody (1:50, Southern Biotech (Birmingham, 
AL)) followed by incubation with donkey-anti-goat-Alexa 488 conjugate 
((1:200, Life Technologies).
 
Transmission- and scanning electron microscopy
The morphology of ciPTEC and its organelles was investigated using 
transmission electron microscopy (TEM) and SEM. In short for TEM, cells 
were primary fixed using 2% (w/v) glutaraldehyde, postfixated in 1% (w/v) 
osmiumtetroxide supplemented with 1% (w/v) potassium ferrocyanide, all 
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dissolved in 0.1 M sodium cacodylatebuffer at room temperature (rT) for 1 
hour. Next, samples were dehydrated through a graded series of ethanol and 
finally embedded in Epon and polymerized at 60°C. After ultrathin sectioning 
and contrasting with uranylacetate and leadcitrate, sections were analyzed 
using a transmission electron microscope JEOL JEM 1010 (Jeol, Akishima 
Tokyo, Japan) at an accelerating voltage of 60 kV and images were captured 
using a Kodak Megaplus camera (San Diego, CA). For SEM purposes, cells were 
washed twice in 0.1M sodiumcacodylate buffer supplemented with 3% (w/v) 
sucrose (SCS) and primary fixed using 2% (w/v) glutaraldehyde in SCS at rT 
for 1 hour. Next, cells were washed three times in SCS and secondly fixed in 1% 
(w/v) osmiumtetroxide in SCS at rT for 2 hours. After this, cells were incubated 
using 1% (w/v) tannic acid in SCS at rT for 1 hour. Subsequently, samples 
were washed three times, processed to 70% (v/v) ethanol and incubated in 
5% (w/v) uranyl acetate dissolved in 70% (v/v) EtOH at rT overnight. Samples 
were dehydrated trough a graded series of ethanol (70%-80%-96%-100% 
(v/v)) and critical point dried. Finally, samples were gold sputtered prior to 
SEM analysis (JEOL JSM-6340F, Tokyo, Japan).
Transepithelial barrier function
Paracellular permeability was determined in the living membrane by endpoint 
quantification of inulin-fluorescein isothiocyanate (FITC) (0.1 mg.ml-1 in 
Krebs-Henseleit buffer (containing MgSO4 (0.14 g/L), KCl (0.35 g/L), KH2PO4 
(0.16 g/L), NaCl (6.9 g/L), CaCl2 (0.37 g/L), NaHCO3 (2.1 g/L) and D-Glucose 
(2.0 g/L)) supplemented with HEPES (10 mM; KHH buffer)) diffusion when 
perfused (6 ml.h-1) using a syringe pump (Terumo STC-521, Terumo Europe 
N.V., Leuven, Belgium) for 13 min at 37°C. The inulin-FITC diffusion in coated 
HFM in the absence of cells was investigated in similar conditions. During 
the experiment, the HFM was connected to a separated in- and outlet glass 
cannula (inner diameter 120 – 150 µm; DMT Trading, Aarhus, Denmark) 
assembled in a custom-made 3D printed cytocompatible polyester device 
(figure S6.1) to enable a separated basolateral (inner HFM, perfusion channel) 
and apical compartment (outer HFM, containing 300 µl KHH buffer). The 
inlet cannula was connected to a tubing system and a syringe pump, whereas 
the outlet cannula was connected to a tubing system and a depot to collect 
perfusate. First, the HFM was rinsed once using KHH buffer. Next, the inulin-
FITC was perfused and 100 µl sample was collected in the apical compartment 
after 13 min. 
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Supplemental figure S6.2 Representative images of ciPTEC performance on HCO 
1100 and MicroPES HFM.
(a) A poor cell adhesion was observed (i.e. no nuclei (blue)) when ciPTEC were cultured 
on double coated PES HCO 1100 HFM (inner diameter 215 µm). (b) Using a similar double 
coating procedure and the same batch of cells as used for HCO 1100 HFM, optimal cell 
adhesion and a tight monolayer formation with abundant ZO-1 expression (green) was 
detected using MicroPES HFM (inner diameter 300 µm).
Supplemental figure S6.1 Schematic presentation of a flow experiment setup 
including a 3D-printed microfluidic chamber.
The microfiber was connected to a separated in- and outlet glass cannula assembled in 
a custom-made 3D printed cytocompatible polyester device. The chamber was printed 
using a calibrated ROBO 3D beta R1 printer (Robo3D LLC, San Diago, CA) and the 
cytocompatible acrylonitril butadiene styrene (ABS) polymer. The ABS print temperature 
was 215°C on a heated bed of 90°C and the thickness of each layer was 100 µm, using a 
nozzle diameter of 0.3 mm. Dimensions as shown in the figure were optimized to have a 
stable system for fiber assembly and a low inner volume of 300 µl buffer, which enabled 
detection of inulin-FITC. Obviously, the buffer covered the fiber completely. For imaging 
purposes, the chamber was connected to a WillCo dish (WillCo Wells B.V., Amsterdam, 
The Netherlands) with a glass bottom using GI-MASK cytocompatible glue (Dental 
Union, Nieuwegein, The Netherlands) to prevent leakage from the chamber. During the 
experiment the system was closed using a cabinet in which 5% (v/v) CO2 was present and 
the temperature was controlled at 37°C. The real-time imaging was performed using a 40x 
magnification water lens of the confocal microscope. To test paracellular permeability 
using inulin-FITC, the chamber was connected to a regular petridish and the temperature 
was controlled at 37°C during the experiment using a heating plate. In both types of 
experiments a flow rate of 6 ml.h-1 was used for 13 min, using a syringe pump. 
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ABSTRACT 
The development of a biotechnological platform for the removal of waste 
products (e.g. uremic toxins), often bound to proteins in plasma, is a 
prerequisite to improve current treatment modalities for patients suffering 
from end stage renal disease (ESRD). Here, we present a newly designed 
bioengineered renal tubule capable of active uremic toxin secretion through 
the concerted action of essential renal transporters, viz. organic anion 
transporter-1 (OAT1), breast cancer resistance protein (BCRP) and multidrug 
resistance protein-4 (MRP4). Three-dimensional cell monolayer formation of 
human conditionally immortalized proximal tubule epithelial cells (ciPTEC) 
on biofunctionalized hollow fibers with maintained barrier function was 
demonstrated. Using a tailor made flow system, the secretory clearance of 
human serum albumin-bound uremic toxins, indoxyl sulfate and kynurenic 
acid, across the renal tubule was confirmed. These functional bioengineered 
renal tubules are promising entities in renal replacement therapies and 
regenerative medicine, as well as in drug development programs.
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BACKGROUND
Chronic renal failure (CRF) is a severe health problem with a high morbidity 
and mortality rate as adequate therapy is currently not available. Impaired 
renal function results in the accumulation of various endogenous uremic 
metabolites (i.e. uremic toxins), which are associated with a broad range of 
pathologies that constitute the uremic syndrome (1-3). The preferred treatment 
option for end-stage renal disease (ESRD) is organ transplantation, however, 
the worldwide organ shortage is profound and many patients experience graft 
failure (4, 5). Chronic dialysis (hemodialysis or peritioneal dialysis) is currently 
the best alternative treatment option, which is widely applied and efficient in 
removal of small water-soluble and middle molecular weight molecules, but 
it insufficiently removes larger and protein-bound uremic toxins (6, 7). The 
latter class comprises end-metabolites that originate from dietary breakdown 
amino acids, such as tyrosine, phenylalanine and l-tryptophan, for which 
their pathological role in the progression of the uremic syndrome has gained 
substantial interest in the last decade (6).
The majority of dietary protein derived l-tryptophan is metabolized to 
l-kynurenine, which in turn can be converted into kynurenic acid. Accumulation 
of kynurenic acid was found to correlate with several symptoms of uremia, 
including neurological disturbances, lipid metabolism disorder and anemia 
(8). Tryptophan can also be metabolized by intestinal bacteria into indoles, 
which are processed further in the liver into indoxyl sulfate, indole-3 acetic 
acid and indoxyl-β-D-glucuronide (9). Indoxyl sulfate as well as the tyrosine 
end-metabolites p-cresyl sulfate and p-cresyl glucuronide are associated 
with cardiovascular disease development via the activation of leukocytes, 
ROS production and their interaction with the vascular endothelium (10-12). 
Furthermore, the p-cresol derivates demonstrated cytotoxicity and a pro-
inflammatory response in renal epithelial cells (13), possibly contributing to 
CRF progression. Also, drug disposition is altered in patients with CRF, not 
only because of diminished kidney function but also due to a direct inhibition 
of drug transporters and drug-metabolism enzymes by uremic toxins (14, 15).
The residual renal function in ESRD patients is not only associated with the 
remaining glomerular filtration capacity, but also the ability of the proximal 
nephron segment to actively secrete protein-bound uremic toxins into 
the pro-urine (16, 17). To this end, proximal tubule epithelial cells (PTEC) 
are equipped with a broad range of transport proteins that accept a wide 
range of xenobiotics, including exogenous compounds such as drugs, and 
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endogenous (waste) metabolites. At the basolateral membrane the organic 
anion transporters 1 (OAT1; SLC22A6) and -3 (OAT3; SLC22A8) of the solute 
carrier family (SLC), are highly efficient in the uptake of the anionic uremic 
toxins such as the l-tryptophan, tyrosine and phenylalanine end-metabolites, 
shifting their protein binding to the free fraction (8, 18, 19). At the luminal 
side, the ATP binding cassette (ABC) transporters breast cancer resistance 
protein (BCRP; ABCG2) and the multidrug resistance-associated proteins 2 
and -4 (MRP2/4; ABCC2/4) are involved in their urinary secretion (20).
As the removal of protein-bound uremic toxins via PTEC is associated with 
better patients survival, the engineering of a bioartificial kidney (BAK) 
containing PTEC cultured on hollow fiber membranes (HFM) could be a 
promising platform to advance uremic toxin clearance. This was the focus of 
the current study using human conditionally immortalized PTEC (ciPTEC), 
expressing endogenously a broad range of functional transporters associated 
with uremic toxin handling (21, 22). Recently, complemented with OAT1 and 
-3 that are generally lost in PTEC upon culturing(23). The cells carry the 
temperature-sensitive mutant U19tsA58 of SV40 large T antigen (SV40T) and 
the essential catalytic subunit of human telomerase (hTERT), allowing the 
cells to proliferate at the permissive low temperature of 33°C and differentiate 
to mature PTEC at 37°C, and maintenance of telomere length preventing 
replicative senescence, respectively. This resulted in stable cell lines that could 
be maintained over a long period of time, and a valuable tool for studying 
renal clearance processes as required for BAK engineering.
In the present study, we demonstrate the development of functional 
bioengineered renal tubules that efficiently clear protein-bound anionic 
uremic toxins. First, the essential role of in- and efflux transporters in the 
removal of uremic toxins was studied in flat monolayers. Subsequently, 
three dimensional, polarized, ciPTEC monolayers on biofunctionalized 
polyethersulfone hollow fiber membranes were developed. Finally, as a 
crucial next step in BAK engineering, the secretory clearance of human serum 
albumin-bound indoxyl sulfate and kynurenic acid was confirmed.
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METHODS
Brief methods are given. For details, the reader is referred to Supplementary 
information.
Chemicals and cell culture materials
Chemicals were purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands) 
unless stated otherwise. The uremic toxins p-cresylsulfate and p-cresyl-
glucuronide were synthesized by the Institute for Molecules and Materials, 
Radboud University, Nijmegen, The Netherlands. MicroPES type TF10 hollow 
fiber capillary membranes (wall thickness 100 µm, inner diameter 300 µm, 
max pore size 0.5 µm) were obtained from Membrana GmbH (Wuppertal, 
Germany). Cell culture plates were purchased from Greiner Bio-One (Monroe, 
NC).
Cell culture of ciPTEC-OAT1 and -OAT3 
The transduction of OAT1 and OAT3 in ciPTEC (22) was performed as previously 
described by Nieskens et al. (23) and cells were cultured in supplemented 
PTEC culture media as described by Jansen et al.(21) Fibers were coated and 
seeded as described by Jansen et al. (27).
Fluorescein inhibition assay 
The potency of a panel of eight anionic uremic toxins to inhibit OAT1- and 
OAT3-mediated fluorescein uptake was investigated in flat monolayers using 
an inhibition assay as previously described by Nieskens et al. (23). Blank 
fluorescence data were subtracted and relative data compared to control 
were plotted.
Uptake of indoxyl sulfate and kynurenic acid by 
ciPTEC-OAT1
In short, active OAT1-mediated uptake of indoxyl sulfate and kynurenic 
acid was investigated using two concentrations of toxins (3 and 30 µM) in 
the presence or absence of probenecid (100 µM), kynurenic acid (100 µM) or 
indoxyl sulfate (100 µM). Intracellular toxin concentrations were analyzed 
using a LC-MS/MS system (Thermo scientific, Breda, The Netherlands) 
following the method described by Mutsaers et al. (14). Data processing was 
performed using the Thermo Xcaliber software (Thermo scientific, version 2.1) 
and absolute data were plotted. 
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Cell viability assay 
An MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cell 
proliferation assay was performed as previously described by Nieskens et al. 
(23). Background values were subtracted and normalized data were plotted.
Monolayer polarization and transepithelial barrier 
function
To investigate the barrier function of matured ciPTEC-OAT1 cultured on HFM, 
fibers were perfused with FITC-inulin (0.1 mg/ml in Krebs-Henseleit buffer 
supplemented with 10mM Hepes (KHH, pH 7.4)) and diffusion was measured 
in real-time. From each single replicate 4 different regions in focus were 
analyzed. Semi-quantification of real-time data was performed using Image J 
software (version 1.40g) and normalized data were plotted. To determine the 
polarization of the ciPTEC-OAT1 monolayer on HFM, the expression of tight 
junction protein zonula occludens-1 (ZO-1) was investigated according to the 
protocol as previously described by Jansen et al. (27). 
Detection of OAT1, BCRP and MRP4 mRNA expression 
The mRNA expression of OAT1, BCRP and MRP4 was examined in ciPTEC-
OAT1 when cultured in flat monolayers and as bioartificial renal tubules 
as previously described by Jansen et al. (21). Gene expression levels were 
normalized to expression levels of the reference gene GADPH and were 
expressed as fold increase compared to matured cells in well plates.
Fluorescein assay
To determine the OAT1 as well as BCRP and MPR4 transport activity in 
matured ciPTEC-OAT1 cultured on HFM, the fibers were connected to a similar 
perfusion set-up as was used for the barrier function assay. To measure active 
fluorescein uptake in real-time, fibers were perfused using 1 µM fluorescein 
in KHH in the presence or absence of specific drug transporter inhibitors or 
uremic toxins. Background corrected data were normalized against fluorescein 
uptake in the absence of inhibitors and were fitted according to one-site total 
binding saturation curve using non-linear regression analysis. In addition, 
Vmax values (i.e. the maximum initial rate of a reaction) were calculated from 
the corrected AFU data according to Michaelis-Menten kinetics using non-
linear regression analysis. 
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Transepithelial transport of indoxyl sulfate and 
kynurenic acid 
Transepithelial transport of indoxyl sulfate and kynurenic acid through the 
HFM with matured ciPTEC was studied using a similar perfusion set-up as 
was used for the barrier function assay. First, fibers were pre-incubated using 
efflux pump EP inhibitors (5 µM) or probenecid (100 µM) for 15 min. Next, the 
fibers were perfused using 100 µM IS or 30 µM KA in the presence or absence of 
inhibitors for 10 min and samples from the apical compartment were collected 
(100 µl). To determine the ability of ciPTEC to initiate a shift from the toxin 
protein-bound fraction to a free fraction for transport, similar conditions 
were investigated in the presence of human serum albumin ((HSA), 1mM). 
The binding efficiency of IS and KA to HSA was determined an ultrafiltration 
technique with a 30 kDA cut-off filter (Merck Millipore, Amsterdam, the 
Netherlands). The mixture was centrifuged for 15 min at 6,500 x rcf at rT 
and the ultrafiltrate containing the free toxin fraction was collected. The 
percentage albumin-bound (Cbound) of indoxyl sulfate and kynurenic acid was 
calculated according to equation 1:
Cbound= ((Ctotal-Cfree)/ Ctotal) * 100 (1)
Where Ctotal is the total concentration of toxin solution and Cfree the free toxin 
concentration present in ultrafiltrate, both in µmol/l. All samples collected 
from the binding analysis and the apical compartment after the transport 
experiment were analyzed using a LC-MS/MS system as described earlier.
In vitro clearance values of the transepithelial transport of both toxins were 
calculated according to equation 2:
Cl = (U * V) / P  (2)
Where U is the apical concentration in µmol/ml, V the volume in the apical 
compartment in ml and P the basolateral concentration in µmol/ml. 
Next, the in vitro clearance was calculated according to equation 3: 
Clin vitro = (Cl / T) / A (3)
Where Cl is the calculated clearance, T is the time in min and A the surface 
of the fiber in cm2. 
202
Chapter 7
All toxin samples were analyzed using a LC-MS/MS system as described 
earlier in this section. 
Endocytosis-mediated albumin uptake in 
bioengineered renal tubules
Matured renal tubules were assembled in our custom-made flow system and 
perfused with BSA-FITC (25 µg / ml) for 30 min at 37°C. In the next condition, 
fibers were perfused with KHH buffer and BSA-FITC (25 µg / ml) was added 
apically and exposed for 30 min at 37°C. As a control, the apical exposure 
was also performed at 4°C in order to inhibit endocytosis. After the uptake 
was arrested, tubules were fixed using 2% (w/v) PFA for 5 min at room 
temperature. Finally, tubules were mounted using Prolong Gold Antifade 
Reagent with DAPI (Cell Signaling Technology, Leiden, The Netherlands) 
and BSA-FITC localization in the cells was examined using the Leica SPE-II 
– DM14000 (Leica Microsystems, Rijswijk, The Netherlands) and images were 
captured using the Leica Microsystems LAS-AF software version 1.00.71.
Data analysis
All data are expressed as mean ± S.E.M of multiple replicates. Inhibition 
data were fitted according to one-site total binding saturation curve using 
non-linear regression analysis and Vmax values were calculated according to 
Michaelis-Menten kinetics using non-linear regression analysis. Statistical 
analysis was performed using one-way ANOVA analysis followed by Dunnett’s 
or Tukey’s multiple comparison test, or, when appropriate, an unpaired 
t test with GraphPad Prism version 5.02 (La Jolla, CA). A p-value of <0.05 was 
considered significant. 
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RESULTS
Uremic toxins inhibit OAT1 and OAT3 activity at clinically 
relevant concentrations
To evaluate the role of uptake transporters in uremic toxin handling, a panel 
of eight anionic uremic toxins was selected to study their affinity to inhibit 
OAT1- and OAT3-mediated uptake in ciPTEC. These toxins were selected 
based on their structure and potential PTEC-mediated urinary secretion, and 
their previously suggested association with complications of CRF (13-15, 19). 
The OAT1 and -3 model substrate fluorescein was used to evaluate transporter 
function (23). A concentration-dependent inhibition of fluorescein uptake 
was shown for all anionic uremic toxins tested (Fig. 7.1), with most potent 
interactions found for kynurenic acid and hippuric acid (Fig. 7.1D and F, 
table 7.1, resp.). The inhibitory potencies of the toxins, as reflected by their 
IC50 values (Table 7.1), were higher for OAT1 compared to OAT3, except for 
p-cresylglucuronide.
The renal excretion of indoxyl sulfate and kynurenic acid 
is OAT1-, BCRP- and MRP4-mediated
Indoxyl sulfate and kynurenic acid were selected for further studies using 
the ciPTEC-OAT1 model, as both showed a strong OAT1-mediated inhibition 
and have been associated severely with ESRD progression and its related 
complications (8, 15, 24, 25). Next to their inhibitory potency, we studied active 
PTEC transport processes. A dose-dependent uptake of indoxyl sulfate by 
ciPTEC-OAT1 monolayers was observed (Fig. 7.2A, 1.2 ± 0.1 and 6.7 ± 0.9 pmol.
min-1.cm-2, at 3 and 30 µM respectively), which was sensitive to probenecid 
inhibition (by 83 ± 6 and 63 ± 5 % for 3 and 30 µM, respectively; p< 0.001), 
a classical OAT inhibitor (26). Indoxyl sulfate uptake was also inhibited by 
kynurenic acid (100 µM; by 64 ± 13 and 61 ± 5 % for 3 and 30 µM, respectively; p< 
0.001), while kynurenic acid uptake by OAT1 was not significantly affected by 
indoxyl sulfate (100 µM), most likely due to a higher affinity of kynurenic acid 
for the transporter than indoxyl sulfate (8). But dose-dependent kynurenic 
acid uptake (Fig. 7.2B, 2.7 ± 0.3 and 5.9 ± 0.5 pmol.min-1.cm-2 for 3 and 30 µM, 
respectively) in ciPTEC-OAT1 was also sensitive to probenecid (53 ± 10 and 
52 ± 12 % inhibition, respectively; p< 0.05).
Using a vesicular transport assay for evaluating the activities of BCRP 
and MRP4 (14), Mutsaers et al. showed previously that indoxyl sulfate and 
kynurenic acid are potent inhibitors of both efflux pumps. Moreover, the 
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Figure 7.1 Concentration-dependent inhibition of OAT1- and OAT3-mediated 
fluorescein uptake by anionic uremic toxins.
(a-h) A concentration range of eight uremic toxins were exposed to matured ciPTEC-
OAT1 (•) and -OAT3 (o) in the presence of 1 µM fluorescein, a known OAT model 
substrate. The intracellular fluorescent signal was detected by measuring samples 
at excitation wavelength 485 nm and emission wavelength 535 nm. Blank data were 
subtracted and data were normalized to control (absence of uremic toxin). Nonlinear 
regression analysis was performed using Graphpad Prism 5.02. Data are shown as mean 
± S.E.M. of three independent experiments performed, at least, in duplicate. 
The eight tested anionic uremic toxins inhibit OAT1- and OAT3-mediated fluorescein 
uptake in a concentration-dependent manner. Mean plasma levels of uremic toxins in 
ESRD patients were extracted from Duranton et al. (6). R square: goodness of fit values 
extracted from non-linear regression analysis.
Table 7.1 Uremic toxins inhibit OAT1- and OAT3-mediated fluorescein uptake.
Uremic toxin Cm (µM) in 
ESRD patients1
ciPTEC-OAT1
(IC50 - µM)
R square ciPTEC-OAT3 
(IC50 - µM)
R square
Indoxyl sulfate 110 25 ± 4 0.92 83 ± 41 0.42
l-Kynurenine 6 65 ± 8 0.92 219 ± 66 0.54
Kynurenic acid 1 6 ± 1 0.95 6 ± 1 0.83
Indole-3-acetic acid 4 19 ± 2 0.93 148 ± 60 0.49
Hippuric acid 398 5 ± 1 0.95 22 ± 9 0.78
Indoxyl-β-glucuronide 9 492 ± 68 0.67 527 ± 218 0.55
p-Cresylglucuronide 44 2650 ± 922 0.28 588 ± 81 0.36
p-Cresylsulfate 675 79 ± 14 0.84 112 ± 19 0.80
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intrinsic PTEC toxicity of the uremic toxins was demonstrated by their ability 
to reduce renal metabolic capacity and to increase free radical production in 
proximal tubule epithelial cells (15, 19). Here, the role of BCRP and MRP4 in 
indoxyl sulfate and kynurenic acid detoxification was studied further using 
a cell viability assay (Fig. 7.2C and D). CiPTEC showed to be slightly more 
sensitive to both uremic toxins when BCRP and MRP4 were inhibited by 
KO143 and MK571 (resp.), as demonstrated by decreased TC50 values (indoxyl 
sulfate: 2.0 ± 0.7 mM; kynurenic acid: 9.0 ± 3.0) compared to the TC50 values 
in the absence of inhibitors, though not significant (Indoxyl sulfate: 3.6 ± 
0.6 mM; Kynurenic acid: not applicable). To support the importance of the 
combined effort of in- and efflux transport pathways especially in indoxyl 
sulfate detoxification, parent ciPTEC models lacking OAT1 demonstrated 
enhanced resistance against indoxyl sulfate in the presence of efflux pump 
inhibitors (TC50 3.0 ± 0.5 mM).
The bioengineered renal tubule shows a three 
dimensional, tight and differentiated epithelial 
monolayer
Further development of a biotechnological platform for the removal of protein-
bound waste products requires an optimal three-dimensional configuration, 
as a two-dimensional system poorly predicts renal xenobiotic handling. We 
recently successfully developed a three-dimensional bioengineered tubule 
system (27), which we here optimized and determined monolayer integrity 
by analyzing paracellular diffusion prior to transport experiments. The 
transepithelial barrier function was measured using a custom-made flow 
system and inulin as a leakage marker labeled with fluorescein isothiocyanate 
(FITC), allowing live imaging of hollow fiber membranes (HFM). Differentiated 
ciPTEC-OAT1 on double-coated HFM were compared to unseeded coated 
HFM (Fig. 7.3A). Within 1 min of perfusion, unseeded-HFM showed a 
sustained leakage compared to the fully PTEC covered HFM (Fig. 7.3B-C, no 
cells: 89 ± 4 % vs. cells: 10 ± 3 %; p<0.001). This effect remained stable until 
the end of the perfusion experiment, thereby confirming the formation of 
a three-dimensional, efficient and stable transepithelial barrier by ciPTEC-
OAT1 on HFM. To further elucidate polarization characteristics of ciPTEC-
OAT1 monolayers when cultured in a 3D HFM environment, the barrier 
function was also evaluated in 2D monolayers cultured on Transwell® filter 
inserts. When exposed to FITC-inulin, monolayers on inserts showed a limited 
barrier function of 20 ± 4% (p= 0.08) compared to unseeded filters (Fig. S7.1), 
confirming poor monolayer formation of ciPTEC-OAT1 using 2D systems in 
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7Figure 7.2 Handling of indoxyl sulfate and kynurenic acid by OAT1, BCRP and MRP4 in flat monolayers.
In matured ciPTEC-OAT1, a concentration-dependent uptake of (a) IS and (b) KA 
(white) was shown using LC-MS/MS analysis of the uremic toxins. In the presence 
of probenecid (P, grey), the uptake of both toxins was attenuated. Moreover, the IS 
uptake was inhibited in the presence of KA (100 µM; black), and vice versa. The role 
of BCRP and MRP4 in the efflux of IS and KA was shown using an MTT assay. The 
experiment was performed in the absence (•) or presence (◦) of efflux pump inhibitors 
(KO143 (10 µM) and MK571 (5 µM)). Nonlinear regression analysis was performed 
using Graphpad Prism 5.02. Data are shown as mean ± S.E.M. of three independent 
experiments performed in triplicate. *= p<0.05, ***= p<0.001 using one-way ANOVA 
analysis followed by Dunnett’s multiple comparison test.
208
Chapter 7
209
7
contrast to the 3D HFM environment. The presence of the tight junction 
protein ZO-1 along the boundaries of the cells (Fig. 7.3D) further endorsed the 
epithelial character of a homogenous and polarized cell monolayer on HFM. 
In addition to monolayer polarization, the expression of OAT1, BCRP and 
MRP4 in ciPTEC was compared between 2D and 3D cultures. Interestingly, 
significantly increased expression levels of OAT1 were observed (Fig. 7.3E) as 
compared to flat monolayers and a trend towards an increase in BCRP and 
MRP4 (Fig. 7.3F – G) was shown, respectively. These data assume that a 3D 
environment induces membrane transporter expression, which might be the 
result of an improved epithelial character in 3D.
Bioengineered renal tubules show organic anion 
transport activity
To study the activity of OAT1, BCRP and MRP4 in the bioengineered renal 
tubules, we used the substrate fluorescein and life confocal imaging (Fig. 
7.4A-B). Perfusion of the tubes with fluorescein solely (I) resulted in an in 
intracellular fluorescent signal, which increased significantly in the presence 
of efflux pumps inhibitors (II). In the presence of indoxyl sulfate (III) and 
kynurenic acid (IV), the fluorescein uptake was inhibited resulting in a less 
intense intracellular fluorescent signal. In the final condition (V), fluorescein 
Figure 7.3 Bioengineered renal tubules show transepithelial barrier function and 
polarized characteristics.
FITC-inulin leakage was measured in matured ciPTEC-OAT1 seeded on coated HFM. 
(a) Schematic presentation of the experimental set-up in the absence (upper panel) or 
presence (lower panel) of cells. (b) Representative eal-time images of the two different 
conditions are shown; unseeded (square) and seeded (circle) HFM. In the absence of 
cells, a bright green fluorescent signal was detected at the apical membrane, whereas in 
the presence of cells the signal was clearly attenuated. Representative real-time images 
of the two different conditions were shown. (c) Semi-quantification of FITC-inulin 
diffusion in the absence (square) and the presence of ciPTEC-OAT1 (circle) on HFM. 
Seeded HFM showed significantly less FITC-inulin leakage demonstrating monolayer 
tightness. From each single replicate 4 different regions in focus were analyzed. (d) The 
expression of ZO-1 (green) was demonstrated in a homogenous cell monolayer cultured 
on HFM. Scale bar: 10 µm. (e-g) The OAT1, BCRP and MRP4 mRNA expression levels 
were investigated in matured ciPTEC-OAT1 cultured in well plates and on HFM. Gene 
expression levels were normalized to expression levels of the reference gene GADPH (h) 
and were expressed as fold increase when cultured on HFM (black) compared to matured 
cells in well plates (white). Data are shown as mean ± S.E.M. of three independent 
experiments performed, at least, in duplicate. *** = p< 0.001, using an unpaired t test.
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Figure 7.4 OAT1-mediated fluorescein uptake in bioengineered renal tubules.
Fluorescein was used as a model substrate in an advanced fiber perfusion system. 
(a) Schematic presentation of the experimental set-up: I. Fluorescein perfusion, II. 
Fluorescein perfusion in the presence of efflux pump inhibitors (EP; (5 µM)), III and 
IV. Fluorescein perfusion in the presence of efflux pump inhibitors and indoxyl sulfate 
(III; 100 µM) or kynurenic acid (IV; 30 µM), V. Fluorescein perfusion in the presence 
of probenecid (P; 100 µM). (b) Representative real-time images of the five different 
conditions. Scale bare: 10 µm. (c) Semi-quantification of fluorescein uptake data in the 
absence or presence of the efflux pumps inhibitors solely, in combination with IS and 
KA, and in the presence of probenecid. From each single replicate 4 different regions 
211
7
in focus were analyzed. Data were fitted according to one-site total binding saturation 
curve using non-linear regression analysis. (d) Vmax values from all conditions were 
calculated from the corrected AFU data according to michaelis-menten kinetics using 
non-linear regression analysis. For statistical analysis, the Vmax values obtained from 
condition EP and P where compared to only fluorescein uptake (F). Conditions IS 
+ EP and KA + EP were compared to EP. Data are shown as mean ± S.E.M. of three 
independent experiments performed in duplicate. *** = p<0.001, using one-way ANOVA 
followed by Dunnett’s multiple comparison test. 
Figure 7.4 Continued
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Figure 7.5 Transepithelial clearance of indoxyl sulfate and kynurenic acid in the 
presence of human serum albumin, and albumin-FITC handling in bioengineered 
renal tubules.
a-d. Transepithelial clearance of indoxyl sulfate and kynurenic acid. Schematic 
presentation of the experimental set up of IS and KA transepithelial transport in the 
absence (a) or presence (b) of HSA is reported. Quantification of IS (c) and KA (d) 
clearance in the absence (-) or presence (+) of HSA. The protein bound fraction of IS 
was 73 ± 5 % and 63 ± 8 % of KA was bound to albumin. Data are shown as mean ± 
S.E.M. of three independent experiments performed in duplicate. *= p<0.05, **= p<0.01 
compared to IS in the absence of HSA, ###= p<0.001 compared to IS in the presence 
of HSA. Statistical analysis was performed using one-way ANOVA followed by Tukey’s 
multiple comparison test. (e-g) Endocytosis-mediated albumin uptake in bioengineered 
renal tubules. Cellular BSA-FITC uptake (green) in renal tubules (nuclei: blue) after 
30 min exposure from the (e) basolateral compartment at 37°C (f) apical compartment 
at 37°C and (g) apical compartment at 4°C. Active uptake was detected solely when 
BSA-FITC uptake was performed at 37°C, as indicated by the red arrows. (h) Collagen IV 
expression (green) in renal tubules showed a highly similar pattern as BSA-FITC uptake 
as shown in b. Scale bare: 10 µm. 
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uptake was studied in the presence of probenecid, a blocker of OAT1, 
which resulted in a strongly diminished uptake. Semi-quantification of the 
normalized time-lapse experiment is presented in Figure 7.4C. For statistical 
analysis, maximum uptake (Vmax) values were calculated from background 
corrected AFU data (Fig. 7.4D). A significant increased fluorescein uptake was 
detected when studied in the presence of efflux pumps inhibitors (208 ± 10 %; 
p<0.001). Again, this was inhibited by indoxyl sulfate (45 ± 13 %; p<0.001) and 
kynurenic acid (83 ± 3 %; p<0.001). In the presence of probenecid, fluorescein 
uptake was clearly attenuated as well (96 ± 3 %; p<0.001). These findings are 
compatible with the formation of a functionally active bioengineered renal 
tubule.
Bioengineered renal tubules facilitate uremic toxin 
secretion despite protein binding
Lastly, we investigated the capability of the bioengineered renal tubules to 
actively secrete protein bound uremic toxins. Active clearance of indoxyl 
sulfate and kynurenic acid in the absence of human serum albumin was studied 
by perfusing the tubules with 100 µM of the uremic toxin and measuring 
transport into the apical compartment. This revealed a clearance of 44 ± 6 
µl.min-1.cm-2 and 72 ± 20 µl.min-1.cm-2 for indoxyl sulfate and kynurenic acid, 
respectively (Fig. 7.5C-D). This secretion was attenuated by probenecid (by 55 
± 6, p<0.05 and 71 ± 7 %, respectively) and by the efflux pumps inhibitors (68 
± 5, p<0.001; 68 ± 6 %, respectively), indicating active transepithelial transport 
of both uremic solutes across the epithelial cell monolayer. In a separate 
experiment we observed that clearance of the uremic toxins was fully restored 
after the probenecid treatment, when the bioengineered tubules were re-
perfused with the toxins (data not shown). These findings confirmed that the 
cell monolayer is still viable after multiple treatments, including probenecid 
incubation, and that probenecid has an inhibitory effect on transport protein 
level solely. To further mimic the physiological situation, the ability of the 
bioengineered tubules to facilitate protein-bound toxin transport was shown. 
In this setup, we achieved a protein binding of indoxyl sulfate slightly lower 
than previously reported (73 ± 3 %) (28) in the presence of 1 mM HSA. Under 
the same conditions, kynurenic acid showed a protein binding of 63 ± 5 %. 
Interestingly, the clearance of protein-bound indoxyl sulfate (74 ± 10 µl.min-
1.cm-2, p<0.01) and kynurenic acid (101 ± 23 µl.min-1.cm-2, ns) was enhanced 
when compared to the clearance of both toxins in the absence of albumin. 
Again, transport was attenuated by probenecid (99.4 ± 0.2, p<0.001; 49 ± 15 %, 
respectively) and by the efflux pumps inhibitors (98.9 ± 0.2, p<0.001; 58 ± 14 
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%, respectively). These findings suggest that protein binding positively affects 
the renal tubular clearance of the uremic toxins. 
To study in more detail the mechanism of protein bound uremic toxin 
handling, we not only performed a basolateral perfusion with FITC-albumin, 
but also studied the uptake of FITC-albumin from the apical site. Wilmer 
and Jansen et al. previously reported on the presence of a megalin-mediated 
albumin reabsorption mechanism in ciPTEC, located at the PTEC apical 
membrane (21-22). Figure 7.5E-G shows BSA-FITC uptake in renal tubules 
after basolateral or apical exposures. Upon basolateral perfusion, intracellular 
BSA-FITC could not be detected (Fig. 5E). This observation is in agreement 
with the retention of albumin in the blood compartment under physiological 
conditions to prevent protein loss (52). Figure 7.5F shows that active uptake 
of BSA-FITC was detectable when exposed to the apical compartment at 
37°C, thereby confirming that reabsorption is functional in renal tubules (red 
arrows). Importantly, this uptake was highly reduced when apical exposure 
took place at 4°C (Fig. 7.5G), thereby further confirming the presence of an 
active endocytosis process in the bioengineered kidney tubules. Note that 
the BSA-FITC reabsorbed at 37°C binds to collagens present in the tubules 
(27). As described by Rueth et al., albumin is known to bind hydrophobic 
compounds like collagen (48). Concurrently, the pattern observed in ciPTEC 
upon BSA-FITC reabsorption indeed showed high similarities to the pattern 
observed when stained against collagen IV (Fig. 7.5H). As a consequence, the 
typical endocytosis BSA-FITC particles, which are usually detected in this 
reabsorption mechanism, are less clear in this setting. Nevertheless, these 
data show that albumin is actively reabsorbed by the apical membrane and 
not transported along with uremic toxins from the basal compartment across 
renal tubules. 
Discussion 
The renal clearance of organic anions, including protein bound endogenous 
metabolites, highly depends on active secretion, which is confined to the 
tubular system. In ESRD, this function is severely compromised resulting 
in the accumulation of these metabolites in patients. Current dialysis 
therapies insufficiently remove the protein bound uremic toxins, which 
contributes to the high morbidity and mortality rates of the disease (29), 
therefore, alternative treatment strategies are warranted. In this study, a 
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bioengineered renal tubule was successfully developed and transepithelial 
transport of albumin-bound uremic toxins was demonstrated. Key in this 
process is the concerted action between (basolateral) uptake and (apical) 
efflux performed by transporters with designated membrane localization. In 
exchange for intracellular α-ketoglutarate, the OATs efficiently translocate 
organic anions from the blood compartment into the intracellular space 
against an electrochemical gradient. The efflux pumps belonging to the ABC 
family of transmembrane transporters then couple ATP hydrolysis to their 
urinary excretion in a unidirectional fashion. Using a unique, robust and 
complete human cell model, we first identified eight anionic uremic toxins 
for their interaction with OAT1- and OAT3-mediated transport in flat cell 
monolayers. Next, the essential role of the ABC transporters BCRP and MRP4 
in cellular detoxification through efflux was demonstrated. Finally, a three-
dimensional bioengineered tubule containing a polarized cell monolayer with 
a clear epithelial barrier function was developed. These human bioengineered 
tubules demonstrated active clearance of albumin-bound anionic uremic 
toxins as a next step in BAK engineering. Note that the formation of a cellular 
barrier is not unique for ciPTEC but also found for intestinal epithelial cells 
when cultured on HFM (data not shown).
The concept of BAK engineering was initiated in the late 80’s of last century 
by Aebischer et al. with non-human cell models (i.e. the canine derived MDCK 
or pig originating LLC-PK1 cells) cultured on HFM (30). Follow-up studies by 
Humes and co-workers used cells of human origin, but with a major focus 
on the immunomodulatory effects for treatment of critically ill patients 
suffering from acute kidney injury (31-33). Phase I and II clinical trials showed 
reduced cytokine levels and long-term survival improvement compared to the 
non-treated group. However, a follow-up clinical phase IIb trial failed due to 
difficulties in the manufacturing process of the BAK and the clinical study 
design (34). One of the challenges to successfully develop a BAK is a suitable 
cell source to replace transport functions of the kidneys (32, 35). Primary 
renal epithelial cells show a high batch-to-batch variability in quality and 
function and dedifferentiation upon prolonged cultivation, and therefore 
hamper reproducibility. Moreover, to obtain a sufficient number of primary 
renal epithelial cells for a BAK approach is another hurdle to overcome (35). 
Recent advances in the application of stem cells (i.e. of embryonic origin 
or induced pluripotent cells) into a PTEC-like phenotype is a promising 
alternative (36-38) , but this has not been characterized sufficiently nor their 
capability to maintain the OATs in culture has been proven. Human renal 
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cells loose the expression of these essential transport proteins and (in part) 
their proximal tubular phenotype upon culturing (21, 39). This phenomenon 
has already been described in 1990 (40) and has, as of yet, not been solved, 
however, stable expression of OATs in renal cell lines is a prerequisite for renal 
functional replacement therapies as emphasized in a BAK. Here, we applied 
a recently optimized, robust and translational human renal cell model that 
endogenously expresses a panel of renal xenobiotic transporters successfully 
complemented with the OATs (21-23). This appeared to be an asset, as we 
demonstrated for the first time active renal tubular secretion of the protein-
bound uremic toxins indoxyl sulfate and kynurenic acid.
Using a conventional two-dimensional approach, the potency of eight uremic 
toxins to inhibit basolateral OAT1 and -3 mediated transport at clinically 
relevant concentrations was demonstrated (6, 20). The inhibitory potencies 
are in good agreement with previously published data obtained in animal 
models or in transfected cell systems expressing OAT1 or OAT3 (18, 20). 
We selected two uremic toxins because of the highest inhibitory potency 
(kynurenic acid, this study) and widely described associations with uremic 
syndrome complications (indoxyl sulfate)(8, 11). Indoxyl sulfate has been 
considered to be a causative factor in CRF progression (41), with most likely 
a dominant role of hOAT1 as its affinity for this transporter is at least 3-fold 
higher as compared to OAT3 (this study and (18)). Parent ciPTEC, lacking 
OAT1, were more resistant against indoxyl sulfate, but in ciPTEC-OAT1 a 
concentration-dependent reduction in cell viability was found. This effect was 
amplified when inhibitors of the efflux transporters, BCRP and MRP4, were 
applied, confirming the concerted action of uptake and efflux transporters 
in uremic toxin handling. Kynurenic acid showed a lower intrinsic toxicity as 
compared to indoxyl sulfate, despite its higher affinity for OAT1 (this study), 
BCRP and MRP4 (14). The molecular mechanisms through which both uremic 
toxins exert their cytotoxic potential are largely unrevealed.
The high affinity of kynurenic acid for OAT1, BCRP and MRP4 was demonstrated 
further by the higher bioengineered renal tubular clearance as compared to 
the elimination of indoxyl sulfate, either in the presence or absence of albumin. 
Moreover, it was shown that albumin itself is not taken up by ciPTEC from 
the basolateral site, but actively reabsorbed from the apical compartment. 
Interestingly, in the presence of albumin the transport of indoxyl sulfate and 
kynurenic acid was enhanced, which emphasizes the ability of ciPTEC to shift 
the protein-binding and allow for active secretion of the free fraction. These 
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data support that albumin may stimulate transport of organic anions, as was 
suggested earlier in the 80’s of last century by Besseghir and Depner et al. They 
showed that albumin facilitated para-aminohippurate uptake in isolated 
rabbit proximal tubules and rat kidney slices (42, 43). Moreover, Pichette 
et al. demonstrated altered dynamics of furosemide in hypoalbuminaemic 
rabbits (44, 45). Furosemide is a known diuretic agent, and organic anion, 
which targets the Na+-K+-Cl− cotransporter-2 (NKCC2) located downstream 
the proximal segment in the apical membrane of the thick ascending limb 
of Henle’s loop. Furosemide is highly protein bound (approx. 98%, (44)) and 
actively secreted via the proximal tubules into the apical compartment. In 
hypoalbuminaemic rabbits, higher furosemide doses were required to achieve 
a similar diuretic effect as in control rabbits (44), supporting the important 
role of albumin in facilitating active transport of the organic anion. This may 
be the result of electronegative to -neutral transition of the compounds when 
bound to albumin and/or post-translational modifications of albumin when 
toxins are bound (46, 47). The tertiary structure of albumin may also stimulate 
the binding and transport of metabolites across the capillary wall into the 
interstitial compartments. As shown recently, the binding capacity of albumin 
was demonstrated to be diminished in CRF patients, most likely due to post-
translational guanidylation of albumin sites (48). The attenuated albumin 
binding capacity in CRF patients will probably contribute to less efficient 
transport of uremic toxins by PTEC, thus resulting in elevated plasma levels 
and their known consequences. Note that the double-coated HFM used in our 
bioengineered renal tubules allow albumin to reach the target transporters, 
emphasizing further the potential of the device in BAK applications. Future 
research should elucidate the impact of modified albumin as observed in 
uremic patients in the removal of uremic toxins using a BAK platform.
Altogether, a successful bioartifical renal tubule was established which 
presented a clear barrier function and facilitated transepithelial transport of 
protein-bound indoxyl sulfate and kynurenic acid. This provides an innovative 
basis for regenerative nephrology through advanced function replacement 
and paves the way to progress towards potential clinical applications focusing 
at: i) optimization and up-scaling of the system with the aim of maintaining 
the best possible cell function under sterile conditions for extended time 
periods; ii) in vitro validation of the bioreactor with respect to uremic toxin 
kinetics; iii) the safety aspects as ciPTEC are classified as GMO’s, for which 
thorough research in agreement with European guidelines for advanced 
therapy medicinal products (European Medicines Agency) is needed to enable 
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the applications of GMO in medicinal products (49); iv) preclinical validation 
of the model, and v) prediction of uremic toxin clearance by the bioengineered 
system in clinical settings, for which research should be directed at building 
a physiologically-based computational model. This allows predicting the 
capacity needed for treatment of uremia and defining the most suitable 
application strategies in function of solute kinetics. Hence, such model 
would not only apply to uremia treatment, but can be used for mimicking 
3D scenarios of kidney disease modeling as well as for drug- toxicity and - 
efficacy testing.
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SUPPLEMENTARY INFORMATION
Methods
Chemicals and cell culture materials
The uremic toxin p-cresylsulfate (pCS) was synthesized via a modified 
literature procedure (50). NaOH was used instead of KOH to afford pCS as 
its sodium salt. 1H-NMR (500 MHz, D2O) δ 7.10 (d, J = 8.0 Hz, 1H), 6.78 (d, J = 
8.0 Hz, 1H), 2.22 (s, 1H). 13C-NMR (126 MHz, D2O) δ 148.85, 136.49, 130.17, 121.33, 
19.95. p-Cresylglucuronide (pCG) was synthesized according to a procedure by 
Desai and Blackwell et al. using a modified workup (51). The crude product was 
purified by silica flash column chromatography (gradient: 0-15% H2O/MeCN), 
after which the appropriate fractions were combined and concentrated in 
vacuo. The purified product was subsequently freeze dried to afford pCG as 
a white solid (60.5%). 1H- and 13C-NMR spectra matched the reported data.
Cell culture of ciPTEC-OAT1 and -OAT3 
In standard cell culture approaches, cells were seeded in well plates or 
Transwell inserts using a density of 63,000 cells/cm2 or 110,000 cells/cm2 for 
ciPTEC-OAT1, respectively, and 82,000 cells/cm2 for ciPTEC-OAT3 and were 
cultured for 24 h at 33°C, 5 % (v/v) CO2, to proliferate and subsequently 
transferred to 37°C, 5 % (v/v) CO2 for 7 days to mature. 
Prior to ciPTEC-OAT1 seeding on the outside of HFM (1.0 x 106 cells/ml), 
fibers were biofunctionalized using a coating combination consisting out of 
3,4-Dihydroxy-L-phenylalanine (L-DOPA; 2 mg/ml) and collagen IV (25 µg/
ml), as previously described by Jansen et al. (27), and cells were seeded and 
cultured accordingly.
Fluorescein inhibition assay 
Briefly, a concentration range (mM – nM) of indoxylsulfate, indole-3-acetic 
acid, indoxyl glucuronide, L-kynurenine, kynurenic acid, hippuric acid, 
p-cresylglucuronide and p-cresylsulfate were exposed to ciPTEC-OAT1 and 
-OAT3 cells in the presence of a known OAT substrate, fluorescein (1 µM), for 
10 min at 37°C, 5 % (v/v) CO2. After uptake arrest, intracellular fluorescence 
was detected at excitation wavelength 485 nm and emission wavelength 535 
nm, using a VictorTM X3 multilabel platereader (Perkin-Elmer, Groningen, The 
Netherlands). 
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Uptake of indoxyl sulfate and kynurenic acid by ciPTEC-OAT1
Active OAT1-mediated uptake of indoxyl sulfate and kynurenic acid was 
investigated using two concentrations of toxins. Prior to the uptake, matured 
cells cultured in 48-well plates were pre-incubated using krebs-henseleit 
buffer supplemented with 10 mM Hepes (KHH buffer, pH 7.4) in the presence 
or absence of probenecid (100 µM), kynurenic acid (100 µM) or indoxyl sulfate 
(100 µM) for 30 min at 37°C, 5 % (v/v) CO2. Next, the cells were exposed to 
either indoxyl sulfate (3 and 30 µM) or kynurenic acid (3 and 30 µM) for 10 
min at 37°C, 5 % (v/v) CO2 and the uptake was arrested using ice-cold KHH 
buffer. Finally, cells were lysed using perchloric acid (3.3 % (v/v)) for 1h at room 
temperature (rT) and were ready for analysis. 
Cell viability assay 
Matured ciPTEC-OAT1 were exposed to a concentration range (mM - µM) 
of indoxyl sulfate or kynurenic acid in serum-free culture medium in the 
presence or absence of the BCRP and MRP4 efflux pump inhibitors, KO143 
(10 µM) and MK571 (5 µM), for 24h at 37°C, 5 % (v/v) CO2. After 4 hours of 
incubation, the intracellular accumulated precipitate was detected by 
measuring samples at a wavelength of 570 nm from which the background 
was subtracted, using a Benchmark Plus plate reader (Bio-rad Laboratories, 
Veenendaal, The Netherlands).
Monolayer polarization and transepithelial barrier function 
To investigate the barrier function of matured ciPTEC-OAT1 cultured on 
HFM, the fibers were mounted on a separated inlet and outlet glass cannula 
(DMT Trading, Aarhus, Denmark) stabilized by a frame glued to a petri-dish, 
forming a separated basolateral (inner HFM) and apical compartment (outer 
HFM), containing KHH buffer (pH 7.4). A syringe pump (Terumo STC-521, 
Terumo Europe N.V., Leuven, Belgium) was connected to the inlet cannula 
by tubing, whereas the outlet cannula was connected by tubing to a depot 
to collect the perfusate. The chamber was installed on the Zeiss LSM510 
META microscope (Zeiss, Oberkochen, Germany). Double coated HFM in the 
presence or absence of matured ciPTEC were perfused with FITC-inulin (0.1 
mg/ml in KHH buffer) and diffusion was measured real-time for 13 min at 
37°C, 5 % (v/v) CO2. 
Fixed and permeabilized cell monolayers were blocked and subsequently 
incubated against ZO-1(1:50 dilution in block solution; Invitrogen, Carlsbad, 
CA) for 1h at room temperature (rT). Next, cells were incubated with goat-
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anti-rabbit-Alexa488 conjugate (1:200, Abcam, Cambridge, UK) and finally 
nuclei were stained using DAPI (300 nM, Life Technologies) for 5 min at rT. 
Images were captured using the Olympus FV1000 Confocal Laser Scanning 
Microscope (Olympus, Tokyo, Japan) and the Olympus software FV10-ASW 
version 1.7.
Detection of OAT1, BCRP and MRP4 mRNA expression 
To extract RNA from matured cells cultured on fibers, the RNAqueous® 
Micro Kit (Ambion, Carlsbad, CA) was used. RNA extraction from cells 
cultured in well plates was performed using the RNeasy® Mini Kit (Qiagen, 
Venlo, Netherlands), both kits were used according to the manufacturer’s 
protocol. Subsequently, cDNA was synthesized using the M-MLV reverse 
transcriptase kit (Invitrogen, Carlsbad, CA). The mRNA expression levels of 
ciPTEC transporter genes were detected using gene specific primer-probe 
sets (Table S7.1) and TaqMan Universal PCR Master Mix (Applied Biosystems, 
Branchburg, NJ). The quantitative PCR reactions were performed using 
the CFX96 Real Time PCR system (Bio-Rad Laboratories, Veenendaal, 
Netherlands) and data were analyzed using the CFX Manager software (Bio-
Rad Laboratories, Veenendal, Netherlands).
Fluorescein assay
To measure active fluorescein uptake, the fibers were perfused using 1 µM 
fluorescein in KHH in the presence or absence of specific drug transporter 
inhibitors (OAT1 inhibitor probenecid (100 µM), and efflux pump (EP) 
inhibitors KO143 (5 µM, to block BCRP), PSC833 (5 µM, to block any minor 
P-gp contribution) (Tocris Bioscience, Minneapolis, MN) and MK571 (5 µM, to 
block MRP4)) for 13 min at 37°C, 5 % (v/v) CO2. Prior to fluorescein perfusion, 
fibers were pre-incubated using similar concentrations of inhibitors in KHH 
for 5 min at 37°C, 5 % (v/v) CO2. To investigate the interaction of fluorescein 
(1 µM) and the uremic toxins indoxyl sulfate and kynurenic acid in ciPTEC 
cultured on HFM, fibers were exposed to indoxyl sulfate (100 µM) or kynurenic 
acid (30 µM) in combination with EP inhibitors for 13 min at 37°C, 5 % (v/v) 
CO2. The fluorescein uptake was examined in real-time and imaging was 
performed using the Zeiss LSM510 META microscope (Zeiss, Oberkochen, 
Germany). Semi-quantification of real-time data was performed using Image 
J software (version 1.40g). From each single replicate 4 different cellular 
regions in focus were analyzed. 
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Methods to figure S7.1
Transepithelial barrier function of ciPTEC-OAT1 monolayers in 2D
To investigate the barrier function of matured ciPTEC-OAT1 cultured on 
2D Transwell inserts, both compartments were washed once using KHH 
prior to FITC-inulin (0.1 mg/ml in KHH buffer) exposure basolaterally for 
1h at 37°C, 5% (v/v) CO2. Fluorescence was detected by measuring samples 
(75 µl) at excitation wavelength 485 nm and emission wavelength 535 nm, 
using a VictorTM X3 multilabel platereader. Blank data were subtracted and 
normalized data were plotted.
Table S7.1: Taqman primer-probe sets.
Gene Catalogue number
OAT1 (SLC22A6) Hs00537914_m1
BCRP (ABCG2) Hs00184979_m1
MRP4 (ABCC4) Hs00195260_m1
GAPDH Hs99999905_m1
Figure S7.1 FITC-inulin diffusion in matured ciPTEC-OAT1 monolayers cultured in 
2D systems.
The FITC-inulin leakage was measured in matured ciPTEC-OAT1 seeded on coated 
Transwell® filter inserts. A limited transepithelial barrier function was observed in the 
presence of cells (white) compared to unseeded Transwell filters (black) after 13 min. 
Data are shown as mean ± S.E.M. of three independent experiments performed in 
triplicate.
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GENERAL DISCUSSION
The kidneys play a pivotal role in the homeostasis of many physiological 
processes in the human body (1). As such, the removal of waste products by 
proximal tubule epithelial cells from blood into the pro-urine is of major 
importance to maintain a healthy balance. Disease onset is often multi-causal 
and an abrupt loss or a severe decline in kidney function will contribute to 
the development of the uremic syndrome and its associated complications 
(2, 3). To substitute kidney function, patients have to be treated with renal 
replacement therapies such as hemodialysis. However, hemodialysis is not 
adequate in the removal of waste products (i.e. uremic toxins) and as organ 
transplants are scarce, the development of new treatment modalities is 
warranted. Therefore, this thesis aimed to develop innovative approaches 
to replace or improve the proximal tubule function. In this chapter, the 
knowledge obtained in this thesis, in particular with respect to bioartificial 
kidney engineering, is being discussed in the current context of regenerative 
nephrology. 
In vitro models to facilitate bioengineering and disease 
modeling
To date, numerous proximal tubule epithelial cell models have been 
characterized and applied in bioartificial kidney (BAK) engineering (4). Initially, 
animal-derived models such as the porcine Lilly Laboratories Cell Porcine 
Kidney proximal tubular cells (LLC-PK1) or dog Madin-Darby Canine Kidney 
(MDCK) cell lines, with limited transporter function, were applied in cell-
based approaches, as human models were not available. Nowadays, human 
primary renal epithelial cell models as well as immortalized cell systems are 
widely used for BAK purposes. Although primary cells reflect most closely the 
physiological demands, a high batch-to-batch variability in function as well 
as the isolation of a sufficient number of cells hampered the implementation 
of primary renal epithelial cells in a BAK (4). As such, Humes and co-workers 
developed the Bioartificial Renal Epithelial Cell System (BRECS) (5). The BRECS 
was designed to maintain a dense population of primary adult human renal 
epithelial cells grown on coated carbon disks within the system. After the cells 
reach an optimal density, the BRECS can be cryopreserved, transported, and 
stored, thereby reducing many practical limitations previously encountered 
by cell-based therapies using primary cells. Although metabolic activity like 
oxygen consumption and the epithelial character was demonstrated by zona 
occludens 1 (ZO-1) and aminopeptidase-N expression in BRECS monolayers, 
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the presence of essential proximal tubule epithelial cell (PTEC) transporters 
has, as of yet, not been demonstrated nor any active excretion of uremic 
toxins (6, 7). Hence, the proof-of-concept with BRECS for BAK purposes to 
treat uremia still needs to be demonstrated. As such, a crucial step in the 
validation of BRECS is to determine anionic and cationic transport activities 
and compare functionality to other PTEC models as described in chapter 2 
and 4 of this thesis. 
The concerted action of organic anion and cation in- and efflux transporters 
is an essential characteristic for a suitable BAK model. It was shown that 
ciPTEC encompass a broad range of PTEC-specific transporters which are 
essential in studying renal transport of pharmaceutical and physiological 
entities as compared to other human renal cell models, such as the widely 
distributed HK-2 cell line which lacks OCTs, OATs and BCRP (4). Initially 
the endogenous expression of the organic anion influx transporters OAT1 
and OAT3 was absent in the ciPTEC models, which is a known phenomenon 
of renal cells in culture (8). However, both organic anion transporters were 
recently successfully incorporated in ciPTEC, as described by Nieskens 
et al. (9). Such, more complete ciPTEC model is a promising tool in BAK 
engineering, but the cell line appears to be suitable for other applications as 
well, like drug- toxicity and - efficacy testing and for kidney disease modeling. 
The latter subject was addressed in Chapter 3, where ciPTEC was used as an 
experimental inflammatory model to mimic septic acute kidney injury in vitro 
and to study molecular processes upon therapeutic interventions. This was 
demonstrated with dexamethasone, for which the molecular mechanism 
involving a mitochondrial target was unravelled. Altogether, ciPTEC models 
represent a broad range of essential drug transporters concerted by a high 
metabolic activity ((10, 11) and this thesis).
 
Another interesting finding in this thesis is the fact that cells isolated from 
urine demonstrated comparable physiological characteristics with respect 
to functional proteins (e.g. drug transporters, endocytosis receptors) when 
compared to kidney tissue-derived cell models (12). Differences found 
between the cell sources were predominantly related to ECM proteins. A 
possible explanation for a reduced capability of urine cells to excrete ECM 
proteins might be the reason to be exfoliated from the renal epithelium, 
which includes the release from the basement membrane followed by urinary 
excretion. As the ECM has a concerted role in cell monolayer formation and 
intracellular signaling pathways (13), one could argue that tissue derived cell 
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lines are more preferred models to apply in BAK applications. Nevertheless, 
using cells originating from urine for BAK applications remains an interesting 
source, especially as this material is easy accessible and urine-derived PTEC 
maintain transport function.
Biofunctionalized scaffolds; the backbone of a 
successful BAK
Defined biomaterials mimicking the native basement membrane and ECM 
composition are a prerequisite to achieve a successful BAK approach, 
which warrant preserved PTEC phenotype and function. Importantly, the 
composition of the scaffold should reflect cyto- as well as hemocompatible 
properties. Furthermore, it should facilitate the transport of albumin-
bound toxins to come in close proximity to the PTEC monolayer to enable 
clearance of waste products. The hollow fiber membranes, as applied in 
this thesis, are the commercially available MicroPES® capillary membranes, 
which consist of a balanced mixture between PES and PVP. The controlled 
and well-characterized composition of these two components allow for 
optimal hydrophilic and biocompatible properties (e.g. anti-fouling) 
for dialysis purposes (14). Although MicroPES membranes demonstrate 
hemocompatible characteristics, unmodified MicroPES membranes reflect 
poor cytocompatible properties as was shown in Chapters 6. The biofunctio-
nalization of these membranes required a thorough investigation to maintain 
the balance between the permeance of molecules and a polarized cell 
monolayer that form a selective barrier. Various research groups provided 
insight in ECM applications for BAK purposes over the past years (15, 16). 
From these, collagen IV appeared to be a crucial component to compromise 
PTEC monolayer formation and differentiation. In addition, Ni et al. showed 
that the combination of 3,4-dihydroxy-L-phenylalanine (L-DOPA) followed 
by collagen IV treatment was the most successful combination (15). Upon 
polymerization, L-DOPA becomes negatively charged and, consequently, will 
attract the positively charged collagen IV. Consequently, the charged collagen 
layer will attract cells with their negative membrane potential and will 
facilitate epithelial differentiation. In addition, membrane hydrophilicity will 
increase after L-DOPA coating due to coexistence of carboxylic and amino 
groups in the L-DOPA molecule, and therefore will further stimulate collagen 
IV adhesion (17, 18). This coating application was optimized for ciPTEC in flat 
cell monolayers (Chapter 5) and consequently for 3D bioartificial renal tubules 
(Chapter 6 and 7). Although coating composition (i.e. L-DOPA (2 mg/ml) and 
collagen IV (25 µg/ml)) remained similar for flat and tubule configurations, 
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the coating times were extended from minutes to hours to obtain polarized 
cell monolayers on tubules. Most likely, the advanced 3D configuration of 
tubules requires a more thorough surface modification to stimulate cell 
adhesion as compared to flat monolayers. In flat membranes, gravity will 
allow the majority of the seeded cells to sink and subsequently adhere to the 
coated membrane present at the bottom of the compartment. In contrast, the 
adhesion of cells on the outside of a curved fiber with an inner diameter of 300 
microns is a more challenging configuration than a flat membrane. Moreover, 
only a minor fraction of the cells present in the suspension will adhere to the 
fiber as a large fraction of the cells will not come in contact with the fiber 
present in the test tube at all. Altogether, a tubule configuration requires a 
comprehensive coating approach to achieve adherence and, subsequently, a 
polarized cell monolayer. 
Next to biological approaches, like L-DOPA/collagen IV as used in the majority 
of our studies, synthetic polymers, so called supramolecular polymers, are 
being developed to mimic the native basement membrane of renal epithelial 
cells (19, 20). These offer a well-controlled approach and have potentially an 
unrestricted accessibility. Synthetic polymers can be mixed with peptides 
based on cell-binding epitopes of ECM proteins to develop a bioactive mesh. 
Subsequently, using electrospinning techniques hierarchical fibrous nano-
microscale membranes can be processed. This was successfully demonstrated 
with HK-2 cell monolayers, however, for ciPTEC poor cell adhesion and 
monolayer development were observed (unpublished data). Still, it would be 
worthwhile to invest in the development a ciPTEC-compatible synthetic mesh 
to further facilitate the bioartificial in vitro environment in future research. 
Finally, native ECM components isolated from pigs or discarded human 
kidneys might be an interesting source to apply for fiber biofunctionalization. 
Nowadays, native ECM scaffolds are under investigation in the field of 
whole organ engineering (21-24). This pioneering research focusses on the 
decellularization of the kidney followed by recellularization in order to induce 
tissue regeneration (21-23). Decellularized ECM scaffolds preserve innate 
architecture, support cell growth when recellularized and demonstrate 
angiogenic capacity to stimulate vasculature (24). Using acellular porcine 
kidney scaffolds, Abolbashari and co-workers injected primary porcine renal 
cells into the cortical region of decellularized kidneys (21). This resulted in 
promising outcomes with respect to cell proliferation into tubular structures, 
gamma-glutamyl transpeptidase (GGT) activity, sodium uptake and, 
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predominantly, aquaporin-1 expression (21). In addition, murine embryonic 
stem cells (mES) have been used to recellularize acellular rat kidneys (25). 
Bonandrini et al. demonstrated that perfusion of stem cells through the renal 
artery system resulted in a uniform distribution of the vascular network and 
glomerular capilliaries but only a few cells reached the tubular compartment 
(25). The differentiation of mES towards an endothelial-like phenotype was 
confirmed by the expression of CD31 and Tie-2 after 24h, indicating that 
decellularized kidney scaffolds indeed preserve native ECM structures to 
support cell adhesion and differentiation. Most likely, using the renal artery as 
well as the ureter for seeding purposes, an improved proliferation of cells in the 
tubular compartment might be stimulated (26). Moreover, the recellularized 
organs should be cultured under flow conditions to supply nutrients and 
oxygen to cells in order to maintain cell viability and functional properties 
(e.g. hyperfiltration, active transport of waste products) upon prolonged 
applications (25). Altogether, using (m)ES as a source to recellularize kidney 
scaffolds is interesting as the pluripotent character of these cells allow for 
differentiation into multiple renal lineages (27). However, ethical concerns 
and tumor formation might hamper the potential of this source for clinical 
applications (21). To overcome these limitations, a promising cell source 
encompass induced pluripotent stem cells (iPSC), which are reprogrammed 
fibroblast and their potential to differentiate into different renal lineages has 
already been shown (28, 29). Moreover, iPS technologies allow for autologous 
applications and will, most likely, be tolerated by the host immune system. 
Although these initial whole organ engineering studies are promising, the 
kidney architecture is highly complex and, therefore, developing cell seeding 
procedures to repopulate acellular kidneys with different renal cell types 
(endothelial and epithelial cell types) in a homogenous manner is a large 
hurdle to take (21, 25, 26). Nevertheless, the knowledge obtained in these 
studies with respect to the role of the native ECM in stimulating renal cell 
differentiation is valuable for BAK purposes as well. Hence, investigating 
the effect of native ECM-coated fibers on ciPTEC adhesion and transport 
properties would be worthwhile to test in future research. 
 
Mechanosensing stimulates PTEC differentiation
One could argue that tubular formation in a 3D environment like hollow fiber 
membranes or decellularized kidneys better resembles the in vivo nephron 
structure than flat culture conditions and would stimulate cell adhesion and 
differentiation. As shown in chapter 6 and 7, cell monolayer polarization was 
indeed enhanced in 3D configurations when compared to flat monolayers. 
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As a consequence, the transepithelial transport of anionic uremic toxins in 
bioengineered renal tubules could be nicely demonstrated. The effect of curved 
biomaterials was also studied by Shen et al. (30). Hollow fiber membranes with 
an inner diameter of 400 microns enhanced renal characteristics such as brush 
border enzyme activity, glucose transport and cell viability when compared 
to flat membranes. It has been shown that membrane curvature has an 
important effect on mechanosensitive molecules such as integrins and focal 
adhesion proteins, followed by a signal transduction towards the cytoskeleton 
where it will influence organelle shape and enzyme and protein activation 
(31, 32). As the in vivo nephron has a diameter of approximately 50 microns, 
one would assume additional improvement of PTEC transport function 
when membrane curvature will further increase. Conversely, poor monolayer 
formation was observed when ciPTEC were cultured on coated PES/PVP 
tubules with an increased curvature (HCO1100 fibers: inner diameter of 215 
microns) when compared to MicroPES fibers (inner diameter of 300 microns). 
This indicates that, next to curvature, also other parameters like membrane 
topography and physico-chemical properties will influence cell adhesion and 
subsequent functional characteristics in vitro (33, 34). Related to membrane 
topography, MicroPES membranes contain relatively large asymmetric pore 
structures as they are applied for plasmapheresis purposes and therefore 
allow free passage of molecules such as albumin and IgG. The HCO1100 
dialyzers have a molecular weight cut-off close to the native glomerulus (~65 
kDa) and hence display different membrane topography with smaller pores. It 
has been shown that different biomaterial surface topographies can influence 
cell adhesion, morphology and even differentiation of human kidney-2 (HK-2) 
cells, a PTEC cell line, and human stem cells towards different lineages (33-
35). To further elucidate the role of membrane properties in PTEC adhesion 
and differentiation, similar topography compositions with varying curvatures 
could be investigated or vice versa. 
Next to membrane topography, fluid flow is a crucial factor that induces 
mechanosignaling and modifies PTEC differentiation via subsequent 
cytoskeleton rearrangements (36-40). In vivo, the apical surface of PTEC is 
exposed to fluidic shear stress of 0.2 dyne. cm-2 due to a constant flow of 
the glomerular filtrate, and flow sensors such as cilia or microvilli induce 
signaling towards the intracellular microenvironment (36, 40). Frohlich et 
al. demonstrated that a certain membrane topography in combination with 
fluid-induced shear stress resulted in a more physiologically relevant in vitro 
PTEC model. The expression of the tight junction protein ZO-1 was clearly 
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enhanced when both conditions were applied as compared to a modified 
surface topography solely (33). In addition, Jang et al. compared physiological 
as well as toxicological responses between primary PTEC cultured in a 
2D micro-fluidic device exposed to an apical shear stress of 0.2 dyne. cm-2 
versus static 2D Transwell insert cultures (38). They found that various PTEC 
characteristics such as cell height, Na+/K+-ATPase and aquaporin 1 expression, 
the number of ciliated cells and alkaline phosphate activity were clearly 
enhanced when cultured in the microfluidice device using flow conditions. 
Moreover, clear differences with respect to albumin reabsorption as well as 
cisplatin-induced toxicity were observed between fluidic vs. static culture. 
It was postulated that the drug transporter OCT2, which is involved in the 
renal handling of cisplatin, is more tightly regulated due to flow as cellular 
differentiation improved (38). A next step would be the implementation of 
continuous flow in a 3D culture environment like hollow fibers. As such, 
membrane characteristics as well as flow would synergistically stimulate the 
mechanosensory system. In an initial study performed by Ng et al., primary 
PTEC were cultured in fibrin-coated hollow fibers (inner diameter of 500 
microns) and were connected to a bioreactor with an apical flow of 200 µl. 
min-1 (41). Though tight cell monolayers as well as apical uptake of solutes 
were observed under flow conditions, a comparison between static conditions 
vs. flow in fibers on the reabsorption and secretion of solutes was not 
investigated thoroughly in this study. In our studies, as presented in chapter 
6 and 7, tubules consisting of a cell monolayer on the outer surface of fibers 
were cultured under static conditions and flow was only applied through 
the fiber during experiments. As the experimental settings were in terms of 
minutes and not in days, the effect of flow in our setup is most likely negligible. 
Culturing bioartificial renal tubules under continuous flow conditions should 
become feasible as soon as bioreactors will be introduced. These systems 
allow for sterile and controlled multi-fiber culture environments and will be 
our next important step in BAK engineering.
The transition from a single renal tubule towards a full 
device
The bioartificial renal tubules (figure 8.1), as shown in this thesis, demonstrate 
promising functional characteristics for further development towards a full 
BAK device. Obviously, a direct translation from a single tubule towards a 
full extracorporeal device containing numerous HFM would not be realistic, 
therefore bioreactors containing 10 - 20 fibers would be an appropriate follow-
up model. The group of Zink and co-workers demonstrated successful cell 
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monolayer formation when primary cells were cultured on the outer surface 
of medium-sized bioreactors containing 25 HFM and large-sized bioreactors 
containing 250 HFM (inner diameter 215 microns) at a flow rate of 80 µl/min 
for 7 days (42). Moreover, cytokine production and organic anion transport of 
a fluorescent model substrate was shown in monolayers cultured in medium-
sized bioreactors. Based on these encouraging results, primary cells were 
cultured on commercially available bioreactors, a PrismafleX HF20 dialyzer 
from Gambro GmbH, containing approximately 2600 HFM. The dense 
packing of HFM resulted in compromised cell performance as monolayers 
Figure 8.1 Schematic presentation of assays performed in bioengineered renal 
tubules to demonstrate functional drug transporters. (a) The OCT2 activity in 
ciPTEC-U monolayers was measured using the cationic substrate 4-(4-(dimethylamino)
styryl)-N-methylpyridinium iodide (ASP+). In chapter 6 it was demonstrated that 
ASP+ uptake could be inhibited by a cationic uremic metabolites mixture and by 
the histamine H2-receptor antagonist, cimetidine, thereby confirming active OCT2-
mediated transport. (b) The secretory clearance of protein-bound indoxyl sulfate and 
kynurenic acid across the renal tubule was confirmed in chapter 7. Transepithelial 
transport of both toxins was mediated by OAT1, BCRP and MRP4 and clearance could 
be reduced using specific inhibitors. To this end, active anionic transport processes in 
our bioengineered renal tubules were confirmed. In conclusion, the results obtained in 
this thesis are important milestone to pave way towards a successful bioartificial kidney 
device to treat uremia in ESRD patients.
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were disrupted. Although culturing cells on outer surfaces of HFM allow for 
relatively easy monitoring of monolayer formation and function, the possible 
mechanical stress between cells in a densely packed dialyzer might hamper 
monolayer maintenance. In the past, various research groups including 
Humes, Saito and also Zink, cultured cells on inner HFM surfaces to study 
the endocrine, metabolic and immunomodulatory effects of primary cells 
(43-46). Nevertheless, it is known that monolayer formation on the inner 
surface of HFM is a major challenge to achieve (42). Technical hurdles such as 
clogging of cells which will result in non-homogenous monolayer formation 
throughout the HFM should be solved, but also sheer stress during injection 
of cells into the narrow HFM should be minimized to avoid loss of function. 
Once successful, monolayers in multi-fiber bioreactors can be expected to 
be more stable as mechanical stress between cell layers will be avoided. In 
addition, the inner seeding configuration might better resemble the in vivo 
nephron architecture and could positively affect mechanosensitive molecules 
like integrins and focal adhesion proteins (31), resulting in improved ciPTEC 
monolayer differentiation and function. Hence, this application will be 
investigated in the near future in our laboratory and the effect on cell 
performance will be studied. 
The balance between membrane curvature, topography and coating in 
combination with flow conditions should finally result in an optimal 
environment for ciPTEC to achieve an efficient clearance of albumin bound 
uremic toxins within a reasonable time span. As current dialysis sessions are 
performed three times a week and already take approximately 4h per session, 
the clearance capacity of a BAK should be sufficient to maintain or preferably 
shorten the current time span of a dialysis session. Based on the in vitro 
clearance of indoxyl sulfate and kynurenic acid detected in bioengineered 
renal tubules as shown in Chapter 7, a rough estimation can be calculated with 
respect to the time required to achieve a clinically relevant clearance of both 
toxins. As calculated in the table below (table 1), it would take approximately 
30 min for both metabolites, using a commercially available dialyzer with a 
membrane surface of 1.8 m2 and using a flow rate of 200 ml.min-1, to achieve 
normal plasma concentrations (table 1; CN) of indoxyl sulfate or kynurenic 
acid. 
Although the estimated treatment time for these two uremic toxins seems 
promising, the in vivo uremic milieu consists of a myriad of factors that could 
reduce PTEC-mediated clearance in a BAK and, thus, will extend treatment 
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8time. For example, as described by members of the EUToX workgroup (www.uremic-toxins.org), over 100 solutes have been characterized as uremic toxins 
in renal failure (48, 49) and, nowadays, many of these uremic toxins are known 
substrates and compete for similar PTEC transporter pathways (47, 50-53). 
Moreover, next to uremic toxins also hormones, like endothelin-1, and drugs 
like cimetidine and metformin impair PTEC-mediated transport function 
(53-55). In addition, it is known that the albumin binding of endo- and 
xenobiotics is decreased in ESRD patients, which is caused by factors such as 
hypoalbuminaemia, competitive binding of substances and conformational 
changes (guanidinylations) in the albumin molecule leading to less available 
binding sites (56-58). As a consequence, attenuated protein binding of 
compounds and metabolites will contribute to an altered pharmacodynamic 
profile, as was demonstrated by Pichette et al. (59, 60) and also in chapter 
7 of this thesis. Altogether, the active uremic toxin clearance via essential 
renal transporter pathways present in our bioengineered renal tubules, which 
Table 8.1 Clearance time calculations to achieve a clinically relevant removal of 
uremic toxins using a BAK
Indoxyl sulfate Kynurenic acid
Plasma concentrationsa (pMol . µl-1) CN: 13; CU: 129 CN: 0.05; CU: 1 
Clearance in bioengineered tubulesb (µl . min-1 . cm-2) 73 101 
Amount of nMol cleared (Plasma CU x Clearance) (IS: nmol . min
-1 . cm-2, KA: 
pmol . min-1 . cm-2)
9.4 101 
Surface BAK (cm2) 180 180 
Total clearance using a BAK (Amount of cleared nMol * surface BAK) (IS: 
µmol . min-1, KA: nmol . min-1)
1.7 18.2 
Dialysis flow rate (ml . min-1) 200 200 
Amount of uremic toxin passing the membrane per min (flow rate x CU) (IS: 
µmol . min-1; KA nmol . min-1)
26 200 
Reduction rate (total clearance using a BAK / amount of toxin passing the 
membrane) 
0.07 0.09
Clearance time required to achieve normal plasma concentrations of a 
uremic toxin (CN=CU*((1-R)
t) (min)
31 28 
a CN: normal plasma concentrations found in healthy volunteers (47); CU: uremic plasma 
concentrations found in ESRD patients (47). b clearance values extracted from Chapter 7. 
R: reduction rate.
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has, as of yet, never been demonstrated by any other BAK before, provides a 
promising platform for future BAK engineering. Obviously, future research 
demands in vitro validation of an up-scaled bioreactor system using uremic 
plasma. These outcomes will gain insight in the actual uremic toxins kinetics 
and will further elucidate the clearance efficacy and efficiency of our BAK. 
Based on these outcomes, a physiologically-based computational model 
to mimic uremic milieus in different renal patients populations could be 
established and allow for a concise prediction of the capacity required for 
ESRD treatment. 
Following in vitro preclinical validation, the efficacy and efficiency of 
extracorporeal BAK approaches should be further evaluated using in vivo 
models. For example, Saito and Humes tested the endocrine and metabolic 
function of a BAK containing porcine or human renal cells in uremic goats and 
dogs suffering from acute kidney injury (46, 61, 62). Testing a BAK using uremic 
pigs might be a more preferable model in translational medicine as the anatomy 
and physiology of these animals resemble human physiology (63). Recently, 
Humes investigated the immunomodulatory effects of an advanced artificial 
kidney in uremic pigs (64). In the Netherlands, pig models are also operational 
and could be applied in the in vivo preclinical testing of a ciPTEC-containing 
BAK (65). One could argue that testing human cells as an experimental 
treatment platform in other species could result in an immunological response. 
This could also occur in humans as ciPTEC are a non-autologous cell source. 
However, the membrane of the hollow fiber with an appropriate composition 
and molecular weight cut-off should prevent direct contact between host 
immune factors and cells in a BAK. Still, small immunological factors such 
as soluble human leukocyte antigens (HLA), which are members of the MHC 
class I molecules (66), could be released from ciPTEC, subsequently end up in 
the patients’ plasma and exert an immune response. Another critical note is 
the application of immortal cells in a therapeutic entity. To date, the Food and 
Drug Administration (FDA) only approved primary renal epithelial cells for 
clinical evaluation (67). Therefore, as ciPTEC are genetically engineered cells, a 
thorough risk and safety management plan should be conducted based on the 
guidelines for advanced therapy medicinal products (ATMPs) developed by the 
European Medicines Agency in collaboration with the European parliament 
and the Council prior to any clinical testing (68, 69). These guidelines describe 
detailed aspects of pharmacovigilance, risk management planning, safety and 
efficacy follow-up of authorized ATMPs and aspects of clinical follow-up of 
patients treated with ATMPs. 
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Important risk parameters to test first in a preclinical environment is the 
possible release of soluble factors by ciPTEC and the possible loss of ruptured 
cells which might end up in the patients’ blood. To prevent such adverse 
effects, membrane modifications and filters should be implemented to capture 
substances and avoid host contact. Another option could be the development 
of a cell model using hTERT immortalization without the proto-oncogene 
SV40 large T, as was successfully developed by Wieser et al. (70). This strategy 
was tested during cell model development as described in Chapter 2, however, 
this immortalization strategy led to impaired renal cell morphology with 
numerous intracellular ‘vacuole-like’ structures. Therefore, we excluded these 
cells for further characterization. Another safety option could be to introduce 
a so called genetically engineered ‘kill-switch’ in the ciPTEC model which is 
activated after the administration of a specific drug and induces elimination 
of ciPTEC if ended up in a patient (71). Altogether, a thorough risk and safety 
assessment should demonstrate the feasibility of using immortal cells as a 
treatment modality. Currently, a preclinical safety evaluation is performed 
within the EU-FP7 Marie Curie International Training Network BioArt 
project. If promising outcomes are being obtained, this device might have the 
potential to achieve approval of the Dutch Ministry of Welfare, Health and 
Cultural Affairs for clinical testing of a BAK containing ciPTEC. 
Alternative strategies to remove protein-bound uremic 
toxins 
Next to bioartificial platforms, there is an increasing interest in advanced 
artificial renal replacement therapies to aid uremic toxins removal (figure 8.2). 
For example, the effect of a modified dialysate composition in the currently 
applied hemodialyzers is under investigation (72). Recently, Bohringer et al. 
studied the effect of a hypertonic dialysis buffer on the release of uremic 
toxins from albumin, in order to stimulate the removal of waste products. It 
was postulated that the ionic strength of the dialysate stimulates the removal 
of the charged free fraction from the patients’ blood and, subsequently, 
contributes to a continuous release of the albumin bound uremic toxins to 
maintain the equilibrium between bound and unbound uremic toxins. In 
vitro dialysis under hypertonic conditions indeed resulted in an increased 
release of phenylacetic acid, indoxyl sulfate and p-cresyl sulfate from albumin 
and improved clearance rates were observed (72). However, it is known that 
hypertonic conditions contribute to volume depletion, cell stress and damage 
and predominantly affect renal cells but also adverse effects on macrophages, 
endothelial cells and neurons have been observed (73). Though healthy 
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mammalian cells can survive a moderated hypertonic environment, using 
hypertonic conditions in patients suffering from ESRD might be harmful. 
Therefore, thorough future research is required to develop a safe though 
efficient dialysis environment to stimulate protein-bound uremic toxin 
removal. 
In addition, a new generation of hollow fiber membranes were developed 
in the field of artificial kidney engineering to adsorb uremic toxins from the 
patients’ blood. The fibers are dual-layered mixed matrix membranes (MMM) 
and consist of a porous macro-void free polymeric inner membrane layer 
to improve hemocompatibilty, which is connected to the activated carbon 
containing outer MMM layer (74, 75). Activated carbon is a known sorbent 
for blood purification and is also a strong uremic toxin’s adsorbent (76, 77). 
As carbon has poor biocompatible properties and thus hamper clinically safe 
applications, the carbon-particle free layer in the MMM at the blood side should 
prevent the release of carbon particles into the patients’ blood. Interestingly, 
the majority of the free fraction of the protein-bound uremic toxins tested, 
viz. p-cresyl sulfate, indoxyl sulfate and hippuric acid, was removed after 4h 
exposure of plasma to the MMM. Moreover, plasma pH values and electrolyte 
concentrations were maintained during the experiment (74). However, 
albumin partially passed through the membranes and, furthermore, binding 
specificity of end-metabolites should be investigated further as a possible loss 
of essential amino acids such as tryptophan should be prevented. In addition, 
although an artificial kidney with adsorptive characteristics can be efficient 
in the removal of the available pre-dialysis free fraction, the ability to restore 
the bound and free fraction equilibrium during dialysis to achieve continuous 
free toxin adsorption might be a challenge (78, 79). In contrast, a bioartificial 
kidney, of which a proof of principle was shown in chapter 7, might be able to 
restore the equilibrium and enable a continuous removal of albumin-bound 
toxins into the dialysate via active transport processes. Still, the development 
of advanced artificial kidneys is an interesting research field as cell-based 
therapies require stringent safety regulations to become clinically approved. 
Charcoal adsorbent is also available as oral applications, known as AST-120, 
and its putative efficacy in uremic toxins removal has been widely studied. 
This drug consists of spheroid carbon particles and has a high affinity to 
adsorb organic compounds like indoles, p-cresol and advanced glycation 
end-products in the gastrointestinal lumen (80, 81). As a result, precursor 
molecules will not enter the liver and the hepatic biosynthesis of end-
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metabolites such as indoxyl sulfate and p-cresyl sulfate will be diminished. 
Several clinical trials were conducted in different patient populations, but 
the actual efficacy of AST-120 in the attenuation of CKD progression is still 
debatable (82). Where previously conducted trials showed promising results 
with respect to a reduction in serum indoxyl sulfate levels and lowering CKD 
progression (83-86), recent multinational randomized placebo-controlled 
trials showed no beneficial effects of AST-120 (82). Differences in the quality 
of study design, dialysis environment, data analysis and interpretation of 
total or subpopulations might result in the discrepancies observed in these 
studies. A thorough systematic analysis of all available data could provide 
more insight in the actual efficacy of AST-120 as a therapeutic intervention to 
reduce CKD progression. 
Another interesting target to reduce uremic toxin levels in CKD patients is 
the colon and in particular the composition of the intestinal microbiome 
(87). Under healthy conditions, the microbial flora influence pathways 
involved in energy metabolism, inflammatory response and to a lesser 
Figure 8.2 Advanced therapeutic interventions to treat uremia in ESRD patients.
An overview of current and future treatment strategies to reduce uremia in ESRD 
patients is shown. 
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extent electrolyte homeostasis (87, 88). Ramezani and Vaziri et al. observed 
an altered gut microbiome composition in CKD rats and ESRD patients 
(88, 89). In particular, a disbalance between saccharolytic and proteolytic 
bacteria was observed in this study. Proteolytic bacteria produce the enzyme 
L-tryptophanase that mediates the formation of uremic toxin precursors 
like indole from tryptophan (90). Upon CKD progression, the biochemical 
environment of the gut alters due to urea influx and secretion of uric acid 
and oxalate by the colonic epithelium and, as a consequence, modifies the 
microbial flora. In addition, antibiotics, iron supplementation or phosphate-
binding substances as well as dietary restrictions of high-fiber products may 
contribute to an altered microbiome (91). Moreover, a clinical complication 
often observed in ESRD patients is constipation and undigested proteins 
in the colon that further stimulates proliferation of proteolytic bacteria 
(91). Various therapeutic interventions have been proposed to modulate 
the gut microbiome of patients suffering from kidney disease. The effects 
of prebiotics (non-digestable food ingredient) and probiotics (living micro-
organisms) to regenerate symbiosis in the intestine flora have been studied 
in hemodialysis populations and CKD rats but showed variable successes (89, 
91). The microbial flora consists of a complex (>1000 bacterial species (92)) 
and dynamic environment, therefore, to establish an optimal intervention 
using pre- or probiotics is a major challenge. In addition, uremic toxin plasma 
levels in colectomized dialysis patients have been studied (93). In patients 
without colons, indoxyl sulfate and p-cresyl sulfate plasma levels were almost 
absent (93). Based on these findings, one could argue that studying the effect 
of a regularly performed rectal lavement, likely in combination with pre- 
and probiotics, could be a promising intervention to reduce plasma levels of 
colonic-derived uremic toxins. 
The future of bioartificial kidney engineering
The cell-based therapies currently under development to replace renal 
function are promising entities in field of regenerative nephrology. To date, 
the scope of BAK research is predominantly focused on the implementation 
of one cell type, namely PTEC, and studying its function and beneficial effects 
in ESRD or AKI. Likely, BAK cell monolayer integrity and transport function 
might be further improved by applying more than one cell type within a 
device. The combination of proximal tubular cells with endothelial cells or 
epithelial cells from down-stream nephron segments might be favorable as 
it is postulated that paracrine factors secreted might maintain or improve 
PTEC function in uremia (4, 102). Preliminary results in our laboratory 
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showed a significantly enhanced transepithelial electrical resistance and less 
inulin diffusion when ciPTEC where co-cultured in the presence of human 
conditionally immortalized glomerular endothelial cells (kindly provided by 
the group of van der Vlag, dept. of Nephrology, Nijmegen) using Transwell® 
filter inserts (unpublished data). Moreover, the expression of the tight junction 
protein ZO-1 was more homogenous in co-culture conditions when compared 
to monocultures. These results suggest an improvement of PTEC monolayer 
integrity possibly induced by paracrine factors secreted by endothelial cells. In 
future studies, techniques like metabolomics could identify these factors and 
this knowledge can be translated further towards BAK development.
In addition, opportunities to combine cell therapy with a wearable or 
implantable artificial system to enable home-dialysis are being investigated. 
Roy and co-workers designed a miniaturized wearable hemodialysis system, 
which vascular access is based on the principle of peritoneal dialysis (94). The 
efficacy of this artificial device was tested in pigs suffering from AKI and in 
human subjects treated with hemodialysis to perform a proof-of-concept 
validation. However, technical hurdles like clotting of the extracorporeal 
circuit hampered further development and more advanced systems were 
designed. In collaboration with Humes, a system containing the combination 
of a silicon nanoporous carbon filter to fulfill ultrafiltration and adsorption of 
solutes with a bioreactor containing renal epithelial cells to replace partly the 
metabolic and reabsorptive functions was developed (95). Still, the cell system 
as developed by Humes and co-workers did not show any beneficial effects 
with respect to albumin-bound uremic toxin clearance so far (5, 6, 43). As the 
researchers aim to develop a bioengineered system to treat patients suffering 
from ESRD, the clearance capacity of albumin-bound uremic toxins using this 
system should definitely be demonstrated in vitro prior to any further clinical 
validation. Obviously, an implantable bioartificial system would be a major 
breakthrough in the field of regenerative nephrology and, next to ameliorated 
health conditions, would improve patients’ socio-economic life significantly. 
However, many challenges like BAK immune tolerance, safety and clearance 
efficiency and efficacy of a miniaturized system should be critically evaluated.
A promising new era in the field of regenerative nephrology is the 
differentiation of autologous stem cells into renal lineages. Extrarenal 
sources, such as bone marrow-derived, embryonic or amniotic fluid stem cells, 
but also CD133+ multipotent stem cells isolated from kidney tissue itself, have 
been differentiated into cells with renal characteristics (5, 27, 96, 97). However, 
limited accessibility, the risk of tumor formation and ethical concerns hamper 
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future research and applications of these sources. Nowadays, cells isolated 
from skin tissue have been successfully reprogrammed into human induced 
pluripotent stem cells (iPSCs) and allow for autologous applications (98-
100). It has been shown that engineered stem cells can give rise to kidney-
like cells and, therefore, iPSC-derived renal cell models might be promising 
platforms to aid autologous BAK engineering (28, 29, 99, 101). Obviously, 
approaches containing autologous cell sources would likely be beneficial to 
enhance BAK immune tolerance. As soon as differentiation processes become 
well-controlled and functional active transport is confirmed in engineered 
kidney cells, an autologous BAK application may become feasible. Recently, 
engineered human kidney cells have been successfully cultured into 3D self-
organizing kidneys, called organoids. The expression of various proteins 
originating from multiple renal lineages showed high similarities with first 
trimester human embryonic kidney development (29). Moreover, specific 
maturation of proximal tubule epithelial cells in organoids was confirmed 
as demonstrated by active endocytosis and toxicity response to a known 
nephrotoxic agent cisplatin (29). In concert, murine organoids reconstitute 
active organic cationic as well as anionic transport as was shown using 
known fluorescent model substrates in the presence or absence of specific 
inhibitors (28). Obviously, organoids are miniaturized kidneys-in-a-dish and 
the development of fully grown kidneys for transplantation will require many 
more years of research. For BAK engineering purposes, it will be a challenge to 
isolate a sufficient number of proximal tubule cells from organoids, for which 
immortalization strategies might be unavoidable. Organoids may, however, 
also be a valuable tool for safety screening of new pharmaceutical entities, 
kidney disease modeling and personalized medicine. But this also holds true 
for the bioengineered renal tubules as developed in Chapter 7. 
As discussed, the development of innovative renal replacement therapies is 
challenging (figure 8.2), and the implementation of many of these platforms 
into clinical practice will require in depth future research. Based on my 
current knowledge, the development of novel renal replacement therapies 
to diminish the uremic syndrome will, most likely, demand a multifaceted 
therapeutic intervention. A well-defined balance between BAK applications 
with nutritional and drug treatment regimes could attenuate uremic toxin 
plasma levels in patients and alleviate the uremic syndrome and its associated 
complications. Moreover, physiologically-based in silico models can become 
useful tools to predict the adequacy of BAK treatment in order to achieve 
a clinically relevant clearance of uremic toxins in ESRD patients. Obviously, 
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to successfully establish a reliable in silico model, thorough in vitro and 
preclinical validations should be performed. 
In conclusion, the work presented in this thesis is one of the first steps to 
pave the way towards a promising renal replacement therapy to treat ESRD 
patients. The established bioengineered renal tubules facilitate the secretion 
of protein-bound uremic toxins, which is mediated by the concerted action of 
essential in- and efflux transporters. Altogether, our findings will contribute 
to the expansion of novel bioengineered platforms to replace PTEC function. 
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SUMMARY
The kidneys consist of approximately 2 million nephrons, which all together 
fulfill the homeostatic regulation of the human body. An important task 
of the kidneys is the removal of waste products from blood into the (pro-)
urine. The proximal tubule epithelial cells (PTEC) present in each nephron 
are equipped with a broad range of transporter proteins that facilitate the 
removal of many solutes from the systemic circulation. During renal failure, 
among others, PTEC function is impaired and the removal of waste products is 
diminished. Consequently, these products accumulate with adverse effects on 
the organism’s homeostasis. Disorders like sepsis, cardiovascular or immune 
disease as well as diabetes mellitus and exposure to nephrotoxic agents 
are associated with the development of renal failure. In addition, inherited 
genetic diseases that primarily affect the kidneys have been described. Kidney 
function has to be replaced when an abrupt loss or a severe decline in kidney 
function (eGFR < 15ml/min/1.73m2) is detected. Current renal replacement 
therapies, like hemodialysis, only replace renal function for approximately 
20% and, as a result, waste products accumulate in the patient. The limited 
clearance capacity of waste products by dialysis treatment is caused by the 
chemical properties of these solutes that hamper their removal. To date, three 
classes of waste solutes have been characterized, comprising approximately 
150 uremic solutes that accumulate in renal failure. The first and second class 
of uremic solutes consist of small water-soluble solutes (Molecular weight 
(MW) <500 Da) and middle molecules (MW >500 Da) and these classes can, 
to a certain extent, be removed using hemodialysis treatment. The third class, 
the albumin-bound uremic solutes, have a MW <500 Da but are difficult to 
remove by dialysis as they are bound to plasma proteins which greatly extents 
their MW. Detailed research showed that many of the uremic retention 
solutes interact negatively with various biological processes in the body and 
are, therefore, described as uremic toxins. The preferred option to replace 
renal function is kidney transplantation. However, as donor organs are 
scarce, the development of novel therapeutic strategies to improve or replace 
(preferentially PTEC) function are of high interest in the field of regenerative 
nephrology.
In a so-called bioartifical kidney (BAK), the implementation of PTEC in an 
extracorporeal device should enable the removal of albumin-bound uremic 
toxins from the patients’ plasma. In this thesis, the handling of uremic toxins 
by PTEC was step-wisely studied. First, novel renal cell lines were developed 
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and transport processes of waste products across tight cell monolayers were 
studied in 2D flat cell monolayers. Next, the biofunctionalization of 3D hollow 
fiber membranes (HFM) to stimulate cell monolayer polarization was studied 
and elimination processes of uremic toxins mediated by bioengineered renal 
tubules were examined. Studying the clearance of waste products across vital 
PTEC monolayers will allow estimating the potency of a cell-based device to 
improve hemodialysis treatment.
A suitable cell model that reflects PTEC function is a prerequisite for 
successful bioartificial kidney development. In Chapter 2, we developed 
conditionally immortalized PTEC (ciPTEC) models with cells isolated from 
human urine and kidney tissue. Based on mRNA expression profiling of PTEC 
transporters, morphology and cell monolayer tightness, two out of twenty 
six kidney PTEC subclones were selected (ciPTEC-T1 and -T2) for detailed 
characterization. An extensive morphological and functional comparison of 
these cells models with a urine-derived model (ciPTEC-U) was set out. The 
selected cell models showed to form confluent and polarized cell monolayers 
when cultured on filter inserts as the expression of the tight junction 
protein ZO-1 was abundantly expressed along the boundaries of the cells. 
Remarkable, a larger diameter of kidney tissue-derived cells was observed 
when compared to urine-derived cells. In addition, also the expression profile 
of extracellular matrix (ECM) genes differed between sources. Where both 
tissue derived cell lines demonstrated a high abundance of collagen I and 
-IV αI, the cells isolated from urine showed a more pronounced expression 
of laminin V and fibronectin I. The endogenous expression and function 
of the uremic toxin transporters Organic Cation Transporter–2 (OCT2), 
Breast Cancer Resistance Protein (BCRP), Multidrug Resistance-associated 
Protein–4 (MRP4) and P-glycoprotein (P-gp) were confirmed in all cell 
lines and only minor differences were observed. Moreover, active albumin- 
and phosphate-uptake was confirmed in the kidney-tissue derived cell 
lines, processes representative of tubular reabsorption. All together, these 
inexhaustible cell lines display robust functional PTEC characteristics and 
can be valuable tools to aid bioartificial kidney engineering. Moreover, these 
cell lines could be useful for the screening of novel pharmaceutical entities 
and are valuable for studying (patho)physiological processes in PTEC. The 
latter was demonstrated in Chapter 3, where PTEC were used to study the 
protective mechanism of dexamethasone, a drug that is often used to treat 
chronic inflammatory diseases, in experimental inflammation induced by 
the endotoxin lipopolysaccharide (LPS). In this study we showed that the 
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cellular alkalisation could be the initiating event underlying LPS-induced 
mitochondrial dysfunction. Upon dexamethasone treatment, pH was 
corrected and, consequently, the mitochondrial function was restored. This 
was shown by improved mitochondrial respiration and membrane potential, 
concerted by reduced ROS levels. In addition, we showed that an enhanced 
mitochondrial Complex V expression and activity act as a compensatory 
mechanism in the dexamethasone-induced acidified environment. Together, 
we nicely demonstrated in this chapter that ciPTEC can be valuable tools in 
studying metabolic pathways and, therefore, are suitable in vitro models for 
studying different renal processes in health and disease. 
In Chapter 4, the current status of BAK engineering was reviewed. To date, the 
development of extracorporeal BAK platforms predominantly demonstrates 
immunomodulatory effects in order to reduce mortality in critically ill patients 
suffering from acute kidney injury (AKI). In the majority of the performed 
BAK studies, primary renal epithelial cells are being applied. These cell 
systems display a high batch-to-batch variability with respect to PTEC quality 
and function. Therefore, ciPTEC could be a promising alternative to aid BAK 
engineering as this system reflects a stable expression and function of PTEC 
transporters and metabolic activity. Another critical step in BAK engineering 
is that the native basement membrane and its extracellular matrix should be 
mimicked in vitro, in order to stimulate monolayer polarization to obtain a 
‘living membrane’ which enables the removal of waste products. An overview 
of biomaterials and coatings applied for BAK purposes so far is summarized 
in this chapter. The natural compound 3,4-dihydroxy-L-phenylalanine 
(L-DOPA) in combination with collagen IV have shown to be a successful 
surface modification to stimulate the formation of a tight PTEC monolayer. 
In addition to the optimization of monolayer formation, thorough preclinical 
and safety evaluation should demonstrate the efficacy and efficiency of 
PTEC monolayers in a BAK to become a feasible approach to treat end-stage 
renal disease (ESRD) patients. Future research will, most likely, advance the 
development of an extracorporeal BAK into a wearable or implantable BAK. 
Concurrently, the possibilities to develop autologous cell-based therapies will 
be further explored in order to improve immune tolerance.
In vivo, the urinary excretion of uremic toxins from the blood into the pro-
urine is mediated by PTEC in- and efflux transporters, a function that should 
be maintained in vitro for successful BAK development. As demonstrated 
in Chapter 5, we first developed a living membrane containing tight 
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ciPTEC monolayers on hemocompatbile PES/PVP flat membranes. The 
biofunctionalization of the membrane was studied thoroughly and the coating 
was optimized, which consisted of a well-defined combination of L-DOPA 
and collagen IV. Optimal cell adhesion and cell monolayer polarization was 
confirmed with ZO-1 expression, without a loss of membrane permeance 
as demonstrated by H2O, albumin and IgG permeance. Consequently, the 
transepithelial clearance of creatinine, a known OCT2 substrate and uremic 
toxin, was confirmed in these cell monolayers. This creatinine flux was 
compared to transport rates observed across ciPTEC monolayers cultured 
on commercially available Transwell inserts. This system is regarded as 
a golden standard in cell culturing, though it has poor hemocompatible 
properties and is therefore not suitable for BAK applications. Interestingly, 
creatinine clearance rates were similar in both systems, confirming that 
ciPTEC transport properties are well preserved when cultured on PES/PVP 
biomaterials. In Chapter 6, this knowledge was translated into 3D PES/
PVP membrane approaches. Hollow fiber membranes were coated with the 
same composition (L-DOPA and collagen IV), though coating time had to be 
extended to achieve a polarized cell monolayer, as shown by ZO-1 and OCT2 
expressions. Importantly, the membrane permeance of H2O and BSA were 
preserved allowing the free passage of albumin-bound uremic toxins through 
the membrane to come in close proximity with cells to enable transepithelial 
clearance. Obviously, the monolayer should maintain tight characteristics to 
avoid loss of host blood components. As a proof of concept, cell monolayers 
on HFM were functionally characterized in real-time using a perfusion 
system by measuring the transport of a fluorescent cationic model substrate 
4-(4-(dimethylamino)styryl)-N-methylpyridinium-iodide (ASP+). Initial ASP+ 
uptake was inhibited by a cationic uremic metabolites mixture and by the 
histamine H2-receptor antagonist, cimetidine. These data confirmed a 
successfully established bioartificial renal tubule of PTEC on MicroPES HFM 
with active organic cation transport.
 
Many of the uremic toxins studied in literature are organic anions, therefore, 
the Organic Anion Transporter - 1 (OAT1) and -3 (OAT3)-mediated handling 
of a panel of eight anionic uremic toxins was investigated. In Chapter 7, we 
first designed 2D experiments and confirmed their potency to competitively 
inhibit OAT-mediated transport. Of these uremic toxins, indoxyl sulfate 
and kynurenic acid transport in PTEC was investigated further and active 
OAT1-mediated transport was demonstrated. We selected these two uremic 
toxins as both showed a strong OAT1-mediated inhibition and are associated 
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with ESRD progression and its related complications. Next, transepithelial 
clearance of indoxyl sulfate and kynurenic acid in the presence or absence of 
human serum albumin across polarized bioartificial renal tubules was shown. 
Interestingly, the clearance of both albumin-bound anionic uremic toxins was 
enhanced as compared to the clearance of toxins in the absence of albumin. 
This observation is nicely in line with literature where albumin is described as 
a carrier protein and stimulates transport processes.
In this thesis we aimed to develop new therapeutic entities to replace PTEC 
function, by studying elimination processes of cationic and anionic uremic 
toxins in vitro in flat cell monolayers and subsequently in 3D bioengineered 
renal tubules. In Chapter 8, the delineated knowledge obtained in this thesis 
was discussed within the current scope of regenerative nephrology and renal 
pharmacology. Moreover, future perspectives of the successfully established 
bioengineered renal tubules regarding (pre)clinical validation processes were 
discussed as well as promising opportunities to further aid regenerative 
nephrology. Altogether, this work may pave the way towards suitable 
approaches to aid ESRD and AKI treatment in the future. 
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SAMENVATTING
De nieren hebben een belangrijke rol in het handhaven van velerlei processen 
in het menselijk lichaam, zoals de regulatie van bloeddruk, hormoonproductie 
en de uitscheiding van afvalstoffen en urine productie. De nieren bestaan 
uit zo’n 2 miljoen filtratie buisjes, genaamd nefronen. Een nefron bestaat 
uit meer dan 20 verschillende celtypen met ieder een belangrijke rol in de 
homeostase van het interne milieu. Een belangrijk onderdeel daarvan is 
de uitscheiding van afvalstoffen door proximale tubulusepitheelcellen 
(PTEC). PTEC bevatten een variëteit aan transporterende eiwitten die 
afvalstoffen vanuit het bloed naar de (voor)-urine kunnen verplaatsen. 
Tijdens nierfalen verlopen diverse processen in de nier minder efficiënt wat 
leidt tot ophoping van afvalstoffen en een verstoorde homeostase van het 
lichaam, gevolgd door progressie van nierfalen uiteindelijk leidend tot het 
uremisch syndroom. Nierziekten kunnen secundair ontstaan door ziektes 
als sepsis, cardiovasculaire aandoeningen en auto-immuunziekten, maar 
ook diabetes mellitus en niertoxische medicijnen zijn bekende factoren die 
nierfalen kunnen veroorzaken. Daarnaast zijn er ook aangeboren genetische 
afwijkingen bekend welke leiden tot een verminderde nierfunctie. Patiënten 
waarvan de nierfunctie gedaald is tot minder dan 15% van de normale functie 
moeten behandeld worden met nierfunctie-vervangende therapieën, zoals 
hemodialyse. Echter, hemodialyse vervangt slechts zo’n 20% van de nierfunctie 
waardoor een belangrijk deel van de afvalstoffen in de patiënt niet verwijderd 
worden. De beperkte klaringscapaciteit van dialyse wordt veroorzaakt door 
de chemische eigenschappen van de afvalstoffen. De afvalstoffen in klasse 
I, de kleine, water oplosbare moleculen (MW < 500 Da), zijn wel middels 
dialyse te verwijderen. Met behulp van een meer poreus dialysefilter zijn ook 
de klasse II, de middelgrote moleculen (MW > 500 Da) tot op zekere hoogte 
te verwijderen. De metabolieten van klasse III zijn op zich niet groot (MW 
< 500 Da) maar doordat ze in het bloedplasma gebonden zijn aan eiwitten 
worden deze moleculen dermate groot en complex dat ze niet met behulp van 
een dialysemembraan verwijderd kunnen worden. Inmiddels zijn er zo’n 150 
metabolieten geïdentificeerd die geassocieerd zijn met negatieve effecten op 
biologische systemen in het menselijk lichaam en daarom geclassificeerd als 
‘uremische toxine’. Van een aantal van deze toxines is bijvoorbeeld inmiddels 
bekend dat zij een directe bijdrage hebben aan de ontwikkeling van hart- en 
vaatziekten bij nierpatiënten, een veel voorkomende complicatie bij nierfalen. 
De meest effectieve wijze om nierfunctie te vervangen is het verkrijgen van 
een donororgaan via transplantatie, echter hiervoor geschikte organen 
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zijn schaars. Derhalve is er de behoefte aan de ontwikkeling van betere 
behandelmethoden zoals de biologische kunstnier (BAK) om de nierfunctie te 
kunnen vervangen of te verbeteren. 
In een BAK zullen specifieke niercellen, namelijk PTEC, geïmplementeerd 
worden in een dialysesysteem om daarmee de uitscheiding van eiwitgebonden 
afvalstoffen te kunnen realiseren. In dit proefschrift is de wijze waarop PTEC 
in vitro omgaan met uremische toxines bestudeerd. Hiervoor zijn in eerste 
instantie 2-dimensionale cellagen gebruikt. Vervolgens is een methode 
ontwikkeld om een 3-dimensionaal systeem te maken dat de functie van 
een nierbuisje kan nabootsen. Hiertoe hebben we holle buisjes met een 
membraan bestaande uit synthetische polymeren voorbewerkt om daar 
vervolgens gepolariseerde PTEC cellagen op te kunnen kweken. Vervolgens is 
het transport van verschillende groepen afvalstoffen gefaciliteerd door deze 
zogenaamde bioartificiële nierbuisjes bestudeerd. Dit onderzoek geeft inzicht 
in de mogelijkheden om humane niercellen te gebruiken als een mogelijke 
therapeutisch platform en draagt hierdoor bij aan de realisatie van een 
klinisch-toepasbare BAK in de toekomst. 
Voor de succesvolle ontwikkeling van een BAK is het cruciaal om een in 
vitro model toe te passen die de functie van de humane nier kan nabootsen. 
Daarom werden PTEC cellen geïsoleerd uit humaan nierweefsel en genetisch 
gemodificeerd om celdeling eigenschappen in stand te kunnen houden 
middels een temperatuurgevoelig systeem (conditionally immortalized 
PTEC; ciPTEC) en verder ontwikkeld tot twee stabiele cellijnen. Zoals 
beschreven in hoofdstuk 2, zijn deze modellen morfologisch en functioneel 
uitvoerig gekarakteriseerd en vergeleken met een cellijn ontwikkeld van 
cellen afkomstig uit humane urine. Alle drie de cellijnen gaven dichte 
monolagen waarin tevens het zonula occludens -1 (ZO1) eiwit kon worden 
aangetoond waarmee polarisatie werd bevestigd. Opmerkelijk was dat de 
cellijnen afkomstig uit nierweefsel bestonden uit beduidend grotere cellen 
dan de cellen uit urine. Bovendien vertoonden de niercellijnen op genniveau 
een ander extracellulaire matrix (ECM) profiel. ECM bestaat uit diverse 
eiwitstructuren, zoals collagenen en fibronectine, welke de verbinding tussen 
de cel en de basaalmembraan in stand houden. Bovendien is de ECM een 
belangrijk depot voor groeifactoren en stimuleert het mede het functioneren 
van en de communicatie tussen cellen. Collagen I en IV kwamen significant 
hoger tot expressie in de niercellijnen, daarentegen was de gen expressie van 
fibronectine I en laminine V hoger in de cellijn afkomstig van urine. Deze 
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bevindingen duiden op het feit dat de cellijn afkomstig uit urine deels het 
vermogen om ECM te produceren heeft verloren. Echter vertoonden de drie 
cellijnen wel overeenkomstige functionele eigenschappen met betrekking tot 
PTEC-specifieke transporteiwitten zoals de organische-kationtransporter 
- 2 (OCT2), P-glycoproteïne (P-gp), Multidrugresistentie-eiwit – 4 (MRP4) 
en het borstkankerresistentie-eiwit (BCRP). Alle cellijnen lieten bovendien 
albumine- en fosfaatreabsorptie zien, echter vertoonde een niercellijn 
beduidend meer albuminereabsorptie en de cellijn uit urine een groter 
vermogen om fosfaat te resorberen. Concluderend kan worden gesteld dat 
deze onuitputtelijke bron aan cellen PTEC-specifieke eigenschappen vertonen 
en ze derhalve toegepast zouden kunnen worden voor de ontwikkeling van 
een BAK. Bovendien zouden deze modellen geschikt kunnen zijn voor de 
screening van nieuwe medicijnen en de mogelijke effecten op nierfunctie, of 
voor het bestuderen van pathofysiologische processen in PTEC. Dit laatste 
wordt weergegeven in hoofdstuk 3, waarin ciPTEC werden behandeld met een 
endotoxine om vervolgens als een experimenteel ontstekingsmodel toegepast 
te kunnen worden. In deze studie werd het moleculaire mechanisme van 
dexamethasone als potentiële behandeling voor acuut nierfalen onderzocht. 
Cellen blootgesteld aan de endotoxine lipopolysaccharide (LPS) vertoonden 
een verhoging in mitochondrieël-geproduceerde zuurstofradicalen, wat door 
dexamethasone werd hersteld. Mitochondriële-zuurstofrespiratie en ook de 
membraanpotentiaal waren beduidend verlaagd in cellen blootgesteld aan 
LPS en ook dit kon worden hersteld door toediening van dexamethasone. De 
pH in cellen blootgesteld aan LPS bleek verhoogd te zijn, wat waarschijnlijk 
de afwijkende metabole activiteit verklaart. Door dexamethasone kon de 
intracellulare pH worden verlaagd en zelfs iets worden verzuurd ten opzichte 
van de controle. Als gevolg daarvan vond een toename in expressie en functie 
van complex V van het oxidatieve-fosforyleringssysteem plaats. Bovendien is 
het pH effect door dexamethasone behandeling waarschijnlijk de aanleiding 
voor het herstellen van de membraanpotentiaal en de mitochondriële 
activiteit. Onze studie toont hiermee aan dat ciPTEC, naast hun potentie als 
model voor BAK toepassingen, ook zeer geschikt zijn voor het bestuderen van 
metabole processen in niercellen. 
In hoofdstuk 4 wordt een overzicht gegeven van de huidige kennis met 
betrekking tot de ontwikkeling van de BAK. Tot op heden zijn door andere 
groepen voornamelijk immuun-modulerende effecten door BAK behandeling 
aangetoond in ernstig zieke patiënten die lijden aan acuut nierfalen. Hiervoor 
zijn met name primaire niercellen gebruikt, echter vertonen deze cellen per 
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batch een hoge variabiliteit in kwaliteit en functie. Vanuit dat oogpunt zouden 
ciPTEC lijnen veelbelovende modellen zijn voor BAK ontwikkeling gezien de 
functionele eigenschappen van specifieke transporteiwitten en hun metabole 
activiteit. Een ander belangrijk aspect is de keuze van het biomateriaal waar 
de cellen op gekweekt moeten worden. Er is reeds veel onderzoek verricht 
naar het simuleren van de in vivo basaalmembraan en de ECM voor in 
vitro applicaties. De combinatie van een geschikt poreus membraan en een 
biologische coating zou de vorming van een dichte en functionele niercellaag 
moeten stimuleren om uiteindelijk een zogenaamd ‘levend membraan’ te 
ontwikkelen dat in staat is om afvalstoffen uit te scheiden. In hoofdstuk 4 
wordt een overzicht gegeven van de tot op heden geteste biomaterialen en 
toegepaste coatings voor BAK doeleinden. Het is gebleken dat bijvoorbeeld 
de combinatie 3,4-dihydroxy-L-phenylalanine (L-DOPA) en collagen IV 
gunstig is voor cellaagvorming. Om de efficiëntie waarmee PTEC monolagen 
in een BAK afvalstoffen kunnen transporteren nader vast te stellen zijn er 
echter nog uitgebreide studies nodig. Bovendien zullen veiligheidsaspecten 
nauwkeurig onderzocht moeten worden om het gebruik van een BAK als 
therapeutische toepassing voor patiënten met nierfalen te kunnen realiseren. 
Daarnaast worden in dit hoofdstuk de mogelijkheden voor een draagbare 
of implanteerbare kunstnier en het gebruik van stamcel technologieën voor 
gepersonaliseerde BAK toepassingen als mogelijk toekomstige toepassingen 
geëvalueerd. 
In de nier wordt de klaring van uremische toxinen vanuit het bloed naar de 
voorurine gemedieerd door PTEC specifieke in- en efflux transporteiwitten. 
Deze uitscheidingsprocessen dienen ook plaats te vinden in een BAK om 
daarmee de huidige hemodialyse technieken te kunnen verbeteren. In 
hoofdstuk 5 wordt de klaring van het kationische creatinine door ciPTEC 
cellagen gekweekt in 2D op gecoate biomaterialen bestudeerd. Eerst is een 
coating, bestaande uit L-DOPA en collagen IV, dermate geoptimaliseerd 
dat er een balans ontstond waarin de permeabiliteit van de PES/PVP 
membraan gehandhaafd werd en er tevens een dichte cellaag ontstond met 
een homogene ZO1 expressie. Het transport van creatinine is bestudeerd in 
ciPTEC cellagen op gemodificeerde PES/PVP membranen en vergeleken met 
cellagen op Transwell inserts. Deze inserts zijn commerciële kweeksystemen 
welke de gouden standaard zijn voor het bestuderen van cellulaire (transport)
processen. Deze systemen zijn echter niet geschikt zijn voor BAK toepassingen 
vanwege de beperkte hemocompatibele eigenschappen. Het transport van 
creatinine door ciPTEC cellagen gekweekt op gemodificeerd PES/PVP was 
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niet verschillend van dat op Transwell inserts. Dit betekent dat ciPTEC 
functie gehandhaafd blijft op hemocompatibele PES/PVP biomaterialen. In 
hoofdstuk 6 is deze kennis verkregen in 2D vertaald naar 3D door gebruik 
te maken van holle buisjes van PES/PVP membranen. Eenzelfde compositie 
van coating worden toegepast, echter was het wel noodzakelijk om de 
coatingtijd te verlengen om goede dichte cellagen te verkrijgen. Opnieuw is de 
membraanpermeabiliteit onderzocht en is de coating afgestemd op de passage 
van moleculen als H2O en albumine, zodat uiteindelijk ook afvalstoffen 
gebonden aan albumine in nabijheid van de cellaag konden komen. Op 
buisjes gekweekte cellen vertoonden naast een gepolariseerd karakter, 
aangetoond middels ZO1 en OCT2 expressie, ook intacte celorganellen en een 
PTEC-specifieke apicaalmembraan met microvilli. De functionaliteit van deze 
buisjes is onderzocht door gebruik te maken van geavanceerde fluorescentie 
microscopie in combinatie met een perfusie systeem om het opname proces 
van een model substraat 4-(4-(dimethylamino)styryl)-N-methylpyridinium-
iodide (ASP+) in de tijd te kunnen volgen. De opname van ASP+ kon worden 
geremd door een mengsel van kationische uremische metabolieten en door het 
geneesmiddel en bekend OCT substraat, cimetidine. Deze bevindingen geven 
aan dat kationische transportprocessen aanwezig zijn in ciPTEC gekweekt 
op holle buisjes en bevestigd daarmee de succesvolle ontwikkeling van een 
functioneel bioartificieel nierbuisje. Naast kationische toxinen spelen met 
name ook anionische uremische toxinen een prominente rol in de progressie 
van het uremisch syndroom. Hiertoe is in hoofdstuk 7 de interactie van 
anionische uremische toxinen op niertransport in 2D onderzocht, en vervolgens 
het uitscheidingsproces in bioartificiele nierbuisjes bestudeerd. Een groep van 
acht uremische toxinen was in meer of minder mate in staat om het transport 
van een organisch-aniontransporter – 1 (OAT1) en - 3 (OAT3) modelsubstraat 
op een competitieve manier te remmen. Uit deze groep zijn indoxylsulfaat en 
kynureninezuur geselecteerd voor nader onderzoek, aangezien deze stoffen 
een hoge potentie vertoonden om OAT-gemedieerd transport te beïnvloeden 
en geassocieerd zijn met diverse uremische complicaties. Het transport van 
beide toxinen door OAT1 kon worden bevestigd in 2D cellagen. Vervolgens 
is voor beide stoffen de uitscheiding door de bioartificiële nierbuisjes 
bestudeerd. Actieve uitscheiding kon worden bevestigd en bovendien werd 
door de aanwezigheid van albumine aangetoond dat eiwit-binding een 
gunstig effect heeft op deze uitscheiding. 
Het doel van dit proefschrift was de ontwikkeling van nieuwe therapeutische 
interventies om PTEC functie te vervangen tijdens eindstadium nierfalen, 
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door de uitscheiding van kationische alsmede anionische uremische toxinen 
in 2D en vervolgens in bioartificiële nierbuisjes te bestuderen. In hoofdstuk 8 
worden de resultaten verkregen in dit proefschrift bediscussieerd. Daarnaast 
wordt noodzakelijk toekomstig (pre)klinisch onderzoek naar de verkregen 
bioartificiële nierbuisjes nader toegelicht en worden de mogelijkheden 
met betrekking tot gepersonaliseerde regeneratieve nefrologie beschreven. 
Samenvattend kan gesteld worden dat dit proefschrift bijdraagt aan een 
eerste stap in de richting van nieuwe nierfunctievervangende therapieën voor 
de toekomstige behandeling van eindstadium nierfalen.  
269
9
270
10
271
10
10 Chapter 10LIST OF ABBREVIATIONSCURRICULUM VITAEBIBLIOGRAPHY & AWARDSRIMLS PORTFOLIO
272
Chapter 10
LIST OF ABBREVIATIONS
ABC ATP-binding cassete 
AKI Acute kidney injury
ASP+ 4-(4-(dimethylamino)styryl)-N-methylpyridinium-iodide 
ATMPs Advanced therapy medicinal products
ADP Adenosine diphosphate
ATP Adenosine triphosphate 
BAK Bioartificial Kidney
BCECF 2’,7’-Bis-(2-Carboxyethyl)-5-(and-6)-carboxyfluorescein acetoxy methyl ester
BCRP Breast cancer resistance protein 
BM Basement membrane
BRECS Bioartificial renal epithelial cell system 
BSA Bovine serum albumin 
CiPTEC-U Conditionally immortalized proximal tubule epithelial cell, urine origin 
CiPTEC-T1 Conditionally immortalized proximal tubule epithelial cell, tissue origin 1 
CiPTEC-T2 Conditionally immortalized proximal tubule epithelial cell, tissue origin 2 
CKD Chronic kidney disease 
CM-H2DCFDA 5-(and-6)-Chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate, acetyl ester
Coll IV Collagen IV 
COX Cytochrome c oxidase
CI-V Mitochondrial respiratory complex I-V
kDa Kilodalton
ECM Extra cellular matrix 
ESCs Embryonic stem cells
ESRD End stage renal disease 
EUtox European uremic toxin (work group) 
FCS Fetal calf werum 
G3PDH Glycerol-3-phosphate dehydrogenase
G418 Geneticin 
GAGs Glycosaminoglycans
GC(R) Glucocorticoid (receptor)
GFR Glomerular filtration rate 
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GGT γ-Glutamyltransferase
GRE Glucocorticoid responsive element
HBSS Hanks’ balanced salt solution 
HEK Human embryonic kidney 
HFM Hollow fiber membranes 
HGF Hepatocyte growth factor
HK-2 Human kidney-2
HPTC Human primary tubular cell cultures
HSA Human serum albumin
hTERT Essential catalytic subunit of human telomerase 
HUVEC Human umbilical vein endothelial cells
IC50 Half maximal inhibitory concentration 
ICU Intensive care unit
IgG Immunoglobulin G 
IL-6/-8 Interleukin-6 / -8
iNOS Inducible nitric oxide synthase 
iPSCs Induced pluripotent stem cells
J Flux 
L-DOPA 3,4-Dihydroxy-L-phenylalanine 
LLC-PK Lilly laboratories cell porcine kidney proximal tubular cells 
LPS Lipopolysaccharide 
MATE Multidrug and toxin extrusion protein 
MDCK Madin-darby canine kidney cells 
MMM Mixed matrix membranes
MRP2/-4 Multidrug resistance protein -2 / -4
mTOR Mammalian target of rapamycin
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide 
MW Molecular weight
NAD Nicotinamide adenine dinucleotide
NBC-1 Sodium-bicarbonate co-transporter -1
NF-κB Nuclear factor κappa bèta
NHE-3 Sodium-proton exchanger-3
NO Nitric oxide 
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(i)NOS (Inducible) nitric oxide synthase 
OA Organic anion 
OAT Organic anion transporter 
OATP Organic anion transporting polypeptide 
OC Organic cation 
OCT Organic cation transporter 
OCTN Carnitine/organic cation transporter 
OXPHOS Oxidative phosphorylation system
PBS Phosphate buffered saline 
PBS-T Phosphate buffered saline - tween 
PES Polyethersulfone 
PGC-1α Peroxisome proliferator –activated receptor (PPAR) gamma coactivator - 1α
P-gp P-glycoprotein
PG Proteoglycan
P:O Phosphate : oxygen
PSF Polysulfone 
PTEC Proximal tubule epithelial cell 
RAD Renal assist device 
ROS Reactive oxygen species
SC Sieving coefficient 
SDS-PAGE Sodium sodecyl sulfate polyacrylamide gel electrophoresis 
SEM Standard error of the mean 
SEM image Scanning electron microscope image 
SLC Solute carrier 
SM Stromal matrix
SV40-T Simian virus 40 large T antigen 
TEER Trans-epithelial electric resistance 
TMRM Tetramethylrhodamine methyl ester
TNF-α Tumor necrosis factor-α
TPA Tetrapentylammoniumchloride 
UGT UDP-glucuronosyltransferases
Upy Ureido-pyrimidinone
URAT Urate reuptake transporter 
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UT(s) Uremic toxin(s) 
V/V Volume/volume 
W/V Weight/volume 
WAK Wearable artificial kidney 
ZO-1 Zona occludens 1 
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opleiding aan de Hogeschool van Arnhem en Nijmegen. Tijdens haar opleiding 
tot Medische Microbiologisch analist liep ze twee stages binnen dit vakgebied 
(Slingeland ziekenhuis, Doetinchem en Canisius Wilhelmina Ziekenhuis, 
Nijmegen). In 2005 behaalde zij haar HLO-diploma en in datzelfde jaar begon 
ze aan de opleiding Biologie aan de Radboud Universiteit Nijmegen. Na enkele 
maanden werd deze studie beëindigd en begon zij haar loopbaan als medisch 
microbiologisch analist in het Canisius Wilhelmina Ziekenhuis te Nijmegen, 
afdeling Medische Microbiologie. Na 2,5 jaar begon zij in 2007 als analist bij QM 
Diagnostics in het RadboudUMC te Nijmegen, waarna zij vervolgens binnen 
het UMC de overstap maakte naar de afdeling kindergeneeskunde. Daar ging 
zij aan de slag bij de DNA diagnostiek onder leiding van Prof. Dr. L.P.W.J. van 
den Heuvel en Ing. W. Heys. Zij verrichte genetische analyses om mutaties op 
te sporen in het oxidatieve fosforyleringssysteem van mitochondriën alsmede 
DNA onderzoek naar genen gerelateerd aan het atypische hemolytisch 
uremisch syndroom. In het najaar van 2010 begon zij als research analist op 
het zogenaamde Biologische Kunstnier project (BioKid P3.01) onder leiding van 
Prof. Dr. R. Masereeuw, Prof. Dr. J.G.J. Hoenderop en Prof. Dr. L.P.W.J. van den 
Heuvel. Dit project maakte onderdeel uit van het onderzoeksprogramma van 
het BioMedical Materials Institute, mede gefinancierd door het ministerie van 
Economische Zaken en ondersteund door de Nierstichting. In dit project werkte 
zij nauw samen met de toenmalige promovendus C.M.S. Schophuizen. Na 2 jaar 
succesvol als research analist gewerkt te hebben, begon zij oktober 2012 haar 
promotieonderzoek naar de ontwikkeling van de Biologische Kunstnier onder 
leiding van Prof. Dr. R. Masereeuw, Prof. Dr. J.G.J. Hoenderop, Prof. Dr. L.P.W.J. 
van den Heuvel en Dr. M.J. Wilmer. Haar onderzoek maakte deel uit van het 
Netherlands Institute for Regenerative Medicine, mede gefinancierd door het 
ministerie van Economische Zaken en ondersteund door de Nierstichting. Jitske 
heeft meerdere studenten begeleid, haar werk gepresenteerd op nationale en 
internationale congressen en ze heeft verschillende prijzen in ontvangst mogen 
nemen. Haar onderzoek heeft geleid tot meerdere gepubliceerde artikelen en dit 
proefschrift. Jitske zet haar wetenschappelijke carrière voort in de regeneratieve 
nefrologie en is momenteel werkzaam als post-doctoraal onderzoeker aan de 
Universiteit Utrecht, departement Farmaceutische Wetenschappen, afdeling 
Farmacologie, onder leiding van Prof. Dr. R. Masereeuw. 
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PHD PORTFOLIO
Name PhD candidate: J. Jansen
Department: Pharmacology & toxicology
Graduate School: Radboud Institute for Molecular Life Sciences
PhD period: 01-10-2012 – 31-12-2015
Promotors: 
Prof. Dr. R. Masereeuw, 
Prof. Dr. J.G.J. Hoenderop, 
Prof. Dr. L.P.W.J. van den Heuvel
Co-promotor: Dr. M.J. Wilmer
Year(s) ECTS
TRAINING ACTIVITIES
Courses & Workshops
- Winterschool Dutch Kidney Foundation
- RIMLS Graduate School
- Systematic review course – SYRCLE
- Course ‘How to write a medical scientific paper’
- MIC user meeting – Leica SP8 intro
- Nephrotools / BioArt workshop
- RU workshop: ‘Get Inspired’
2013
2013
2013
2013
2014
2014
2014
1.75
1.75
0.2
0.2
0.1
0.2
0.2
Seminars & lectures
- Prof. Dr. R. Kleta – EAST syndrome
- Technical Forum Tissue Engineering
- Prof. Dr. D. Markovich - NaS1 and Sat1 transporters in PTEC
- Noon-spotlight seminar: Chemical and Physical biology
- Kidney Theme – Tissue engineeringb
- Prof. Dr. F. Ashcroft – ATP-sensitive K+ channels and neonatal diabetes
- Kidney Theme – Uremic toxins
- Dr. R. Xavier- Biology in immunity
- Prof. Dr. D. Humes
- Dr. S. Tornroth – Structural basis for regulation of eukaryotic aquaporins
-  Noon-spotlight seminar: Zebrafish as a model system to study the function and 
pathology of new genes
-  Prof. Dr. R. Vanholder – An update on the Cinderella of protein-bound uremic 
toxins
- Kidney Theme – Brainstorm session
- Dr. B. Gloss – Trends in transcriptomics
- Prof. Dr. R. Walker – Mechanisms of drug nephrotoxicity
- Dr. C. Lee-Thedieck – The significance of material properties for stem cells
- Radboud Research Rounds – Renal disorders
-  Prof. Dr. S. Dryer – Multimodal gating of podocyte TRPC6 channels and dysregu-
lation in a rodent model of FSGS
- Kidney Theme meeting
- Kidney Theme meetings (8x)
-  Radboud Research Rounds Plus: Prof. Dr. M. Little - How to build a kidney: 
organogenesis to regeneration and back again.
2012
2013
2013
2013
2013
2013
2013
2013
2013
2013
2013
2014
2014
2014
2014
2014
2014
2014
2014
2015
2015
0.1
0.1
0.1
0.1
0.35
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.8
0.1
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- Radboud Research Rounds Plus: Meet the Professor. Prof. Dr. M. Little
-  Dr. J. de Boer – Talking to cells: surface topography as a tool to evoke cellular 
responses
2015
2015
0.1
0.1
Symposia & congresses
- New Frontiers in Personal Genomics
- IGMD Science Daya 
- Dutch Nephrology Daysa
- PLAN Dayb
- RIMLS PhD retreat
- Spring meeting Dutch Society of Pharmacology
- BMM annual meetingb 
- NIRM annual meetinga
- REFORM symposiumb
- NCMLS PhD retreata
- Dutch Nephrology Daysb
- NfN Najaarssymposiuma
- New Frontiers in Regenerative Medicinea*
- NIRM annual meetinga
- ASN conference, Philadelphia, USAa,b
- EUtox meeting Marseille, Franceb,b
- Spring meeting Dutch Society of Pharmacologya
- RIMLS PhD retreatb
- Nephrotools conference, Liverpool, UKa
- Radboud Frontiers in Cilia Medicine
2012
2013
2013
2013
2013
2013
2013
2013
2013
2014
2014
2014
2014
2014
2014
2015
2015
2015
2015
2015
0.5
0.5
0.75
0.35
0.5
0.25
0.5
0.75
0.5
0.5
0.5
0.5
0.75
0.5
2.25
1.5
0.5
0.5
1.0
0.5
Other
- Voorlichtingsdag Biomedische Wetenschappenb
- Publieksavond ‘Nier op maat’- Demo experimental setup
- Van Noordwijk Stipendium – Battle of the Universities*
- Co-organizer World Kidney Day 2015 event – Clean the Waal beach
- Membership Renal Theme Board – Representative PhD students
2013
2014
2014
2015
2015
0.1
0.2
0.5
0.5
0.5
TEACHING ACTIVITIES
Lecturing
- Capita Selecta: De biologische kunstnier
- Capita Selecta: De biologische kunstnier
2014
2015
0.5
0.5
Supervision of internships / other
- Supervision K. Jansen – lab intro excellent student programme
- Supervision D. den Braanker – Master thesis
- Supervision Y. van Deursen – Master internship
- Supervision J. Stoop – Bachelor internship
- Supervision I. Donderwinkel – Bachelor internship
- Supervision BMW students – Writing a research paper (5AM08)
2013
2013
2013-14
2014
2014
2014
0.1
0.05
2
2
1
0.1
TOTAL 29.3
 
a poster presentation, b oral presentation, * awarded.
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DANKWOORD
Promoveren. Of ik het traject ook ingegaan was als ik toen wist wat ik nu weet? 
Een volmondig JA! Dit overtuigende antwoord is te danken aan het team 
professionals om me heen en de mensen uit mijn privé omgeving. Daarom wil 
ik in dit dankwoord graag een aantal personen bedanken die een belangrijke 
bijdrage hebben gehad aan de totstandkoming van dit proefschrift.
Prof. dr. R. Masereeuw, beste Roos. Jouw bijdrage in mijn ontwikkeling van 
analist tot gepromoveerd onderzoeker is enorm geweest en ik wil je dan 
ook graag hartelijk danken voor al je ondersteuning en het vertrouwen in 
mij. Dat het ons is gelukt om functionerende nierbuisjes te ontwikkelen is 
fantastisch en jouw aandeel hierin is essentieel geweest. Jouw enthousiasme, 
kennis en doorzettingsvermogen ervaar ik dan ook als zeer inspirerend. Als we 
lastig interpreteerbare resultaten hadden wist jij altijd weer met een goede 
oplossing te komen zodat ik vol goede moed weer verder ging. Ondanks 
je drukke agenda vind je altijd weer even de tijd om mee te denken of een 
manuscript te reviewen. Dank daarvoor!
Maar zeker waardeer ik ook je oprechte en sociale karakter, waardoor je bij 
jou altijd met alles terecht kunt. Als er weer eens iets was met de honden, of 
voorheen met t paard dan werd dat net zo goed besproken als het experiment 
van de afgelopen week. Of gewoon gezellig een borrel op vrijdag middag, je 
deelname aan Döner-donderdag of een etentje bij je thuis, dit alles maakt 
je een bijzonder plezierig persoon om mee samen te werken. Ik ben dan ook 
dankbaar dat ik mijn wetenschappelijke carrière voort mag zetten onder 
jouw supervisie. De mogelijkheden die je mij geeft als postdoc binnen jouw 
onderzoeksgroep aan de Universiteit Utrecht bieden mij de kans om het 
avontuur in de onderzoekswereld verder aan te gaan, veel dank daarvoor! Ik 
hoop dat we samen nog veel wetenschappelijke hoogtepunten zullen bereiken 
(en vieren J )!
Prof. dr. J.G.J. Hoenderop, beste Joost. Ik begon als analist op het BioKid project 
bij jou op het lab en later als promovendus verhuisde ik naar farmacologie. 
Ik heb door de jaren heen altijd van jullie faciliteiten gebruik mogen maken 
(en de feestjes, gebak, etc. J ) en was meer dan welkom. Ik heb daardoor 
de samenwerking tussen de verschillende afdelingen binnen mijn project dan 
ook als zeer positief ervaren. Dank daarvoor! Je kennis en gedrevenheid is 
enorm en de input die jij gaf tijdens onze BioKid werkbesprekingen waren 
zeer waardevol en vaak de trigger om experimenten nog net even iets verder 
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uit te werken. Jouw bijdrage heeft er mede voor gezorgd dat mijn onderzoek 
succesvol is geworden. En ik nu alle figuren in mijn presentaties uitlijn, even 
groot maak, zelfde kleur/stijl/font size toepas, etc. J Behalve je professionele 
vaardigheden was je ook regelmatig in voor een geintje tussendoor (Martijn’s 
introductieweek bij fysiologie bijvoorbeeld) of gewoon een praatje bij de 
koffiemachine. Naast het onderzoek gaf je me ook de mogelijkheid om me 
verder te ontwikkelen op meer organisatorisch vlak en beleidsniveau binnen 
het Nier thema. Ik wil je dan ook graag bedanken voor alle ondersteuning. En 
natuurlijk niet te vergeten de organisatie van World Kidney Day 2015 en 2016. 
We hebben samen twee succesvolle edities georganiseerd en wat mij betreft 
volgen er nog velen!     
Prof. dr. L.P.W.J. van den Heuvel, beste Bert. Bij jou is het min of meer 
allemaal begonnen, toen ik als analist in de DNA-groep in aanraking met 
het wetenschappelijk onderzoek kwam. Na een paar jaar had ik de behoefte 
om me verder te ontwikkelen en je vertelde me iets over het BioKid project 
en dat er geld was voor een research analist. Na het sollicitatiegesprek met 
Roos en Joost kreeg ik het heuglijke nieuws dat ik aangenomen was en ‘the 
rest is history’. Ik wil je dan ook bedanken voor de ondersteuning tijdens de 
afgelopen jaren. Naast het delen van je kennis over de nieren ben je ook altijd 
in voor een ‘social talk’; even een update geven over de fopshop, je fobie voor 
vrijdag de 13e of de status van de door jou zelf in elkaar geknutselde auto, dit 
soort onderwerpen werden op vermakelijke wijze besproken. Het hoogtepunt 
was natuurlijk ons (jij, Marieke van Mullem en ik) karaoke optreden tijdens 
een labuitje van kindergeneeskunde. Vol overgave zongen we samen ‘Maak 
me gek’ van Gerard Joling. Top optreden. Bedankt voor de mooie tijd!
Dr. M.J. Wilmer, beste Martijn. Toen ik bij kindergeneeskunde kwam zat jij te 
zwoegen aan je proefschrift. Ik wist dat je iets met nieren deed, maar veel meer 
dan dat ook niet. En de term ‘ciPTEC’ kwam verdacht vaak voorbij, maar wat 
je daar aan had?! Verder was het duidelijk dat je als echte Limburger van een 
feestje hield en je in spraakmakende outfits carnaval vierde. Later raakte ook 
ik besmet met het ‘ciPTEC-virus’ en het werd zelfs een succesvolle besmetting. 
Ik heb veel van je geleerd en heb altijd prettig met je samengewerkt. Jij als 
ciPTEC-vader wist als geen ander hoe experimenten in te richten met deze 
cellen en je kennis was dan ook essentieel. Ik wil je hartelijk danken voor al 
je hulp, ondersteuning en ook de gezelligheid op feestjes. Je bent nu je wilde 
haren kwijt, gesetteld en zelfs vader; chapeau J!
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Graag wil ik de leden van manuscript commissie, Prof. dr. D.W. Swinkels, 
Dr. ir. W.F. Daamen en Prof. dr. M.C. Verhaar, hartelijk danken voor de 
zorgvuldige beoordeling van mijn proefschrift. Ook wil ik graag de overige 
leden van de oppositie bedanken voor hun bereidheid zitting te nemen in de 
commissie voor de promotie.  
Rachel en Marthe, mijn lieve paranimfen! Ik ben blij dat jullie aan mijn zijde 
staan tijdens het uur van de waarheid, bedankt dat jullie mijn paranimf willen 
zijn. Rachel, soms kom je mensen tegen in je leven waarbij je je vanaf minuut 
één op je gemak voelt en dat had ik bij jou. We verstaan elkaar moeiteloos, 
of het nu gaat om wetenschap, versieren van werkplekken of de passie voor 
honden en dat is bijzonder plezierig. Jouw doorzettingsvermogen, kennis en 
gedrevenheid zijn bewonderenswaardig en je hebt daarmee een mooie positie 
weten te vergaren in de groep van Prof. dr. D.W. Swinkels. Ik wil je bedanken 
voor je steun tijdens de afgelopen jaren en hoop dat we onze interesses nog 
lang mogen blijven delen! Marthe, bij kindergeneeskunde hebben we menig 
sequentie reactie samen ingezet en onze samenwerking verliep altijd bijzonder 
soepel. Daarnaast hadden we gemeenschappelijke passies en dus voldoende 
gespreksstof tijdens ons werk; namelijk de paarden en honden (en soms de 
mannen bij genetica J). Verder denk ik bij deze periode met plezier terug aan 
de Jillz-avond, al lust ik na die avond gek genoeg geen Jillz meer. Uiteindelijk 
gingen we beide een andere kant op, maar altijd hebben we nauw contact 
behouden. Het is fijn om een vriendin te hebben waarbij ik altijd terecht kan 
in voor- en tegenspoed, bedankt!
Het ontwikkelen van een biologische kunstnier is een uitdagende expeditie, 
hetgeen enkel succesvol kan worden in een goed draaiend team. Ik wil dan 
ook graag de Biokiddies bedanken voor hun samenwerking. Carolien, samen 
begonnen we aan de uitdaging om nierbuisjes te maken voor de biologische 
kunstnier, jij als promovendus en ik in eerste instantie als analist. Menig cellijn, 
PES-membraan, transportexperiment, potjes L-DOPA en collageen zijn door 
onze handen gegaan en al ‘t noeste arbeid heeft uiteindelijk geleid tot twee 
proefschriften. Ik wil je ontzettend bedanken voor de plezierige samenwerking, 
jouw geduld om zaken uit te zoeken en te regelen en je hulp bij het schrijven 
van het eerste artikel over de cellijnen. Daarnaast was je altijd bereid om te 
helpen met experimenten en dus weer, voor de zoveelste keer, met de step 
richting de toren te komen (en je ons dus ook even een update kon geven over 
je surf hunk J ). Jouw aandeel in de totstandkoming van mijn proefschrift is 
essentieel geweest. Bedankt voor al je support en veel geluk voor de toekomst! 
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Rick M, ‘Mister Uremic Toxin’. Toen Carolien en ik op het Biokid project 
begonnen was jij al even bezig om rol van niertransporters in uremie te 
onderzoeken. Samen met Martijn heb je mij ondergedompeld in de wondere 
wereld van de celkweek en mij de kneepjes van dit vak en de weg naar de 
Aesculaaf geleerd. Jouw kennis en creatieve houding zijn een waardevolle 
bijdrage geweest voor het Biokid project. Dank daarvoor! Michèle and Miloš, 
you were highly valuable members in the Nijmegen BioKid team, but I will 
acknowledge you in the Utrecht section J.
Prof. dr. D. Stamatialis, dear Dimitrios, I am very grateful for our enjoyable 
collaboration during the past years. Our vivid scientific discussions were really 
valuable to expand my (biomaterials) knowledge and to bring our research 
to the next level, but I also appreciated the social talks during meetings very 
much. Together we published several nice papers and hopefully that number 
will rise in the future. Natalia, Ilaria and Sandra, many thanks for the fruitful 
collaboration. I wish you all the best for the future!
Prof. dr. R.A. Bank, beste Ruud. Ik wil je hartelijk danken voor de prettige 
samenwerking tijdens het BioKid project. We hebben een mooi artikel over de 
cellijnen samen weten te publiceren, welke het fundament is geweest voor de 
ontwikkeling van de biologische kunstnier.
Prof. dr. L.B. Hilbrands en Prof. dr. J.F. Wetzels, beste Luuk en Jack, jullie 
klinische inbreng in dit project is zeer waardevol geweest. Jullie expertise en 
kritische noot heeft er mede voor gezorgd dat we er in zijn geslaagd om de 
nierbuisjes te publiceren in mooie vakbladen. Daarnaast was de toegang tot 
controle en uremisch plasma altijd binnen handbereik, hartelijk dank daar 
voor. 
Tevens wil ik ook graag de overige projectleden van de TU Eindhoven, de 
Nierstichting en PharmaCell bedanken voor de prettige samenwerking.  
Moreover, I would like to thank the Renal Theme board members for the 
inspiring meetings and the opportunity for me to learn more about regulatory, 
research and teaching affairs within the Renal Theme. 
Tevens wil ik graag mijn mentor, Dr. J. van der Vlag, bedanken voor zijn 
begeleiding tijdens mijn promotietraject. Beste Johan, eens per jaar kwam ik 
met mijn RIMLS Trainings- and Supervision Plan onder mijn arm bij je langs 
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om de stand van zaken met betrekking tot mijn promotieonderzoek door te 
nemen. Het waren altijd prettige gesprekken en als ik je kamer verliet ging ik 
altijd met een gerust hart weer verder met mijn onderzoek. Tijdens ons laatste 
mentorgesprek, toen ik toch wat twijfelde over wat ik nou moest gaan doen 
na mijn PhD, gaf je me een helder advies. Ik heb dit advies dan ook opgevolgd, 
behalve dan dat ik het Radboud heb verlaten J. Ook wil ik je bedanken voor 
de mogelijkheid om jullie nierendotheelcellen te gebruiken in een aantal pilot 
studies, wie weet komen onze epitheelcellen en jullie endotheelcellen nog 
weer eens samen in de toekomst.  
Daarnaast zijn er veel (oud-)collega’s binnen de verschillende afdelingen die 
het werk tijdens mijn promotietraject bijzonder aangenaam hebben gemaakt. 
Janny, ik wil je bedanken voor je betrokkenheid en oprechte interesse in het 
onderzoek, maar ook de gezellige ‘social talks’ over niet-werk gerelateerde 
zaken. Als die ($%$!) fibers kuren hadden, wist je me altijd weer op te beuren. 
Daarnaast zorg jij er mede voor dat het lab goed draait en is het fijn om iemand 
op de werkvloer te hebben waarbij je altijd terecht kunt met praktische vragen 
en van op aan kunt. Rick G en Karl, onze Boer-Zoekt-Vrouw groepsapp 
gaat hopelijk ook in het nieuwe seizoen weer van start. Als nuchtere mede-
achterhoekers verstonden we elkaar goed, bedankt voor jullie support en de 
gezelligheid binnen en buiten het lab! Tom S., waar die ciPTECs niet allemaal 
goed voor zijn J. We hebben samen een mooi artikel bij elkaar gepipetteerd 
over de energiecentrales in niercellen. Je bent nu al een succesvol onderzoeker 
en tevens bijzonder goed in t prakken van kilo’s koeienweefsel. Bon, bedankt 
voor de fijne samenwerking en veel succes in Cambridge! Jelle en Tom N, 
mede-ciPTECers die als geen ander weten hoe lastig het kan zijn om het de 
niercellen naar hun zin te maken. Onze samenwerking was altijd bijzonder 
soepel (en gezellig in de aesculaaf J) en daarvoor wil ik jullie hartelijk danken. 
Veel succes met jullie PhD projecten! Esther, mijn Philly-buddy, wat hebben 
we een coole week gehad tijdens de ASN in de US. Al waren we beide blij dat 
we weer veilig aan de grond stonden op Schiphol na die horrorvlucht. Bedankt 
voor je support tijdens mijn PhD-project en succes met de laatste loodjes van 
jouw boekje. Ria, bedankt voor je support tijdens mijn onderzoek en de gezellig 
tijd op t lab, tijdens pauzes, borrels, interesse in de honden etc. Veel succes 
met je onderzoek en houd die CDL mensen een beetje in toom! Lindsey en 
Maarten, ook voor jullie is de eindstreep van het promotietraject in zicht. Hoe 
fijn is dat J. Bedankt voor jullie gezelligheid, luidruchtigheid J en de wijze les 
om constructen vooral kant-en-klaar te kopen. Helaas geen vierdaagsefeestjes 
meer op het balkon bij Lindsey.. Jeroen, mijn U-genoot en Mr. labguru, 
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bedankt voor de support in het lab (lekkere antilichamen J) en de social 
talks over van alles en nog wat. Jeanne en Vivienne, de eerste keer dat ik die 
minuscule glazen cannules zag dacht ik: hoe dan?! Maar nu een paar jaar later 
pruts ik zonder enige moeite een fiber aan zo’n cannule en heeft het al geleid 
tot twee mooie publicaties! Hartelijk dank voor jullie hulp en interesse tijdens 
mijn onderzoek! Petra en Ab, jullie analytisch vermogen is een belangrijke 
spil geweest in de analyse van de uremische toxines. Hartelijk dank voor jullie 
hulp! Sanna, Hanneke, Anita, Elnaz, Sabrina, Marieke, Niels, Kim, Julien-
let’s-cover-Karl’s-bench-with-balloons-Beyrath J, Wendy (De liefste Bruce 
Springsteen-fan die ik ken!), Bas, Robert, Jan, Gerard, Kees, Frans and all 
other colleagues; many thanks for supporting my research and for celebrating 
the victories! It was a great pleasure to work with you in the department of 
Pharmacology & Toxicology. I wish you all the best for the future!
Annemieke, ik vind het erg leuk dat we altijd nog contact hebben en waardeer 
zeer je toewijding en support zoals ik die ervaren heb tijdens (maar ook voor 
en na J ) mijn promotietraject. Dankjewel!
I also would like to thank Sjoerd, Ellen, Liz, Omar, Lauriane, Andreas, 
Femke, Silvia, Kukiat, Mohammed, Paco, Claudia, Jenny, Sami, Sabina, 
Caro, Jeroen, Theun, Anne, Irene, Dennis, Prof. dr. P.M.T. Deen and all other 
colleagues from the department of Physiology for the enjoyable time I had in 
the lab (and beyond J) and the nice discussions during the Friday lab meetings. 
Special thanks to Prof. dr. R.J.M. Bindels. Dear René, I admire your enthusiastic 
approach to science and would like to thank you for your advises and fruitful 
discussions during meetings but also the joyful time during dinners.
We shared the Pharmacology & Toxicology lab with the department of 
Biochemistry and I would like to thank Lisanne, Marco, Jori, Herman, 
Marleen, Federica, Mina, Sander G, Sjenet, Dania, Hoa, Ganesh, and all 
others for the nice interactions with you guys during the coffee breaks or in 
the cell culture. In het bijzonder wil ik Sander bedanken, baron van Asbeck. 
Dankzij jouw betrokkenheid is het gelukt een eerste generatie microfluidic 
te 3D printen waardoor wij onze transportexperimenten in de fibers hebben 
kunnen uitvoeren. Veel dank daarvoor! Maar zeker ook onze BCRP CRISPR/
Cas expeditie mag er zijn, bedankt voor je behulpzaamheid en geduld. 
Uiteraard waren ook de chats over honden, vrouwen J en andere niet-
werkgerelateerde zaken altijd erg leuk. Nog even doorknallen en dan kom ik 
graag je verdediging bijwonen!
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Huib en Jack, veel dank voor jullie hulp bij het imagen en het opzetten van 
de opstelling met de fibers. Als de Mic weer eens kuren had waren jullie altijd 
bereid mij uit de brand te helpen (1x zelfs bijna letterlijk J ). Dank daarvoor!
De collega’s van de afdeling kindergeneeskunde wil ik bedanken voor de 
leerzame en leuke tijd die ik heb gehad tijdens mijn periode als analist 
bij de DNA-groep, maar ook voor de samenwerking daarna tijdens mijn 
promotietraject. Marieke, wij zaten gelijktijdig op het HLO en later werden 
we collega’s. Je enthousiaste en betrokken houding op de werkvloer zijn enorm 
plezierig en al snel groeide dit uit tot een mooie vriendschap. Etentjes zijn 
altijd erg gezellig en onder het genot van een wijntje worden alle ‘ins and outs’ 
besproken. Ook je medewerking aan ‘het mooiste cadeau in het donker’ en 
je hulp bij het maken van de knapzakjes voor de kerstmarkt in Keulen zal ik 
nooit vergeten J! Bedankt voor je betrokkenheid bij mijn promotieonderzoek, 
maar ook je oprechte interesse in huis-tuin-en-keuken onderwerpen waardeer 
ik zeer. Roel en Edwin, PCR-masters, jullie hebben mij alle kneepjes van 
het PCRen, sequencen etc. bijgebracht. Bedankt daarvoor! Ook werd mijn 
muziekkennis door jullie wat opgeschroefd en wist ik wat SV Hatert had 
gedaan na het weekend. Dit laatste natuurlijk mede door de bezoekjes aan het 
lab door Prof. Zegers. Beste Frans, jij kwam elke dag even langs om het laatste 
nieuws te bespreken, van sport tot en met je vakantie plannen naar Afrika. Je 
bracht altijd weer even wat schwung in het lab! Je gesigneerde shirt waarmee je 
kampioen bent geworden met SV Hatert heb ik altijd nog zorgvuldig bewaard. 
Maaike Bras, Maaike Brink, Saskia, Inge, Paulien, Mariël, Maurice, 
Wilmien, Karin, Rutger, Cindy, Conny, Jessica, Thea, Annelies, Dineke, 
Irma, Jacqueline, Frans, ‘Spiergroep’, An, Richard en alle andere collega’s 
bedankt voor de samenwerking en de gezelligheid tijdens feestjes!
De oud-collega’s van QM diagnostics wil ik bedanken voor de prettige tijd 
die ik bij jullie heb gewerkt (kort maar krachtig J). In het bijzonder wil ik 
Marloes bedanken, nadat ik vertrok bij QM hebben we altijd nog contact 
gehouden en spraken we af voor lunch om gezellig bij te kletsen of we gingen 
bij elkaar op bezoek. Bedankt voor je interesse en support gedurende mijn 
promotietraject en laten we vooral blijven afspreken J.
Als laatste wil ik de oud-collega’s van het Canisius Wilhelmina Ziekenhuis en 
het Slingeland Ziekenhuis, afdeling Medische Microbiologie bedanken voor de 
leerzame en leuke tijd. Ik heb met veel plezier gewerkt op de afdeling serologie 
van het CWZ, tijdens de bepalingen werd het weekend doorgenomen, de 
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laatste nieuwtjes besproken, Theo, Toon, Jack en Bert die ‘diepgaande’ 
gesprekken hadden en Bea, Mary, Dorine en later Fien die de mannen een 
beetje in toom hielden. Ook op de afdelingen bacteriologie en moleculaire 
biologie (Margret, Annet, Dirk, Jos, Sabrina, Maaike B, Sandra, Hanneke, 
Maaike (DNA), Corina, Kim, Bart, Theo, e.v.a.) heb ik met veel plezier 
gewerkt, bedankt voor de fijne tijd! In het bijzonder wil ik Romana bedanken, 
nadat we beide vertrokken bij het CWZ hebben we altijd nog contact onder 
houden. Je bent een luisterend oor voor mij geweest en het is altijd gezellig 
als we elkaar weer zien. Vielen Dank Liebe Romana! De allereerste kneepjes 
van het microbiologisch vak zijn me bijgebracht door Frits Florestein en 
Mariëtte Nusselder onder leiding van Medisch Microbioloog Ron Bosboom 
en toenmalig labhoofd Johan van der Elzen, in het Slingeland ziekenhuis te 
Doetinchem. Ik wil alle medewerkers van deze afdeling hartelijk danken voor 
de kennis die ze met mij hebben gedeeld en de gezelligheid op en ook buiten 
het lab. 
Ook wil ik graag de studenten die ik begeleid heb tijdens mijn promotie traject 
bedanken voor hun inzet, Yvette, Ilze, Jesse en Ursula. Mede dankzij jullie is 
er mooie data gegenereerd en heb ik mijn geduld-gen (een soort van ) ontdekt. 
Ik wens jullie veel succes voor de toekomst!
Mijn huidige collega’s van de afdeling Farmacologie, Universiteit Utrecht, wil 
ik bedanken voor hun warme onthaal in de groep en hun interesse in mijn 
promotieonderzoek alsmede in mijn huidige project. Ook de borrels op het 
dakterras zijn bijzonder gezellig en nu al legendarisch met de Roos-Johan 
plek J. Momenteel zijn de werkzaamheden binnen de subgroepen nog vrij 
uiteenlopend, maar ik heb er alle vertrouwen in dat er mooie bruggen te slaan 
zijn en we hopelijk vele successen samen mogen beleven. Manoe, Miloš, Pedro 
and Michèle, my former Nijmegen colleagues who are actually now my Utrecht 
colleagues. Thanks for the support during my PhD project, the scientific 
discussions during meetings, but also the nice social activities we had during 
the past years! Also many thanks for the nice introduction in the Utrecht 
group, I was comfortable within no time. Manoe I really admire your scientific 
attitude and your patience with students. I am sure you were born for a career 
in science! Miloš, the Italian from Servia or the other way around J. I think you 
are one of the most critical (in particular on your own data) and hard-working 
persons I know and always willing to help out colleagues. Thanks for your 
collaboration, it is a pleasure working with you. Pedro, If something was lost 
(e.g. my pipettes) I always knew where to find it (your lab bench). Also, thanks 
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to you, we now know that our cells can survive overnight at room temperature. 
Unfortunately, you are going to leave our lab as you almost graduate. It was 
always fun working with you but also from a scientific point of view it was great 
to collaborate with you. I wish you all the best in Germany, or the Antarctic as 
you call it, you will manage! Michèle, together we published two nice papers! 
Your enthusiastic, social character and your interest in science will be key in 
your graduation to doctor. Ga zo door J! Paul, als jongste telg binnen de ‘Roos-
groep’ staat je nog heel wat te wachten, maar met jouw sympathieke, vrolijke 
karakter en goede aanpak van wetenschappelijke vraagstukken weet ik zeker 
dat we over een paar een Dr. Paul in ons midden hebben. Katja and Amer, as 
of September you will start your PhD fellowship in Roos’ group. I am looking 
forward to our collaboration and the papers we will publish in the future! To all 
(semi-)young and senior researchers in the department of Pharmacology: I am 
looking forward to celebrate scientific victories or PhD graduate parties in the 
future J. Aletta, Paula and Johan, no matter what, I will never forget my first 
conference abroad within this department. Thanks Aletta for taking care of us! 
Uiteraard zijn er ook buiten het werk om veel mensen die me altijd gesteund 
hebben. Allereerst wil ik graag de familie Jansen en Gudde bedanken voor 
hun hartverwarmende steun en interesse. De appjes, mailtjes, kaartjes en 
smsjes om mij succes te wensen voor een congres, te feliciteren als er een 
artikel geaccepteerd was of als ik een prijs had gewonnen waardeer ik enorm! 
Ook al wisten jullie niet precies wat ik dan gepubliceerd had of wat ik moest 
presenteren, jullie waren er niet minder trots om. Veel dank daarvoor! Eén van 
de hoogtepunten betreffende support was de ontvangst na mijn dynamische 
Turkije trip; Vicky, Bianca, Stender, tante Rikie en ma met n spandoek, 
champagne en bloemen op station Veenendaal-de Klomp. Dat was echt 
fantastisch en zal ik nooit vergeten! Brigitte, bedankt voor de feedback op mijn 
NL samenvatting, ik sluit de kans niet uit dat er in dit dankwoord hier en daar 
wat bijwoorden niet geheel correct zijn J. Daarnaast wil ik de familie Albers 
bedanken voor hun support, de gezellige feestjes zorgden er altijd weer voor dat 
ik het werk even kon loslaten. In het bijzonder wil ik schoonma bedanken; bij 
jou staat de deur altijd open voor een bakkie koffie en een gezellig praatje. Jouw 
energieke en positieve houding is bewonderingswaardig! Bedankt voor je steun 
in voor- en tegenspoed. 
Zeker ook wil ik Linda, Jan-Willem, Sven, Jeantine, Chris, Miriam en Tom 
bedanken voor jullie interesse in mijn promotiewerk en de support tijdens deze 
periode. De gezelligheid tijdens feestjes, Normaal concerten, Zwarte Cross en 
295
11
andere events zit altijd goed en het is dan ook erg fijn om mensen zoals jullie om 
me heen te hebben. Linda, we kennen elkaar al vanaf de HLO en zijn altijd nog 
goede vriendinnen. Het is bijzonder prettig om te weten dat er mensen zijn bij 
wie de deur altijd open staat! Marleen en fam. Albers, menig uur heb ik tijdens 
mijn promotieonderzoek bij jullie paardgereden en daardoor kon ik mijn hoofd 
even helemaal leeg maken. Fijn dat dit mogelijk was! Roos (Heck), als ik ging 
lessen bij jou dan stapte ik naderhand altijd met een positieve flow van mijn 
paard en kon ik met nieuwe energie weer aan het werk. Dank daarvoor! 
En dan natuurlijk Sebastiaan en Elmy, bedankt voor jullie belangstelling naar 
mijn promotie onderzoek de afgelopen jaren. Het is fijn om familie om je heen 
te hebben waarvan je weet dat ze er voor je zijn; van het samen vieren van 
behaald succes tot het regelen van een nieuwe eettafel nadat deze een Canis 
lupus aanval niet overleefd had. Dank daarvoor! 
Pa en ma, toen ik de kans kreeg om het PhD-traject in te gaan was er vanuit 
jullie kant geen minuut twijfel of ik het wel zou volbrengen. Echter, zonder jullie 
enorme toewijding, steun en vertrouwen was dit proefschrift niet geworden 
wat het nu is. Letterlijk niet, gezien pa voor de eerste fiber experimenten nog 
een op maat gemaakte ring heeft ontwikkeld zodat ik de functionele testen 
uit kon voeren. Als er een artikel werd afgewezen of experimenten mislukten, 
wisten jullie me wel weer te stimuleren zodat ik vol goede moed verder ging. 
Het is bijzonder fijn om een warme (ook letterlijk: lang leve de roodgloeiende 
houtkachel) en liefdevolle familie om je heen te hebben! Deze mijlpaal is nu 
bereikt, maar ik hoop nog vele (wetenschappelijke) hoogtepunten met jullie te 
mogen vieren. Dankjulliewel!
En dan natuurlijk, mijn rots in de branding: Bennie. Op jou kan ik vertrouwen 
en ik weet dat je er altijd voor me bent. Je laat me vrij in wat ik wil doen en staat 
altijd achter mijn keuzes, zonder enige twijfel. Bedankt voor je onvoorwaardelijke 
steun en liefde! Een goede thuisbasis is het fundament voor succes, zeker ook in 
de wetenschap. En dat zit bij ons wel goed! Ik hoop dat we in de toekomst nog 
veel successen samen mogen vieren, bedankt dat je er voor me bent! 

